# ClickDose — full content for LLMs Generated from the live English pages. 56 pages. Equivalents exist in: Danish (`/da/`), English (`/en/`), German (`/de/`), Norwegian (`/no/`), Swedish (`/sv/`), French (`/fr/`), Spanish (`/es/`), Italian (`/it/`), Japanese (`/ja/`), Polish (`/pl/`), Brazilian Portuguese (`/pt/`), Arabic (`/ar/`). --- Source: https://clickdose.io/en/index.html - ClickDose — Pen Click Counter JavaScript is required for the click counter. The reference content below is still accessible. ClickDose — Pen Click Counter Count clicks and calculate your dose automatically Important: ClickDose is an assistive tool only — not a medical device. Always verify your dose visually on the pen itself. Choose pen type Wegovy — Semaglutide — weight loss (Novo Nordisk) - Mounjaro — Tirzepatide — weight loss / diabetes (Eli Lilly) - Ozempic — Semaglutide — type 2 diabetes (Novo Nordisk) Loading counter… ## What is ClickDose? ClickDose is a free tool that counts the clicks on a GLP-1 injection pen — Wegovy, Ozempic or Mounjaro — and turns them into a precise dose. On these pens, each click you hear while dialling corresponds to a fixed, known increment of medicine, so counting clicks lets you dial a smaller "split" dose. That helps when you titrate slowly to ease side effects, or stretch an expensive pen further. The click detection runs entirely in your browser using your device's microphone — your audio and dose calculations are never uploaded or stored. ClickDose also works offline once installed as an app. ## Important — not a medical device ClickDose is an assistive tool only, and is not affiliated with, endorsed by, or funded by Novo Nordisk or Eli Lilly. Click counting can be inaccurate due to background noise or microphone differences — always verify your dose visually on the pen and follow your doctor's instructions. It is built by Tue Topholm, a software engineer and patient/family member (not a clinician). ## Learn more - Is dose-splitting safe? What to know first - How click counting works - GLP-1 side effects and how to manage them - Browse all articles → --- Source: https://clickdose.io/en/wegovy-click-counter.html ClickDose is a free browser-based tool that uses your phone's microphone to automatically count the clicks on your Wegovy pen. Instead of counting manually and risking errors, ClickDose listens to each click and tells you exactly when to stop dialing — making dose-splitting safer and more convenient. Whether you are on a low starting dose or splitting a higher-strength pen, knowing the exact number of clicks per dose is essential. Below you will find complete click reference tables for every Wegovy pen strength. ## How Many Clicks in a Wegovy Pen? Each Wegovy pen strength has a specific number of total clicks and a fixed amount of medication per click. The tables below show the full-dose click count, the mg per click, and common sub-dose click counts for each pen. ### Wegovy 0.5 mg pen (1.5 mL) | Dose | Clicks | mg per click | | 0.25 mg | 18 | 0.0134 | | 0.5 mg (full dose) | 37 | 0.0134 | ### Wegovy 1 mg pen (3 mL) | Dose | Clicks | mg per click | | 1 mg (full dose) | 75 | 0.0134 | ### Wegovy 1.7 mg pen (3 mL) | Dose | Clicks | mg per click | | 1 mg | 44 | 0.0227 | | 1.7 mg (full dose) | 75 | 0.0227 | ### Wegovy 2.4 mg pen (3 mL) | Dose | Clicks | mg per click | | 0.25 mg | 8 | 0.032 | | 0.5 mg | 16 | 0.032 | | 1.0 mg | 31 | 0.032 | | 1.7 mg | 53 | 0.032 | | 2.0 mg | 63 | 0.032 | | 2.4 mg (full dose) | 75 | 0.032 | ### Try ClickDose for Free Let ClickDose count the clicks for you — accurate, fast, and stress-free. Select your Wegovy pen and target dose, and we handle the rest. ## How Does Wegovy Click Counting Work? Wegovy pens use a dial mechanism to measure doses. When you twist the dose knob, the pen produces a distinct clicking sound for each increment. Each click corresponds to a precise amount of semaglutide — the active ingredient in Wegovy. By counting these clicks, you can determine the exact dose being loaded into the pen before injection. This click mechanism is the same across all Wegovy pen strengths, but the amount of medication delivered per click varies depending on the pen's concentration. That is why it is important to know the correct click-to-dose ratio for your specific pen strength. ## Frequently Asked Questions ### How many clicks is a full dose of Wegovy 2.4 mg? A full dose of Wegovy 2.4 mg requires 75 clicks. The 2.4 mg pen contains 3 mL of solution and delivers 0.032 mg per click. ### Can I split a Wegovy dose? Yes, it is technically possible to split a Wegovy dose by counting a specific number of clicks to deliver a lower dose. However, dose-splitting is considered off-label use and is not officially recommended by the manufacturer. Always consult your doctor or pharmacist before splitting doses to ensure it is safe and appropriate for your situation. ### How long does a Wegovy pen last after first use? An opened Wegovy pen is stable for up to 6 weeks (42 days) after first use, when stored properly at room temperature below 30 °C (86 °F) or in the refrigerator. This makes multi-week dose-splitting practical from a single pen. ### Is Wegovy click counting safe? Click counting can be a useful guide for determining your dose, but it should always be verified visually using the dose window on the pen. Miscounting clicks can lead to receiving too much or too little medication. Tools like ClickDose help reduce the risk of counting errors by automating the process. ### How does ClickDose count clicks? ClickDose uses your device's microphone to detect the distinct clicking sound produced by the pen's dial mechanism. The app processes the audio in real time, counts each click as it happens, and alerts you when you have reached your target dose. No data is sent to any server — all processing happens locally in your browser. --- Source: https://clickdose.io/en/ozempic-click-counter.html If you use Ozempic (semaglutide) and need to count the clicks on your FlexPen, ClickDose can help. ClickDose is a free web-based tool that listens to the clicks of your injection pen through your phone's microphone and counts them automatically. No more manual counting, no more guessing — just select your Ozempic pen strength and target dose, and ClickDose tells you exactly when to stop dialing. ## How Many Clicks in an Ozempic Pen? All Ozempic FlexPen strengths deliver a fixed 0.01 mg per click. This makes the math straightforward: divide your desired dose (in mg) by 0.01 to get the number of clicks. Below is a quick reference table for every Ozempic pen. ### Ozempic 2 mg pen (1.5 mL) | Dose | Clicks | | 0.25 mg | 25 clicks | | 0.5 mg | 50 clicks | ### Ozempic 4 mg pen (3 mL) | Dose | Clicks | | 0.5 mg | 50 clicks | | 1.0 mg | 100 clicks | ### Ozempic 8 mg pen (3 mL) | Dose | Clicks | | 1.0 mg | 100 clicks | | 2.0 mg | 200 clicks | --- Source: https://clickdose.io/en/mounjaro-click-counter.html ClickDose is a free, browser-based tool that listens to your Mounjaro KwikPen through your phone's microphone and counts every click automatically. No app to install, no manual counting, no guesswork — just accurate, real-time click detection so you always know your exact tirzepatide dose. ## How Many Clicks in a Mounjaro KwikPen? Every Mounjaro KwikPen — from 2.5 mg to 15 mg — contains exactly 60 clicks. The pens all deliver the same volume of liquid; what changes is the concentration of tirzepatide. Here is the mg per click for each pen strength: | Pen Strength | Clicks | mg per Click | | 2.5 mg | 60 | 0.04 mg | | 5 mg | 60 | 0.08 mg | | 7.5 mg | 60 | 0.13 mg | | 10 mg | 60 | 0.17 mg | | 12.5 mg | 60 | 0.21 mg | | 15 mg | 60 | 0.25 mg | Half-dose tip: 30 clicks = half a dose. This is useful for patients who split doses for slower titration or cost saving. Dose splitting is off-label — always discuss with your doctor first. ### Try ClickDose now Place your phone next to the pen, press start, and let ClickDose count every click for you — free, private, no sign-up. ## How Mounjaro KwikPen Works The Mounjaro KwikPen is a disposable, pre-filled injection pen made by Eli Lilly. Unlike Wegovy and Ozempic pens (which vary in click count by strength), every Mounjaro pen uses the same mechanical design: 60 clicks delivering a fixed volume. The difference between a 2.5 mg pen and a 15 mg pen is purely the concentration of tirzepatide in the solution — not the number of clicks or the volume injected. This consistent 60-click mechanism makes Mounjaro particularly well suited for click counting and dose splitting. Once you know how many clicks correspond to your desired dose, the math is the same for every pen strength. ## Frequently Asked Questions ### How many clicks are in a Mounjaro pen? Every Mounjaro KwikPen contains exactly 60 clicks, regardless of the pen strength. Whether you have a 2.5 mg pen or a 15 mg pen, the mechanical click count is always 60. ### Can you split a Mounjaro dose? Yes. Because every KwikPen has 60 clicks, you can dial 30 clicks for a half dose. For example, 30 clicks on a 5 mg pen delivers 2.5 mg. This is off-label use and should be discussed with your prescribing doctor before attempting. ### Is the Mounjaro KwikPen single-dose? The KwikPen is marketed as a single-dose device — one pen, one injection. However, mechanically it contains 60 individually clickable increments, so it is possible to use it for multiple smaller injections via click counting. This is off-label, and you must use a new sterile needle for each injection and store the pen correctly between uses. ### How long does a Mounjaro pen last after first use? Once punctured, a Mounjaro KwikPen must be used within 30 days when stored at room temperature (up to 30 °C). This is shorter than Wegovy, which allows 6 weeks. If you are splitting doses, plan your injections accordingly. ### What is the difference between Mounjaro and Wegovy? Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist that acts on two incretin hormones. Wegovy contains semaglutide, which targets only the GLP-1 receptor. Both medications promote weight loss and blood sugar control, but their mechanisms differ. Mounjaro's dual action may produce different efficacy and side-effect profiles compared to Wegovy. ## References Content on this page has been reviewed for factual accuracy against the official prescribing information and summary of product characteristics listed below. - Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. FDA. pi.lilly.com - European Medicines Agency. Mounjaro Summary of Product Characteristics. ema.europa.eu - Novo Nordisk. Wegovy (semaglutide) Prescribing Information. FDA, revised 2023. accessdata.fda.gov --- Source: https://clickdose.io/en/dose-splitting-guide.html GLP-1 medications like Wegovy, Ozempic and Mounjaro are life-changing — but they are expensive. Dose splitting is a practical strategy that lets you buy a higher-strength pen and dial fewer clicks per injection, stretching a single pen across multiple doses. The result: savings of up to 75% on your medication costs, without sacrificing your treatment. This guide walks you through everything you need to know — from choosing the right pen to counting clicks accurately with ClickDose. ## What Is Dose Splitting? Dose splitting means using a pen that contains more medication than your prescribed dose, then dialling only the number of clicks needed for a smaller, partial dose. For example, instead of buying a Wegovy 0.5 mg pen for a single injection, you buy a Wegovy 2.4 mg pen and take four separate 0.5 mg doses from it. The medication in the pen is exactly the same — you simply use a fraction of it per injection. The key is knowing how many clicks correspond to your target dose, and counting them accurately. ## Step-by-Step Guide ### Step 1: Choose Your Pen Select the highest-strength pen that your doctor can prescribe. Larger pens contain more medication per unit cost, making them more economical to split. | Medication | Best Pen for Splitting | Total Content | Click Value | | Ozempic | 8 mg pen (red label) | 8 mg semaglutide | 0.01 mg / click | | Wegovy | 2.4 mg pen | 2.4 mg semaglutide | Varies by pen | | Mounjaro | 15 mg pen | 15 mg tirzepatide | Varies by pen | ### Step 2: Calculate Clicks Needed Each pen delivers a specific amount of medication per click. For Ozempic, this is straightforward: the 8 mg pen delivers exactly 0.01 mg per click. So for a 2 mg dose, you need 200 clicks. For a 1 mg dose, 100 clicks. | Target Dose (Ozempic) | Clicks Needed | Doses per 8 mg Pen | | 0.25 mg | 25 clicks | 32 doses | | 0.5 mg | 50 clicks | 16 doses | | 1.0 mg | 100 clicks | 8 doses | | 2.0 mg | 200 clicks | 4 doses | For Wegovy and Mounjaro pens, the click values vary. Use the ClickDose app to look up the correct number of clicks for your specific pen and target dose. ### Step 3: Count Clicks Accurately This is the most critical step. Miscounting by even a few clicks can mean the wrong dose. You have two options: - Use ClickDose — hold your phone near the pen while dialling. ClickDose listens to the clicks and counts them automatically, giving you real-time feedback. - Count manually — dial slowly in a quiet room and count each click. This works but is more error-prone, especially at higher click counts (100+). ### Step 4: Store Your Pen Properly Once opened, pens have a limited shelf life at room temperature: - Wegovy & Ozempic: up to 6 weeks (42 days) at room temperature below 30°C. - Mounjaro: up to 30 days at room temperature below 30°C. Always replace the pen cap after each use, store it away from direct sunlight, and use a fresh needle for every injection. ### Count clicks with confidence ClickDose counts the clicks on your injection pen automatically — so you always get the right dose, without the stress. ## How Much Can You Save? The savings from dose splitting depend on the price difference between pen strengths and how many doses you can extract. Here are two real-world examples: ### Wegovy: 2.4 mg pen → 4 × 0.5 mg doses Instead of buying four separate 0.5 mg pens, buy one 2.4 mg pen. You get 4 doses from a single pen, saving approximately 75% compared to buying individual low-dose pens. ### Ozempic: 8 mg pen → 4 × 2 mg doses The Ozempic 8 mg pen contains enough medication for 4 full 2 mg doses. At one injection per week, that is a full month of treatment from a single pen — at a fraction of what four individual prescriptions would cost. Exact savings depend on your pharmacy, insurance and country. But the principle is the same everywhere: fewer pens purchased = lower total cost. ## Frequently Asked Questions ### Is dose splitting legal? Yes. Dose splitting is legal. It is considered off-label use, meaning the manufacturer does not officially recommend it, but there is no law preventing you from using your prescribed medication this way. Your doctor can prescribe a higher-strength pen with instructions for partial dosing. ### Is it safe? Dose splitting can be safe when done correctly. Always consult your doctor before starting. Use sterile technique: clean the injection site with an alcohol swab, attach a fresh needle for each injection, and follow the pen's storage instructions carefully. ### Which pen is best for dose splitting? The Ozempic pen is the easiest for dose splitting because it delivers a fixed 0.01 mg per click. This makes it straightforward to calculate the exact number of clicks for any target dose. Wegovy and Mounjaro pens can also be split, but the click values are less uniform. ### How do I count clicks accurately? Use the ClickDose app to count clicks automatically via your phone's microphone. Simply hold your phone near the pen while dialling, and ClickDose will display the count in real time. Alternatively, count manually in a quiet room — but this is more error-prone at high click counts. ### Can my doctor help with dose splitting? Yes. Many doctors are familiar with dose splitting and actively support it, especially when cost is a barrier to treatment. Your doctor can help you choose the right pen strength, calculate the correct number of clicks, and monitor your progress. Dose splitting is an off-label practice. This guide is for informational purposes only and does not replace medical advice. Always discuss dosing changes with your doctor or pharmacist before adjusting your treatment. --- Source: https://clickdose.io/en/about/index.html ## Who is behind ClickDose ClickDose is built by Tue Topholm, a software engineer and founder of Gaijin. Tue is not a medical doctor or pharmacist — he is a patient and family member who built the tool after seeing first-hand how hard it is to count clicks accurately by ear on a GLP-1 injection pen. ClickDose began as an open-source side project to help others using Wegovy, Ozempic, or Mounjaro — especially people splitting doses to make an expensive pen last longer, or titrating slowly to reduce nausea and other side effects. Today it is available in twelve languages, so people can count their clicks and read the supporting information in their own language wherever these medications are sold. ## Why ClickDose exists GLP-1 medications are expensive and, in many countries, in short supply. To cope, many people dose-split or titrate in small steps — but the prefilled pens are designed for a handful of fixed doses, not the amounts in between. On most pens, each "click" you hear while dialling corresponds to a fixed, known increment of medicine. If you can count those clicks reliably, you can dial a precise partial dose. Counting them by ear is surprisingly error-prone — which is exactly the problem ClickDose was built to solve. ## How it works — and your privacy ClickDose listens through your device's microphone, detects each pen click, and converts the count into a dose for your specific pen. The detection runs entirely on your device: your microphone audio and your dose calculations are never uploaded, shared, or stored on a server. ClickDose installs as a Progressive Web App and works offline. The site uses privacy-friendly, cookie-less analytics for aggregate page views only — it does not profile individuals or sell data. ## Independence and funding ClickDose is free, carries no ads, and is not affiliated with, endorsed by, or funded by Novo Nordisk (Wegovy, Ozempic) or Eli Lilly (Mounjaro), or any other manufacturer. The source code is open and publicly auditable on GitHub. There are no sponsorships or commercial relationships that could influence the health information published here. ## Our editorial process Health content on ClickDose follows these principles: - Every clinical claim is backed by a primary source — FDA prescribing information, EMA Summary of Product Characteristics (SmPC), or peer-reviewed studies. Sources appear at the bottom of each article. - Figures and statistics are quoted directly from the manufacturers' official documents (Novo Nordisk for Wegovy/Ozempic, Eli Lilly for Mounjaro). - Articles are updated when new label revisions are published, or when readers report errors. - ClickDose is not a medical device. All content is informational — always verify your dose visually on the pen and talk to your doctor. ## Seeking medical reviewer We are actively looking for a pharmacist or physician to review content before publication. If you are a relevant professional interested in collaborating (credited with name and title), please email tt@gaijin.dk. ## Contact Questions, factual corrections, or suggestions: tt@gaijin.dk.Source code and bug reports: github.com/ttopholm/click-counter. --- Source: https://clickdose.io/en/articles/choose-the-right-pen.html If you are splitting doses of Wegovy, Ozempic, or Mounjaro, choosing the right pen is one of the most important decisions you will make. Not all pens are created equal — they contain different concentrations of medication, different volumes, and deliver different amounts per click. Picking the wrong pen could mean you cannot reach your target dose, or that you waste expensive medication. This guide walks you through the key differences between pens and helps you find the best match for your prescribed dose. ## Why Concentration Matters Each click on an injection pen delivers a fixed amount of medication — but that amount varies from pen to pen. A higher-concentration pen delivers more medication per click than a lower-concentration one. This means two different pens can require very different click counts to deliver the same dose. When you are dose-splitting, you need to know exactly how many clicks correspond to your target dose. That is why the first step is always to identify which pen you have and what its concentration is. ## Wegovy Pens in Detail Wegovy (semaglutide) comes in four different pen strengths. Each pen has its own concentration and therefore its own milligrams-per-click value: | Pen | Volume | mg/click | Possible Doses | | 0.5 mg | 1.5 mL | 0.0134 | 0.25 mg or 0.5 mg | | 1 mg | 3 mL | 0.0134 | 0.5 mg or 1 mg | | 1.7 mg | 3 mL | 0.0227 | 1 mg or 1.7 mg | | 2.4 mg | 3 mL | 0.032 | 0.25 mg to 2.4 mg | The 0.5 mg pen and the 1 mg pen share the same concentration (0.0134 mg/click), but the 1 mg pen contains twice as much medication. Both are well suited for lower doses like 0.25 mg and 0.5 mg. The 1.7 mg pen has a higher concentration (0.0227 mg/click), making it a good choice if you are titrating up and need doses in the 1 mg to 1.7 mg range. The 2.4 mg pen is the most versatile. At 0.032 mg per click, it can deliver anything from 0.25 mg all the way up to the full 2.4 mg dose. If you are dose-splitting and want flexibility, the 2.4 mg pen is often the best option. ## Mounjaro Pens Mounjaro (tirzepatide) works a bit differently. All Mounjaro pens have exactly 60 clicks, regardless of strength. This makes the math straightforward: you choose the pen strength that matches your target dose, then calculate the number of clicks as a fraction of 60. For example, if you have a 5 mg pen and want 2.5 mg, you dial half the pen's clicks — that is 30 clicks. Always choose the pen strength closest to your desired dose for the best precision. ## Ozempic Pens Ozempic (also semaglutide, but dosed differently from Wegovy) has a consistent concentration of 0.01 mg per click across all pens. The difference between Ozempic pens is the maximum dose they can deliver. Choose your Ozempic pen based on the highest dose you need. Since all pens share the same concentration, the click calculation is identical — you just need to make sure the pen contains enough medication for your dose. ## Practical Advice for Choosing Your Pen - Match the pen to your dose: Choose a pen where your target dose falls within the pen's range. Do not use a pen that is too small for your intended dose. - Think about precision: Lower-concentration pens give you more clicks per milligram, making it easier to fine-tune doses. Higher-concentration pens require fewer clicks, but each click "counts for more." - Storage matters: A Wegovy pen can be used for up to 6 weeks after first use, as long as it is stored correctly (below 30 degrees Celsius, protected from light). When dose-splitting, it is important to track when you first opened the pen. - Reduce waste: If you dose-split from a larger pen, you get more doses per pen and reduce waste of expensive medication. ## Let ClickDose Do the Math You do not need to sit with a calculator and concentration tables. ClickDose shows you the exact number of clicks for any combination of pen and dose. Select your medication, choose your pen strength, and the app tells you precisely how many clicks to dial. This eliminates guesswork and reduces the risk of dosing errors — especially important when you are dose-splitting and precision is everything. --- Source: https://clickdose.io/en/articles/diet-and-exercise-on-glp1.html GLP-1 medications like Wegovy, Ozempic and Mounjaro help your body eat less and burn fat. But the medication alone is not enough. What you eat and whether you exercise has a major impact on whether you lose fat — or fat and muscle. This article gives you practical advice that is easy to follow, whether you are a beginner or an experienced exerciser. ## Why do you lose muscle during weight loss? When the body loses weight quickly, it is not only fat that disappears. Studies show that 20–40% of the weight lost during GLP-1 treatment can come from muscle mass. That might sound like a small percentage, but muscles matter: they keep your metabolism up, give you strength in daily life, and help you maintain your weight in the long run. The good news is that you can protect your muscles with two simple steps: eating enough protein and doing strength training. Research from Massachusetts General Hospital shows that patients who combine GLP-1 medication with regular resistance training and adequate protein intake can preserve the vast majority of their muscle mass. ## How much protein do you need? Protein is the most important nutrient when you are in weight-loss treatment. It keeps you full, requires energy to digest, and is the raw material your muscles are built from. A good rule of thumb is to aim for 1.2–1.6 grams of protein per kilogram of body weight per day. If you weigh 80 kg (176 lb), that is 96–128 grams of protein daily. As a minimum, you should eat at least 60 grams of protein per day, even if you are eating very little overall. Spread your protein intake across 3–4 meals and aim for 20–30 grams of protein per meal — this gives your body the best opportunity to build and maintain muscle continuously. ### Good protein sources - Chicken, turkey and lean beef - Fish and seafood (salmon, cod, shrimp) - Eggs and egg whites - Greek yoghurt, cottage cheese and skyr - Legumes (lentils, chickpeas, beans) - Tofu and tempeh ## What should you avoid? GLP-1 medication slows the rate at which the stomach empties — food stays in the stomach longer than usual. This means that fatty and fried foods can worsen side effects such as nausea, reflux and stomach discomfort. Avoid or limit: - Fried and high-fat foods (fries, fast food, fatty sauces) - Sugary drinks and sweets - Heavily processed foods with low nutritional value - Large portions — it is better to eat frequent, smaller meals - Alcohol — it irritates the stomach lining and can worsen side effects ## What should you eat more of? Prioritise foods that are nutrient-dense and filling, without containing too many calories. While on GLP-1 treatment, most people automatically eat less, so it is especially important that what you eat is of high quality. - Vegetables — packed with fibre, vitamins and minerals. Eat them with every meal. - Whole grains — oats, wholegrain bread and brown rice provide slow-release energy and fibre. - Healthy fats — avocado, nuts, olive oil and fatty fish support heart health. - Water — GLP-1 medication can reduce your sense of thirst. Actively drink at least 1.5–2 litres of water per day to avoid dehydration. ## Calorie intake: how little is too little? Many patients find that their appetite drops dramatically on GLP-1 medication. It is tempting to eat very little, but it is important not to go below 1,200 calories per day for women or 1,500 calories for men. Eating too little risks: - Accelerated muscle loss - Vitamin and mineral deficiencies - Fatigue and dizziness - A slowed metabolism in the long term Talk to your doctor or a dietitian if you are unsure about what you should be eating. ## Exercise: what works best? You do not need to become an athlete. But regular movement — particularly strength training — makes a significant difference to whether you lose fat or muscle. ### Strength training (2–4 times per week) Strength training is the most effective form of exercise for preserving and building muscle mass. It does not have to take place in a gym — bodyweight exercises (squats, push-ups, lunges) are perfectly adequate, especially at the start. Key principles: - Train the major muscle groups: legs, back, chest, shoulders and arms - Aim for 2–3 sets of 10–15 repetitions per exercise - Gradually increase resistance as you get stronger ### Cardiovascular exercise (2–3 times per week) Walking, cycling, swimming and dancing are excellent for your heart and fitness. Cardio burns calories and improves blood sugar — but it does not replace strength training when it comes to muscle preservation. Combine both types for the best results. ### Everyday movement counts too You do not only need to train in sets and series. Taking the stairs instead of the lift, walking to the shops and standing up from your desk once an hour all contribute to your overall activity level. Research shows that daily general activity has significant health benefits regardless of organised exercise. ## When will you feel the effects? Many people find that the first 4–8 weeks are the hardest to maintain good habits, as appetite is already low and fatigue can be an issue. Start gently and gradually increase the intensity. Even 10–15 minutes of strength training 2–3 times a week is better than nothing. After 2–3 months, most people notice that their energy levels rise, movement feels easier, and it becomes easier to maintain the routine. Remember: the medication helps you eat less — it is your diet and exercise that shape your body as you lose weight. ## A typical day Here is an example of how a day might look during GLP-1 treatment: - Breakfast: Greek yoghurt with berries and nuts + a glass of water (approx. 25 g protein) - Lunch: Chicken salad with avocado and vegetables (approx. 35 g protein) - Snack: Cottage cheese or a handful of nuts - Dinner: Salmon with steamed vegetables and quinoa (approx. 40 g protein) - Movement: 30 minutes of walking or strength training ## Summary GLP-1 medication is a powerful tool, but it works best in combination with the right diet and regular exercise. The most important advice: - Eat at least 1.2–1.6 g of protein per kg of body weight per day - Do strength training 2–4 times per week - Avoid fatty, fried and sugary foods - Drink enough water — at least 1.5 litres per day - Do not go below your minimum calorie intake - Combine cardio with strength training With these habits in place, you are well equipped to get the most out of your GLP-1 treatment — and to maintain the results in the long run. ## Sources - Massachusetts General Hospital — Fitness for People Taking GLP-1 Agonists - Frontiers in Clinical Diabetes (PMC) — GLP-1 agonists and exercise: the future of lifestyle prioritization - Mayo Clinic Diet — 5 ways to increase weight loss on Wegovy - Ohio State University Health — Foods to limit and prioritize on GLP-1 - ACE Fitness — GLP-1s and Lean Mass: What the Research Shows --- Source: https://clickdose.io/en/articles/dose-splitting-safety.html Dose-splitting — dividing a single injection pen into multiple smaller doses — has become common among users of GLP-1 medications like Wegovy, Ozempic, and Mounjaro. People do it to save money, to taper up slowly, or because their doctor has recommended a custom dose. But it is important to understand that dose-splitting is off-label use, and it requires careful technique to be done safely. ## What does "off-label" mean? When a medication is used off-label, it means it is being used in a way that the manufacturer did not design or seek regulatory approval for. Wegovy pens, for example, are designed as single-use pens — one pen, one dose, one injection. When you split the pen into multiple injections, you are using it in a way that Novo Nordisk has not tested in their clinical trials. This does not necessarily mean it is dangerous. Doctors prescribe off-label treatments every day in clinical practice. But it does mean that the responsibility falls more heavily on you and your prescriber, and that you should understand the risks involved. ## Sterility and hygiene The most important safety consideration when dose-splitting is sterility. Each time you insert a needle into the pen, you break the sterile seal. Here are the key rules: - Always use a new needle — never reuse needles between injections. A used needle can introduce bacteria into the pen. - Clean the rubber membrane with an alcohol swab before attaching a new needle. - Wash your hands thoroughly with soap and water before handling the pen. - Store the pen with the cap on and without a needle attached between uses to prevent contamination. - Do not use the pen if the liquid looks cloudy, discolored, or contains particles. ## Storage and shelf life A common question is how long a pen remains safe to use after first use. Here are the official guidelines: - Wegovy (the EU multi-dose FlexTouch pen) is stable for up to 6 weeks after first use at room temperature (below 30°C / 86°F) or in the refrigerator. In the US, Wegovy pens are single-dose and are discarded after one injection. - Ozempic can be stored after first use for up to 6 weeks according to the EU label — the US label allows up to 56 days (8 weeks) — at room temperature (below 30°C / 86°F) or in the refrigerator. - Mounjaro (the EU multi-dose KwikPen) can be stored for up to 30 days at room temperature (below 30°C / 86°F) after first use, and for no more than 4 doses. In the US, Mounjaro pens and vials are single-dose. These timeframes are critical when dose-splitting because the pen will be in use over a longer period. Keep track of the date of first use, and discard the pen when the shelf life has expired — regardless of whether medication remains. ## Proper technique When dose-splitting, you count clicks on the pen's dose knob to measure the precise dose. This requires concentration and accuracy: - Count slowly and carefully — each click should be distinctly felt and heard. - Always perform an air shot (priming) with a new needle before setting your dose. This removes air bubbles and ensures the needle is filled with medication. - Keep the needle in the skin for at least 6 seconds after injection to ensure the full dose is delivered. - Log your dose — write down how many clicks you used and when you injected. ## When NOT to dose-split Dose-splitting is not for everyone. You should avoid it in the following situations: - If your doctor advises against it — your prescriber's recommendation should always carry the most weight. - If you are unsure about the technique — incorrect dosing can have consequences. Have your doctor or pharmacist demonstrate the technique first. - If you have reduced fine motor skills — conditions such as neuropathy, tremor, or impaired vision can make it difficult to count clicks accurately. - If the pen is damaged — if the dose knob is hard to turn or the pen looks damaged, discard it. - If you have any doubts — it is always better to ask a professional than to guess. ## Talk to your doctor or pharmacist No matter how much you read online, you should always involve your healthcare provider. A doctor can help you: - Assess whether dose-splitting is appropriate for your specific situation - Determine the correct dose based on your treatment plan - Show you the proper technique and safety procedures - Monitor your treatment and adjust as needed Your pharmacist is also a valuable resource — they understand pen mechanics and can answer questions about storage and handling. ## A balanced perspective Many thousands of people dose-split GLP-1 medications every week without problems. When done correctly — with clean needles, proper storage, and accurate dosing — the risk is relatively low. But as with anything in medicine, it is important to take it seriously, understand the risks, and take proper precautions. ClickDose is designed to eliminate one of the biggest sources of error: manual click counting. By automating this step, you can focus on good technique and hygiene — the factors that truly matter for safety. ## References Content on this page has been reviewed for factual accuracy against the official prescribing information and summary of product characteristics listed below. - Novo Nordisk. Wegovy (semaglutide) Prescribing Information. FDA, revised 2023. accessdata.fda.gov - European Medicines Agency. Wegovy Summary of Product Characteristics. ema.europa.eu - Novo Nordisk. Ozempic (semaglutide) Prescribing Information. FDA. accessdata.fda.gov - European Medicines Agency. Ozempic Summary of Product Characteristics. ema.europa.eu - Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. FDA. pi.lilly.com - European Medicines Agency. Mounjaro Summary of Product Characteristics. ema.europa.eu --- Source: https://clickdose.io/en/articles/dose-titration.html When you begin treatment with a GLP-1 medication like Wegovy (semaglutide), Ozempic (semaglutide) or Mounjaro (tirzepatide), you always start at a very low dose and work your way up over several weeks or months. This is not arbitrary — it is a deliberate, evidence-based part of the treatment plan, designed to make the journey as safe and comfortable as possible. ## What is dose titration? Dose titration means starting at the lowest possible dose and increasing it at regular intervals until you reach the recommended maintenance dose. The approach is used with many types of medication, but it is particularly important for GLP-1 receptor agonists, because they affect the body in several ways simultaneously: they slow stomach emptying, influence satiety signals in the brain, and regulate blood sugar. ## Why not start at the full dose straight away? Clinical studies consistently show that gastrointestinal side effects from GLP-1 medications are directly dose-dependent: the higher the dose, the greater the risk of nausea, vomiting and diarrhoea. An analysis of the major STEP trials with semaglutide (published in the journal Obesity and cited in PMC) found that side effects occurred primarily during the dose-escalation phase and decreased significantly as the body adapted to each dose level. A dedicated clinical study of tirzepatide dose-escalation regimens (PMC, 2020) showed that a slower, step-by-step escalation resulted in significantly fewer gastrointestinal side effects compared to rapid escalation — and this finding directly informed the slower titration schedule used in the pivotal SURPASS trials. In short: your body needs time to adjust to the new hormonal signals, and dose titration is the way to give it that time. ## Wegovy and Ozempic: Dose titration schedule Semaglutide is injected once weekly. The titration schedule is designed to minimise side effects while the body adapts: | Week | Dose (Wegovy) | | Weeks 1–4 | 0.25 mg | | Weeks 5–8 | 0.5 mg | | Weeks 9–12 | 1.0 mg | | Weeks 13–16 | 1.7 mg | | Week 17 onwards | 2.4 mg (maintenance) | Ozempic follows the same titration pattern, but the maintenance dose is typically 1.0 mg or 2.0 mg depending on indication (diabetes vs. weight management) and individual response. Important: The 0.25 mg and 0.5 mg doses are titration doses only. They are not intended to produce significant weight loss — their purpose is to let the body adapt. Most people begin to experience noticeable satiety and weight loss from around 1.0 mg. ## Mounjaro: Dose titration schedule Tirzepatide acts on two receptors (GLP-1 and GIP) and is titrated over 20 weeks to reach the maintenance dose: | Week | Dose (Mounjaro) | | Weeks 1–4 | 2.5 mg | | Weeks 5–8 | 5 mg | | Weeks 9–12 | 7.5 mg | | Weeks 13–16 | 10 mg | | Weeks 17–20 | 12.5 mg | | Week 21 onwards | 15 mg (maintenance) | The longer Mounjaro titration — 20 weeks — reflects the fact that tirzepatide is a dual-agonist with a stronger effect profile, and the body benefits from a more gradual introduction. ## When does the medication start working? A common question is: "Is the medication even doing anything at the low starting dose?" The honest answer is: not fully — and that's by design. The initial doses are calibrated for tolerability, not maximum effect. Most people begin to experience meaningful satiety and initial weight loss from around 1.0 mg semaglutide and 5–7.5 mg tirzepatide. The full therapeutic potential is reached at the maintenance dose. According to the STEP 1 trial published in the New England Journal of Medicine, participants on 2.4 mg semaglutide achieved an average weight loss of 14.9% over 68 weeks — and the majority of that loss happened after they reached the maintenance dose. ## What to do if a dose increase is too tough You don't have to tough it out at all costs. The FDA-approved prescribing information provides official options for adapting the titration: - Delay a dose increase by up to 4 weeks if side effects are too disruptive. It is safe to stay at your current dose a little longer. - Temporarily reduce the dose: if you cannot tolerate Wegovy 2.4 mg, you may drop back to 1.7 mg for a period and then try again. - Talk to your doctor: for Mounjaro, your doctor can individualise the pace of titration. Slowing the titration is not a failure — it is a clinically recognised approach. In the STEP 1 trial, only 4.5% of participants discontinued treatment due to gastrointestinal side effects. The vast majority reached the maintenance dose, even if some needed more time. ## Practical tips during dose escalation - Eat smaller portions — your stomach empties more slowly, so large meals can cause discomfort. - Avoid fatty and fried foods around a dose increase — fat delays stomach emptying further. - Inject in the evening so you sleep through the period when side effects are typically strongest. - Stay well hydrated — dehydration worsens nausea. - Track your clicks — remember that the number of clicks on your pen changes with every dose step. ## Dose titration and click counting Keep in mind that your pen delivers a different number of clicks at each dose step. A Wegovy pen set to 0.25 mg requires fewer clicks than one set to 2.4 mg. ClickDose helps you track exactly which dose you are on — and counts correctly at every stage of your titration, so you never have to guess what you are injecting. ## Conclusion Dose titration is not a compromise — it is evidence-based medicine. The gradual escalation protects you from unnecessary side effects and increases the likelihood that you will complete the full course of treatment and achieve the maximum therapeutic benefit. Be patient with the process, and speak openly with your doctor if any step feels difficult. ## Sources - FDA — Wegovy (semaglutide) prescribing information 2024 - FDA — Mounjaro (tirzepatide) prescribing information 2022 - NEJM — STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity - PMC — Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg - PMC — Tirzepatide dose-escalation regimens: randomised clinical study (2020) - Mayo Clinic — Semaglutide (subcutaneous): dosing and side effects - Mayo Clinic — Tirzepatide (subcutaneous): dosing and side effects --- Source: https://clickdose.io/en/articles/glp1-and-alcohol.html Many people who start Wegovy, Ozempic, or Mounjaro report a surprising side effect: they drink far less alcohol than before. For some, the urge to pour a glass of wine at dinner almost completely disappears. For others, they simply stop after one drink instead of two or three. Is this a coincidence — or is there science behind it? ## How GLP-1 Affects the Brain's Reward System GLP-1 receptors are not only found in the gut and pancreas. They are also present in the brain, particularly in areas that control reward, craving, and impulse control — including the nucleus accumbens and the ventral tegmental area. These are the exact same brain circuits that are activated by alcohol, nicotine, sugar, and other potentially addictive substances. When semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro) binds to these receptors, it dampens the dopamine release that normally occurs in response to tempting stimuli. The result is that alcohol — and other "rewards" — simply becomes less appealing. This same mechanism is likely why many people on GLP-1 medications also report reduced cravings for sweets, fast food, and nicotine. ## What Does the Research Say? The research is still developing, but the findings so far are promising: - Real-world population study (2024): A large analysis of US patient data found that people taking semaglutide had a 50–56% lower risk of developing or relapsing into alcohol use disorder compared to patients on other anti-obesity medications — over a 12-month follow-up period. - Randomised clinical trial (2025): The first randomised, controlled trial of semaglutide in adults with alcohol use disorder found that participants receiving low-dose semaglutide drank significantly fewer drinks per drinking episode and reported lower weekly alcohol cravings. No serious adverse events or alcohol interactions were observed. - Animal studies: Laboratory experiments have shown that semaglutide reduces alcohol consumption across different drinking models and species, with the mechanism likely involving changes to GABA neurotransmission in the brain. It is important to note that GLP-1 medications are not yet approved to treat alcohol use disorder. The trials are promising, but larger studies are needed before this can be formally recommended. ## Is It Safe to Drink Alcohol on GLP-1 Medication? For most people, moderate alcohol consumption is compatible with GLP-1 treatment — but there are some important caveats: ### Risk of Low Blood Sugar Semaglutide and tirzepatide do not by themselves lower blood sugar enough to cause hypoglycaemia (low blood sugar). However, if you are also taking insulin or sulfonylureas (another type of diabetes medication), alcohol can increase the risk of dangerously low blood sugar. Alcohol inhibits the liver's glucose production, and the combination can in rare cases lead to hypoglycaemia — even many hours after drinking. ### Alcohol Can Worsen Nausea Nausea is one of the most common side effects of GLP-1 medications, especially during the start-up phase. Alcohol can significantly worsen this nausea. Many people find that they react much more strongly to alcohol than before — even a single drink can cause discomfort. ### Calories and Weight Loss Alcohol is calorie-dense (about 7 kcal per gram) and provides no nutritional value. High alcohol intake can slow your weight loss progress by adding empty calories and disrupting your appetite and food choices. ### Liver Health Severe obesity is often associated with fatty liver disease. Alcohol puts additional strain on the liver. Talk to your doctor if you have existing liver problems and are considering drinking alcohol during treatment. ## Practical Tips Here are some guidelines if you want to drink alcohol while on GLP-1 treatment: - Start cautiously: Your alcohol tolerance may have changed. Start with a small amount to see how you respond. - Eat first: Never drink on an empty stomach. Food slows alcohol absorption and reduces the risk of discomfort and low blood sugar. - Stay within guidelines: Follow your country's health authority recommendations for low-risk drinking — and aim for well below those limits while on medication. - Avoid alcohol during the start-up weeks: In the first 4–8 weeks on a new medication, your body is adjusting. Alcohol can make side effects worse during this period. - Tell your doctor: Always let your doctor know about your alcohol use, especially if you are taking other medications that affect blood sugar. ## What About People Who Struggle With Alcohol? For the many people who struggle with excessive alcohol consumption, the potential effects of GLP-1 medications are an exciting development. Research is currently underway to determine whether semaglutide could be approved as a treatment for alcohol use disorder. If you have concerns about your drinking, talk to your doctor — your GLP-1 treatment may already be helping, and additional support is available. ## Conclusion Many people on GLP-1 medications spontaneously notice reduced cravings for alcohol — and the research suggests this is no coincidence. Semaglutide and tirzepatide influence the brain's reward system in a way that dampens the urge to drink. For most people, moderate alcohol consumption is acceptable during treatment, but you should be aware of increased sensitivity, the risk of nausea, and — when combining with insulin — the risk of low blood sugar. Always talk to your doctor about your alcohol use. ## Sources - Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population — PMC/NIH (2024) - Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial — PMC/NIH (2025) - The GLP-1 analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission — PMC/NIH (2023) - Semaglutide (subcutaneous route) — Mayo Clinic --- Source: https://clickdose.io/en/articles/glp1-and-blood-pressure.html High blood pressure — hypertension — is one of the most common chronic conditions in the world. According to the WHO, over 1.28 billion adults live with elevated blood pressure, and many don't even know it. The condition dramatically raises the risk of heart attack, stroke, and kidney disease, and it is especially prevalent among people with obesity. That makes it particularly good news that the new generation of weight loss medications — GLP-1 receptor agonists — don't just help you lose weight. They also have a direct, well-documented effect on blood pressure. ## What is high blood pressure? Blood pressure is measured as two numbers: the systolic (the top number, when the heart contracts) and the diastolic (the bottom number, when the heart rests). Normal blood pressure is below 120/80 mmHg. Hypertension is diagnosed when blood pressure is consistently above 140/90 mmHg. Obesity is one of the strongest risk factors for hypertension. Research shows that losing one kilogram of body weight lowers systolic blood pressure by approximately 1 mmHg. Since GLP-1 medications can reduce body weight by 10–20 %, they naturally have a significant impact on blood pressure — but the benefits go even beyond weight loss. ## Does GLP-1 medication lower blood pressure? Yes — and the evidence is solid. In the major clinical trials with semaglutide (the STEP programme), systolic blood pressure fell by an average of 5–6 mmHg over 68 weeks. With tirzepatide (the SURMOUNT programme), reductions of 5–8 mmHg were observed, depending on the dose and study. That may not sound dramatic, but population studies show that a sustained 5 mmHg reduction in systolic blood pressure corresponds to roughly 10 % fewer deaths from heart attack and stroke. For people already at elevated cardiovascular risk, this is clinically very meaningful. ## Mechanisms: how does it happen? The blood-pressure-lowering effect likely involves several mechanisms acting simultaneously: ### Weight loss The most direct cause: the less you weigh, the less strain on your heart and blood vessels. Fatty tissue produces hormones and inflammatory substances that raise blood pressure. As weight decreases, this pressure gradually eases. ### Natriuresis — the kidney effect GLP-1 receptors are found in the kidney tubules, which regulate salt balance. Activating these receptors increases the excretion of sodium (salt) in the urine — a process called natriuresis. Less sodium in the body means lower blood volume and therefore lower blood pressure. This effect is independent of weight loss and appears early in treatment. ### Vasodilation — blood vessels relax GLP-1 affects the inner lining of blood vessels (the endothelium) and stimulates the production of nitric oxide (NO), which causes blood vessels to relax and widen. This reduces vascular resistance and lowers blood pressure — again independent of weight. ### Reduced sympathetic nervous system activity The sympathetic nervous system — the body's "fight or flight" system — increases heart rate and constricts blood vessels. Emerging research suggests that GLP-1 medications reduce sympathetic activity, contributing further to blood pressure reduction. ## What the major trials show ### The STEP programme (semaglutide) In STEP 1, the largest individual trial of semaglutide 2.4 mg for weight management, systolic blood pressure fell by an average of 5.1 mmHg compared with placebo over 68 weeks. Diastolic pressure fell by 1.1 mmHg. These results were consistent across the STEP trials. ### The SELECT trial (cardiovascular outcomes) The SELECT trial followed 17,604 overweight adults with established cardiovascular disease for up to four years. Semaglutide 2.4 mg reduced the risk of major cardiovascular events (cardiovascular death, heart attack, stroke) by 20 % compared with placebo. The sustained blood pressure reduction almost certainly contributed to this benefit. ### The SURMOUNT programme (tirzepatide) SURMOUNT-1 demonstrated systolic blood pressure reductions of 5.8–8.0 mmHg with tirzepatide, depending on dose (5, 10, or 15 mg). The higher the dose — and the greater the weight loss — the larger the blood pressure improvement. ## Who benefits most? The blood-pressure-lowering effect is greatest for people who: - Already have elevated blood pressure (the higher the starting point, the more room for improvement) - Lose the most weight during treatment - Take higher doses (semaglutide 2.4 mg rather than 0.5 mg; tirzepatide 15 mg rather than 5 mg) - Have metabolic syndrome (a combination of obesity, high blood sugar, high blood pressure, and abnormal blood lipids) If your blood pressure is already normal, the reduction will be more modest — and it may not be desirable to lower it further. ## Should I adjust my blood pressure medication? This is an important question. If you already take one or more blood-pressure-lowering medications (such as ACE inhibitors, ARBs, beta blockers, or calcium channel blockers), combining them with GLP-1 therapy can push blood pressure too low — a condition called hypotension. Signs of low blood pressure include dizziness (especially when standing up), fatigue, blurred vision, and palpitations. If you experience these symptoms, contact your doctor, who can assess whether your blood pressure medication needs to be reduced. However, never reduce your blood pressure medication on your own without speaking to your doctor first. A sudden spike in blood pressure can be dangerous. Plan regular blood pressure checks — home monitoring works well — and share the readings with your doctor at each visit. ## Practical tips for monitoring blood pressure during treatment - Measure consistently: Take your blood pressure at the same time each day — ideally in the morning, before medication and coffee. - Sit quietly for 5 minutes before measuring. Feet flat on the floor, arm at heart level. - Take two readings one minute apart and record the average. - Keep a log — so you can show your doctor a trend over time, not just individual readings. - Tell your doctor you have started GLP-1 medication, so they can review your other prescriptions. ## When will I notice the effect? Blood pressure reduction typically begins within the first 4–8 weeks of treatment, partly because the natriuretic (salt-excreting) effect kicks in quickly. The full effect builds gradually over months as weight loss accumulates. Most trials measure the primary outcome at 68 weeks (about 16 months). Note that nausea — common during the dose escalation phase in the first weeks — can cause mild dehydration, which may temporarily lower blood pressure further. Stay well hydrated. ## GLP-1 and blood pressure in type 2 diabetes High blood pressure is extremely common in type 2 diabetes — up to 70 % of people with diabetes have hypertension. Here GLP-1 medications play a dual role: they improve blood sugar control and lower blood pressure. Major trials such as LEADER (liraglutide) and SUSTAIN-6 (semaglutide) showed significant reductions in cardiovascular events, with blood pressure improvement being one of the contributing mechanisms. ## Sources - Wilding et al. (2021): Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine - Lincoff et al. (2023): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — New England Journal of Medicine - Jastreboff et al. (2022): Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine - WHO: Hypertension Fact Sheet - NHS: High blood pressure (hypertension) --- Source: https://clickdose.io/en/articles/glp1-and-bones.html Wegovy, Ozempic, and Mounjaro have generated enormous excitement — and for good reason. They deliver substantial weight loss, and the research shows impressive effects on everything from blood sugar control to heart health. But there is one side effect that often gets overlooked in the enthusiasm: what happens to your bones? The short answer is that GLP-1 medications can reduce bone density, and over time this may increase the risk of osteoporosis and fractures. This is not a reason to panic, but it is something worth knowing and planning for. In this article we walk through what the research shows, who is most at risk, and what you can do to protect your skeleton. ## What does the research show? In recent years, solid evidence has emerged that GLP-1 medications can have a negative impact on bone density. A 2024 randomized controlled trial (Hansen et al.) followed participants for 52 weeks and found that semaglutide reduced hip bone mineral density (BMD) by 2.6% and lumbar spine BMD by 2.1% compared to placebo. That may not sound like much, but for people who already have low bone density, even a small decline can have real consequences. A separate 2024 study published in JAMA (195 adults, 52 weeks) found an important and encouraging result: participants who combined GLP-1 treatment with regular exercise maintained their bone density — while those who took the medication without an exercise program saw it decline. This shows that exercise is not just a nice addition, but a genuine protective factor. A larger observational study of around 150,000 adults found that approximately 4% of GLP-1 users developed osteoporosis over the study period, compared to around 3% in the comparison group — a relative risk increase of roughly one third. It is not alarming in absolute terms, but it is a real difference worth being aware of. Wegovy's prescribing information also includes a notable warning: hip fractures were reported in 1% of women in the trial versus 0.2% on placebo — a fivefold difference in frequency, even though the absolute numbers are small. ## Why does GLP-1 medication affect bones? There are two main mechanisms at work: - Reduced mechanical load (Wolff's Law): Bones adapt to the forces placed upon them. When you weigh more, your bones carry more load — and therefore become denser and stronger. When you lose weight rapidly, that mechanical stimulus decreases, and the body gradually reduces bone mass because it "no longer needs it." This is the same mechanism that causes astronauts to lose bone density after months of weightlessness. - Reduced nutrient intake: GLP-1 medications dramatically reduce appetite — that is the point. But the unintended consequence is that many users eat too little calcium, vitamin D, and protein, all of which are essential for bone health. There is also some good news from the research: GLP-1 receptors are found directly on osteoblasts (the cells that build new bone), and some studies suggest that GLP-1 receptor agonists may have a direct positive effect on bone formation. The picture is therefore not entirely negative, and research in this area is ongoing. ## Who is most at risk? Not everyone needs to worry equally. The groups with the greatest reason to pay attention are: - Postmenopausal women: Estrogen protects bones, and after menopause this protective layer disappears. Women over 50 are therefore particularly vulnerable to additional bone loss. - Adults over 65: Bone density naturally decreases with age, and a GLP-1-related decline on top of that can push someone from "normal" into the osteoporosis range. - Those with already low bone density: If you are already in the at-risk zone for osteoporosis, talk to your doctor about how GLP-1 treatment might interact with your bone health. - People with limited physical activity: Lack of exercise removes the most important defense against bone loss during weight loss. ## How to protect your bones The good news is that bone loss during GLP-1 treatment is far from inevitable. Here are the most effective protective steps: - Resistance and weight-bearing exercise: This is the single most important factor. Strength training — using weights, machines, or your own body weight — stimulates bones to maintain and build density. The evidence is clear: GLP-1 plus exercise preserves bone. Aim for at least 2–3 sessions per week with exercises that load the hips, spine, and legs. - Adequate calcium: Most adults should aim for 1,000–1,200 mg of calcium per day from food (dairy products, leafy greens, fortified foods) — or from supplements if diet falls short. - Vitamin D: Vitamin D is essential for the body to absorb calcium. Deficiency is common, especially in northern latitudes during winter. Talk to your doctor about an appropriate supplement — typically 800–2,000 IU per day for adults. - Enough protein: Protein is not just important for muscles — it also plays a role in bone structure. Prioritize protein-rich foods even when appetite is low. - Avoid smoking and excessive alcohol: Both weaken bones and increase fracture risk. ## When to talk to your doctor It is always a good idea to mention bone health to your doctor when starting GLP-1 treatment — but it is especially important if you: - Are a postmenopausal woman or over 65 - Have a family history of osteoporosis or fractures - Have already been diagnosed with low bone density (osteopenia or osteoporosis) - Take medications that can affect bones (such as corticosteroids) Your doctor may consider ordering a DEXA scan (bone density measurement) at the start of treatment and again after a year to track changes. In some cases, bone-protecting medication may be appropriate alongside your GLP-1 treatment. ## Keeping perspective: the benefits still weigh heavily It is important to keep the bigger picture in mind. GLP-1 medications have well-documented benefits for obesity, type 2 diabetes, cardiovascular disease, and a wide range of related conditions — and the absolute risks of bone harm are relatively low for most users. Bone health is an area to monitor and actively protect, not a reason to avoid treatment altogether. With the right approach — regular exercise, good nutrition, and ongoing dialogue with your doctor — most people can continue treatment confidently while keeping their skeleton in good shape. ## Sources - PMC: Effects of GLP-1 agonists on bone health — systematic review - Frontiers in Aging: BMD pilot trial — GLP-1 and bone mineral density - NBC News: GLP-1s may increase risk of osteoporosis, new research finds - Drugs.com: Do GLP-1 drugs like Ozempic and Wegovy affect bone density? --- Source: https://clickdose.io/en/articles/glp1-and-brain.html Many people taking Wegovy or Ozempic report effects that seem to go well beyond the stomach. Reduced cravings — not just for food but also for alcohol and cigarettes. A strange quietness in the mind when it comes to thoughts about eating. Sometimes, a sharpening of focus that wasn't expected. These experiences are not coincidences. GLP-1 medications interact directly with the brain, and researchers are increasingly excited about what this means for long-term neurological health. ## Where in the brain are GLP-1 receptors found? GLP-1 (glucagon-like peptide-1) is a natural hormone produced primarily by the gut — but its receptors are found in key brain regions: - Hypothalamus: Controls hunger, satiety, and metabolic rate - Hippocampus: Central to memory formation and learning - Prefrontal cortex: Decision-making and impulse control - Amygdala: Emotional regulation and stress responses - Brainstem (nucleus tractus solitarius): Processes signals arriving via the vagal nerve from the gut Both semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) activate these receptors. Semaglutide in particular can cross or signal through the blood-brain barrier at low concentrations, making it especially interesting for neuroscientists studying brain disease. ## Why does appetite suppression happen in the brain? The most noticeable brain effect of GLP-1 medications is a change in how hunger is experienced. This happens via two main routes: - Direct: The drug binds to receptors in the hypothalamus, reducing hunger signals and increasing feelings of fullness - Indirect: The gut sends signals via the vagal nerve to the brainstem, which relays them into hunger and reward circuits This combined mechanism is why GLP-1 medications suppress appetite more effectively than simply eating smaller portions — they change how hunger and fullness are perceived at a neurological level. ## What happens in the brain's reward system? One of the most striking effects reported by patients — and supported by early research — is a change in the brain's dopamine-driven reward circuitry. The nucleus accumbens and prefrontal cortex, key reward centres, have abundant GLP-1 receptors. This connection helps explain several reported phenomena: - Reduced "food noise": The constant intrusive thoughts about food that many people with obesity describe simply become quieter - Reduced alcohol cravings: Multiple studies and the large SELECT cardiovascular trial found meaningful reductions in alcohol consumption among semaglutide users - Reduced nicotine and gambling urges: Early case reports and smaller studies suggest similar effects on other compulsive reward-seeking behaviours ## Does GLP-1 medication improve cognitive function? Many users describe experiencing a sense of "mental clarity" after starting GLP-1 therapy. The underlying mechanisms likely include: - Improved blood sugar regulation, reducing the "brain fog" associated with insulin resistance - Reduced systemic inflammation — including neuroinflammation — which may improve neural signalling - Direct effects of GLP-1 receptors in the hippocampus on memory consolidation and learning A 2024 observational study found that people with type 2 diabetes who used GLP-1 receptor agonists showed better cognitive performance over time compared to those on other diabetes medications. These are promising signals — but randomised controlled trials specifically targeting cognition are still needed to establish causation. ## GLP-1 and dementia — what does the research say? This is where the science is generating the most excitement. Several large studies published in 2023–2025 have suggested that GLP-1 receptor agonists may significantly reduce dementia risk: - A study published in Nature Medicine (2024), drawing on data from over one million patients, found that semaglutide was associated with a significantly lower risk of Alzheimer's disease compared to other weight-loss and diabetes medications - Analyses of UK Biobank data have suggested reduced incidence of both Alzheimer's and Parkinson's disease in long-term GLP-1 users The proposed mechanisms include: - Reduced neuroinflammation: GLP-1 receptors on microglia (brain immune cells) dampen inflammatory signalling - Improved brain insulin sensitivity: Insulin resistance in the brain is strongly linked to Alzheimer's disease risk - Reduced amyloid and tau accumulation: Some animal studies show GLP-1 agonists reduce buildup of the proteins associated with Alzheimer's pathology - Better cerebral blood flow: Via reductions in blood pressure and cardiovascular risk Crucially, these are observational studies and cannot prove that GLP-1 medications prevent dementia. Randomised controlled trials are in design or underway, and the field awaits their results with anticipation. ## GLP-1 and Parkinson's disease Parkinson's disease is caused by the progressive loss of dopamine-producing neurons in the substantia nigra — a brain region that expresses GLP-1 receptors. This has led researchers to ask whether GLP-1 medications could slow the disease's progression. The evidence so far is cautiously optimistic: - A Phase 2b trial using liraglutide, published in the New England Journal of Medicine in 2024, showed reduced decline in motor function on the MDS-UPDRS scale compared to placebo - Earlier trials with exenatide also showed promising signals for preservation of both motor and cognitive function - Larger Phase 3 trials with semaglutide in Parkinson's disease are now planned This remains one of the most active and closely watched research areas in neurology. ## What does this mean if you are taking GLP-1 medication? If you are using Wegovy, Ozempic or Mounjaro for weight management or type 2 diabetes: - The potential brain benefits are a possible bonus — but they are not the approved reason for taking these medications - Do not start GLP-1 therapy specifically for dementia prevention without discussing it with your doctor — the evidence is promising but not yet sufficient to recommend this - The "mental quieting" and reduced cravings many people experience are real, well-recognised phenomena linked directly to brain GLP-1 receptors - If you notice significant changes in mood, cognition, or behaviour while on treatment, mention them to your healthcare provider ## Conclusion The science of GLP-1 and the brain is moving remarkably fast. What began as a medication for blood sugar and weight is increasingly showing potential as a neurological medicine. The appetite-control effect is mechanistically understood. The reward-system effects explain many of the experiences patients report. And the early signals for neuroprotection — against dementia and Parkinson's — are generating genuine scientific excitement. Larger, well-designed clinical trials are needed to confirm these effects. But for people already on GLP-1 therapy, the possibility that the medication is also helping to protect the brain is an encouraging thought. Always speak to your doctor about your treatment and any concerns you have. ## Sources - Meissner WG et al. Trial of Liraglutide in Parkinson's Disease — NEJM (2024) - Lincoff AM et al. (SELECT trial). Semaglutide and Cardiovascular Outcomes in Obesity — NEJM (2023) - GLP-1 receptor agonists and dementia risk — observational cohort study (2024) - GLP-1 in the brain — review article, Nature Reviews Endocrinology (2023) --- Source: https://clickdose.io/en/articles/glp1-and-cholesterol.html High cholesterol is one of the most common chronic conditions worldwide. Around half of all adults have cholesterol levels that their doctor would want to improve — yet many people have no idea, because raised cholesterol rarely causes noticeable symptoms. Left unmanaged, it quietly promotes the build-up of fatty plaques in blood vessel walls, raising the risk of heart attack and stroke over the years. That makes it genuinely good news that the latest generation of weight-loss medications — GLP-1 receptor agonists — don't just help with weight. They also improve the full lipid profile directly, and the evidence is now robust across multiple large clinical trials. ## What is cholesterol, and which types are there? Cholesterol is a fatty substance that travels through the bloodstream bound to transport proteins called lipoproteins. The key types are: - LDL cholesterol (Low-Density Lipoprotein) — often called "bad" cholesterol. High levels promote the build-up of plaques inside arteries, increasing the risk of heart attack and stroke. - HDL cholesterol (High-Density Lipoprotein) — "good" cholesterol, which carries excess cholesterol back to the liver for processing. Higher HDL is generally protective. - Triglycerides — a type of fat stored as energy. Elevated triglycerides (above roughly 1.7 mmol/L) are linked to increased cardiovascular risk, especially when combined with low HDL. Together, these three measurements make up your "lipid profile," which your doctor uses to assess your overall cardiovascular risk. ## Do GLP-1 medications improve cholesterol? Yes — and the evidence is clear across multiple major studies. The headline figures look like this: - LDL cholesterol: falls by 3–8% (semaglutide ~3–4%, tirzepatide ~7–8%) - Triglycerides: fall by 20–28% — the most dramatic improvement - HDL cholesterol: rises by 6–10% The triglyceride reduction is particularly striking. A drop of 20–28% is comparable to what you'd expect from dedicated triglyceride-lowering drugs such as fibrates. For the many people with obesity or type 2 diabetes who have elevated triglycerides, this is an important bonus on top of the weight-loss benefit. ## The mechanisms behind the lipid effect Why do GLP-1 medications improve cholesterol? Several mechanisms work simultaneously: ### Weight loss The most straightforward reason: when you lose weight, your body burns fat and produces fewer triglycerides. Visceral fat — the fat stored around internal organs — is a major source of VLDL particles, which are converted to LDL in the bloodstream. Less visceral fat means fewer VLDL particles and therefore lower LDL and triglyceride levels. ### Direct suppression of hepatic VLDL production GLP-1 receptors are present in liver cells. When these receptors are activated, the liver's production of VLDL (Very Low-Density Lipoprotein) — the triglyceride-rich particles that are precursors to LDL — is reduced. This effect occurs independently of weight loss and is likely one reason why the triglyceride reduction is so pronounced. ### Improved insulin sensitivity Insulin resistance — very common in people with obesity — drives the overproduction of triglycerides and VLDL by the liver. When GLP-1 medications improve insulin sensitivity, this signal weakens, and the liver produces fewer triglyceride-rich lipoproteins. ### Slower gastric emptying reduces fat absorption GLP-1 slows the rate at which food leaves the stomach, meaning dietary fat is absorbed more gradually in the gut. This slower absorption reduces the sharp post-meal spikes in triglycerides that are damaging to blood vessels over time. ## What do the major studies show? ### STEP 1 (semaglutide 2.4 mg) The STEP 1 trial — published by Wilding et al. in the New England Journal of Medicine in 2021 — is the landmark randomised controlled trial for semaglutide 2.4 mg as a weight-loss treatment. Over 68 weeks with 1,961 participants, it showed: - Triglycerides: −23.8% compared with placebo - LDL cholesterol: −4.2% - HDL cholesterol: +6.2% Average body weight fell by 14.9% — and the lipid improvements were clearly present beyond what weight loss alone could explain. ### SURMOUNT-1 (tirzepatide) The SURMOUNT-1 trial — published by Jastreboff et al. in the NEJM in 2022 — studied tirzepatide, the newer dual agonist (GIP+GLP-1). The lipid results were even more striking: - Triglycerides: −22–24% depending on dose - LDL cholesterol: −7–8% - HDL cholesterol: +8–10% Tirzepatide's stronger LDL reduction is likely related to its dual receptor activity (GIP and GLP-1) and its larger weight loss — up to 20.9% of body weight at the highest dose. ### SELECT trial — the cardiovascular outcome The SELECT trial (Lincoff et al., NEJM 2023) followed 17,604 overweight adults with established cardiovascular disease for up to four years. Semaglutide 2.4 mg reduced the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% compared with placebo. The improvement in lipid profile — particularly the triglyceride reduction — is considered one of the contributing mechanisms behind this heart-protective effect. ## GLP-1 and statins — should I stop my cholesterol medication? The short answer is: no, do not stop your cholesterol medication without talking to your doctor. Statins (such as atorvastatin, rosuvastatin, and simvastatin) and GLP-1 medications work through different pathways and are complementary, not competing. Statins primarily lower LDL by inhibiting the liver's cholesterol production, while GLP-1 medications primarily reduce triglycerides and VLDL production. The combination can deliver a better overall lipid profile than either medication alone. Furthermore, statins have an extremely well-established track record of reducing cardiovascular events in people with existing heart disease — an effect that is stronger and more consistent than GLP-1 medications alone have demonstrated so far. Stopping your statin abruptly risks a rebound rise in LDL. Talk to your doctor if you are wondering about adjusting your cholesterol medications. It may be sensible to retest your lipid profile after 3–6 months on GLP-1 medication and then discuss whether your statin dose needs revisiting. ## Who benefits most? The lipid benefit is generally present for everyone using GLP-1 medications, but is greatest for: - People with elevated triglycerides at baseline — the higher the starting level, the more room for improvement - People with metabolic syndrome — the combination of obesity, raised blood sugar, high blood pressure, and abnormal blood lipids - Those on higher doses (semaglutide 2.4 mg rather than 0.5 mg; tirzepatide 15 mg rather than 5 mg) - Those who achieve a greater degree of weight loss, since part of the lipid effect is weight-mediated If your lipid levels are already in a healthy range, improvements will be more modest — but still present. ## Practical advice - Get your lipid profile checked before starting GLP-1 medication and again after 3–6 months. This gives you a clear picture of what the medication is doing for you specifically. - Diet adjustments help: A diet high in fibre (vegetables, legumes, oats) and low in saturated fat and added sugar amplifies the lipid benefit of the medication. - Alcohol raises triglycerides — cutting back on alcohol is one of the most effective ways to lower triglycerides and works synergistically with GLP-1 medication. - Tell your doctor that you are on GLP-1 treatment so they can review your overall cholesterol management and adjust statins if needed. - Do not stop statins on your own — even if your cholesterol numbers improve significantly. A gradual dose reduction under medical supervision is the right approach. ## Sources - Wilding et al. (2021): Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine - Jastreboff et al. (2022): Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine - Lincoff et al. (2023): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — New England Journal of Medicine - NHS: High cholesterol - Mayo Clinic: High cholesterol — symptoms and causes --- Source: https://clickdose.io/en/articles/glp1-and-constipation.html You may have heard that nausea is the most talked-about side effect of GLP-1 medications — but constipation is not far behind. Many people starting Wegovy, Ozempic or Mounjaro find that their bowel habits change noticeably in the first weeks of treatment. Stools become harder, less frequent, and sometimes difficult to pass. Understanding why this happens — and what you can do about it — can make a real difference to your comfort and confidence in continuing treatment. ## How common is constipation with GLP-1 medication? Constipation is one of the most frequently reported gastrointestinal side effects of GLP-1 receptor agonists. In the landmark STEP 1 trial (semaglutide 2.4 mg, the active ingredient in Wegovy), approximately 24% of participants reported constipation, compared to 11% in the placebo group. The SURMOUNT-1 trial for tirzepatide (Mounjaro) reported constipation rates of around 17–24% at higher maintenance doses. In practical terms: if you experience constipation on one of these medications, you are far from alone. It is a recognised, expected side effect — not a sign that something has gone seriously wrong. ## Why does GLP-1 medication cause constipation? GLP-1 receptors are found not only in the pancreas and brain, but throughout the gastrointestinal tract. When the medication activates these receptors, several things happen that slow the movement of food and waste through the bowel: - Slowed gastric emptying: GLP-1 reduces how quickly the stomach empties food into the small intestine. This is actually part of why you feel full for longer — but it also means the entire digestive process is delayed. - Reduced intestinal motility: GLP-1 receptors on smooth muscle cells in the large intestine slow the muscular contractions (peristalsis) that normally push stool towards the rectum. - Lower food intake: Because you eat significantly less on these medications, there is simply less bulk in the bowel. Less bulk means weaker signals for defecation. - Reduced fluid intake: Appetite suppression can also reduce the urge to drink, leading to mild dehydration — which causes the colon to absorb more water from stool, making it harder and more difficult to pass. These effects are dose-dependent: constipation is often most noticeable during dose escalations, when you have just stepped up to a higher strength. ## When does constipation typically start? Most people notice changes in bowel habits within the first two to four weeks of starting treatment, or shortly after a dose increase. This is consistent with the body adapting to GLP-1 activity in the gut. For some, constipation is only a temporary issue that resolves within a few weeks as the body adapts. For others, it can persist at a lower level throughout treatment — particularly if dietary habits and fluid intake do not change to compensate. ## What can you do about constipation? The good news is that constipation caused by GLP-1 medication is almost always manageable with the right approach. Here are the most effective strategies: ### 1. Drink more water This is the single most important change you can make. When stool stays in the colon longer, the colon absorbs more water from it — resulting in hard, dry, difficult-to-pass stools. Aim for at least 2–2.5 litres of water per day (more if you exercise or live in a warm climate). Set a reminder if you find yourself forgetting to drink. Herbal teas and diluted fruit juices also count. Limit caffeinated drinks and alcohol, which can dehydrate you further. ### 2. Eat more fibre Dietary fibre adds bulk to stool and helps it move through the intestine. Because you are eating less overall on GLP-1 medication, you may unintentionally consume less fibre. Make a conscious effort to prioritise fibre-rich foods: - Vegetables: broccoli, spinach, carrots, peas - Fruit: prunes, pears, apples (with skin), berries - Whole grains: oats, wholemeal bread, brown rice - Legumes: lentils, chickpeas, black beans Increase fibre gradually — a sudden large increase can cause bloating and gas. If you find it hard to get enough fibre through food alone, a psyllium husk supplement (mixed into a glass of water) is a gentle, well-tolerated option. ### 3. Keep moving Physical activity stimulates peristalsis — the wave-like contractions of the intestinal wall that move stool forward. Even a 20–30 minute walk each day can make a meaningful difference to bowel regularity. You don't need intensive exercise; gentle movement is enough to get things moving. ### 4. Consider a gentle laxative if needed If lifestyle changes alone are not sufficient, over-the-counter laxatives are safe to use alongside GLP-1 medication. The recommended first step is an osmotic laxative such as polyethylene glycol (PEG / Macrogol), which draws water into the bowel to soften stool. This is a very gentle option that is not habit-forming. Stool softeners (such as docusate) are another mild option. Avoid stimulant laxatives (such as bisacodyl or senna) as a first choice — they are stronger and better reserved for cases where milder options have not worked. Always speak to your doctor or pharmacist before starting any laxative if you are on other medications or have any underlying conditions. ## When should you contact your doctor? Most cases of constipation on GLP-1 medication are mild and manageable at home. However, you should seek medical advice if: - You have not had a bowel movement in more than 5–7 days - You experience severe or worsening abdominal pain - You notice blood in your stool - You feel bloated, sick or generally unwell alongside the constipation - Constipation is so severe that it is affecting your quality of life and home remedies are not helping In rare cases, severe constipation can lead to faecal impaction — a blockage that requires medical treatment. This is uncommon, but is the reason not to ignore prolonged, severe constipation. ## Can a dose adjustment help? If constipation is severe or significantly affecting your daily life, it is worth discussing your dose schedule with your doctor. Slowing the pace of dose escalation — or temporarily staying at a lower dose — can give the gut more time to adapt and often reduces the severity of gastrointestinal side effects, including constipation. This is a recognised and accepted strategy in clinical practice. Never adjust your dose without first consulting your prescribing doctor. ## Does constipation eventually go away? For many people, constipation improves significantly after the first few weeks as the body adapts to the medication. Symptoms are often most pronounced in the early weeks and after each dose increase. Once you reach your maintenance dose and your gut has adjusted, bowel habits often normalise — especially if you maintain good hydration and fibre intake. A proportion of people do experience persisting mild constipation throughout treatment. With the right dietary habits, this can usually be managed comfortably without significantly impacting wellbeing. ## Medical disclaimer This article is intended for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare professional regarding your specific treatment, symptoms, or concerns. Do not adjust your medication without medical guidance. ## Sources - STEP 1 Trial — Semaglutide 2.4 mg for Weight Management, NEJM (2021) - SURMOUNT-1 Trial — Tirzepatide for Obesity, NEJM (2022) - NHS — Side effects of semaglutide (Wegovy) - Gastrointestinal effects of GLP-1 receptor agonists — PMC review (2023) - FDA Prescribing Information — Wegovy (semaglutide) injection --- Source: https://clickdose.io/en/articles/glp1-and-energy-levels.html You started Wegovy, Ozempic or Mounjaro feeling hopeful — and then, a few days in, you hit a wall of exhaustion. You feel heavy, unmotivated, and wonder whether something is wrong. You are far from alone. Fatigue and low energy are among the most frequently reported experiences in the early weeks of GLP-1 treatment, and understanding why it happens makes it much easier to manage. ## Why am I so tired on GLP-1 medication? There is no single reason — several things happen at once when you start or increase your dose: ### You are eating significantly less GLP-1 medications are highly effective at reducing appetite and slowing gastric emptying. Within days, most people eat noticeably less — sometimes without even trying. This caloric deficit is the primary driver of weight loss, but it also means your body receives less fuel than it is used to. The result is predictable: you feel tired. This is the same fatigue many people experience at the start of any calorie-restricted diet. ### Nausea reduces what you can eat Nausea is the most common side effect of GLP-1 medications, affecting up to 40–50% of users in the early weeks. When nausea is present, eating becomes difficult — and the foods you can manage may not be the most nutritious. Insufficient calories combined with poor nutritional quality can compound feelings of fatigue significantly. ### Blood sugar stabilises — and that feels different Before starting GLP-1 treatment, many people had patterns of blood sugar spikes and crashes, particularly after meals. These fluctuations can create short bursts of energy followed by pronounced dips. GLP-1 medications smooth this out substantially — which is beneficial, but the new, flatter rhythm can feel unfamiliar. Some people interpret the absence of energy spikes as low energy, when in reality their blood sugar is simply more stable. ### Your body is adapting its metabolism When you eat significantly less, your body gradually shifts from relying primarily on glucose to burning more fat for fuel — a process sometimes called metabolic adaptation. During this transition, which typically takes two to four weeks, your cells are essentially relearning how to operate efficiently on a different energy substrate. During this period, fatigue is common and physiologically normal. ### Dehydration plays a role People on GLP-1 medication often drink less than usual, partly because reduced hunger extends to reduced thirst, and partly because nausea can make drinking uncomfortable. Mild dehydration — even as little as 1–2% of body weight — can cause fatigue, headaches and difficulty concentrating. It is a surprisingly overlooked factor. ## Does the fatigue get better? For the vast majority of people, yes — and fairly quickly. In the STEP 1 clinical trial with semaglutide (the active ingredient in Wegovy and Ozempic), fatigue was reported most frequently in the first four weeks and diminished significantly over the following months. By month three, most participants reported fatigue at rates similar to the placebo group. After the adaptation period, many people actually report more energy than before treatment — largely because losing weight reduces the physical burden on the body, improves sleep quality, and in many cases improves sleep apnea, a condition that causes significant daytime fatigue. ## What can you do to improve your energy levels? ### 1. Prioritise protein at every meal When your overall food intake drops, protein is the nutrient most at risk of falling short. Yet protein is essential not just for muscle maintenance but also for energy metabolism. Aim for at least 1.2–1.6 grams of protein per kilogram of body weight per day. In practice, this means making protein the centrepiece of every meal and snack — eggs, Greek yogurt, chicken, fish, legumes and cottage cheese are all excellent choices. If nausea makes eating difficult, cold, protein-rich foods such as yogurt or a protein shake are often better tolerated than hot meals. ### 2. Stay well hydrated Set a conscious goal of drinking at least 1.5–2 litres of water or other non-caffeinated fluids per day. If nausea makes plain water unappealing, try sparkling water, diluted fruit juice, or warm broth. Carrying a water bottle serves as a useful visual reminder to keep drinking throughout the day. ### 3. Move gently — even when you don't feel like it It may seem counterintuitive to exercise when you feel tired, but gentle movement — a 20-minute walk, light stretching, or yoga — stimulates circulation and reliably improves energy levels in the short term. Avoid high-intensity exercise in the early weeks, as this can worsen fatigue when your caloric intake is reduced. As your body adapts and your energy returns, gradually reintroduce more demanding workouts. ### 4. Protect your sleep Sleep is when the body repairs itself and regulates energy systems. If you are sleeping poorly, fatigue on GLP-1 medication will be significantly worse. Keep a consistent sleep schedule, limit screen exposure in the hour before bed, and keep your bedroom cool and dark. If you suspect sleep apnea — which is very common in people with obesity and often goes undiagnosed — speak to your doctor, as GLP-1 treatment itself can improve or resolve it over time. ### 5. Consider your injection timing Many people report feeling their worst in the first 24–48 hours after their weekly injection. Some find that injecting in the evening means the peak side-effect period overlaps with sleep, reducing its impact on daily functioning. Talk to your doctor before changing your injection day, but it is a simple adjustment worth exploring if fatigue consistently peaks after your shot. ### 6. Consider electrolytes When eating and drinking less, it is easy to fall short on electrolytes — particularly sodium, potassium and magnesium. Low electrolyte levels can cause fatigue, muscle weakness and brain fog. A pinch of salt in water, a banana, or a magnesium supplement may help. If in doubt, mention it to your doctor or a dietitian. ## When should you contact your doctor? Most fatigue in the early weeks of GLP-1 treatment is a normal part of the adaptation process. However, you should contact your healthcare provider if: - Fatigue is severe enough to prevent you from carrying out daily activities - Fatigue persists beyond three months of treatment - You notice unusual symptoms alongside fatigue, such as rapid heartbeat, shortness of breath, severe dizziness, or yellowing of the skin - You are losing weight so rapidly that you suspect you are not eating enough to sustain basic functioning Your doctor can check for other potential causes of fatigue — such as thyroid dysfunction, anaemia, or vitamin B12 deficiency — that can sometimes coexist with GLP-1 treatment and are easily identified with a blood test. ## What does the long term look like? The good news is encouraging. As weight loss progresses, most people experience meaningful improvements in energy and overall vitality. Carrying less body weight reduces the physical effort of everyday movement. Improved metabolic health means the body is using energy more efficiently. And for many, better sleep — including resolution of sleep apnea — creates a compounding positive effect on how alert and energised they feel each day. Think of the first few weeks as the price of entry: a temporary period of adaptation that the majority of people move through and leave behind. ## Conclusion Fatigue on GLP-1 medication is real, common, and — for the majority of people — temporary. It is driven by eating less, potential nausea, metabolic adaptation and sometimes mild dehydration. With adequate protein, hydration, gentle exercise and good sleep habits, most people find their energy stabilises within one to three months. If fatigue is severe or prolonged, always discuss it with your doctor. This article is for general information only and does not constitute medical advice. Always consult your doctor or pharmacist about your treatment. ## Sources - Wilding et al. — STEP 1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity — NEJM (2021) - NHS — Obesity treatment options including GLP-1 medications - FDA prescribing information for semaglutide (Wegovy) - GLP-1 receptor agonists and fatigue — review of adverse event profiles — PMC (2023) - Mayo Clinic — GLP-1 receptor agonists: What to expect --- Source: https://clickdose.io/en/articles/glp1-and-eye-health.html If you take Wegovy or Ozempic, you may have heard about new warnings regarding eye health. In September 2024, the FDA updated the safety labels of both medications to include a warning about a rare but serious eye condition. For many people, this news came as a surprise — and understandably raised questions. Here is a clear, honest look at what the research actually shows, who is most at risk, and what practical steps you can take. ## What is NAION and what does the research show? NAION stands for Non-Arteritic Anterior Ischemic Optic Neuropathy. It is a condition where blood flow to the optic nerve is suddenly reduced, causing painless but rapid vision loss — usually in one eye, and often noticed upon waking. Unfortunately, the vision loss is permanent in most cases. In 2024, a study published in JAMA Ophthalmology (Hathaway et al.) found that people with type 2 diabetes taking semaglutide — the active ingredient in Ozempic and Wegovy — had approximately four times higher risk of developing NAION compared to those taking other diabetes medications. A separate study in Ophthalmology Science found similar results. This sounds alarming — but context is essential. NAION is a rare condition, affecting roughly 2 to 10 people per 100,000 per year in the general population. A fourfold relative increase still means the absolute risk remains very low for most people. The studies were also observational, meaning they identify an association rather than a proven cause-and-effect relationship. That said, the FDA considered the evidence significant enough to update the safety labeling for Ozempic and Wegovy in September 2024. Why might GLP-1 medications affect the eye at all? Researchers have found that GLP-1 receptors are present in the eye — including in retinal cells. The exact mechanism behind a potential NAION link is not yet fully understood and remains an active area of research. ## Who is most at risk? Not everyone on GLP-1 medication faces the same level of risk. People most likely to develop NAION tend to share certain characteristics: - Small optic disc with little cup-to-disc ratio — sometimes called an "at-risk disc". This is a structural feature only an eye doctor can identify, and it is the single strongest risk factor. - Pre-existing cardiovascular disease — reduced blood flow elsewhere in the body may affect optic nerve blood supply too. - High blood pressure (hypertension) — a known risk factor for NAION in general. - Sleep apnea — causes repeated drops in overnight oxygen levels, which can affect optic nerve health. - Being male and over 50 — NAION is more common in this group overall. - A previous episode of NAION in the other eye — significantly raises the risk of a second event. If several of these risk factors apply to you, it is especially worth discussing eye health with your doctor before starting or continuing GLP-1 treatment. ## What about diabetic retinopathy? There is a separate eye concern specifically for people with diabetes: diabetic retinopathy. This is damage to the tiny blood vessels in the retina caused by long-term elevated blood sugar — and it affects a significant proportion of people with type 2 diabetes. When blood sugar drops quickly — as it can when starting or intensifying GLP-1 therapy — existing retinopathy can temporarily worsen. This was observed in the SUSTAIN-6 clinical trial, where 3.0% of patients taking semaglutide experienced retinopathy complications, compared to 1.8% in the placebo group. This effect is most relevant for people who already have poorly controlled diabetes and established retinopathy. The rapid drop in blood sugar, rather than the medication itself, appears to be the key driver. People without pre-existing retinopathy are at much lower risk of this particular complication. ## Are there also benefits for eye health? Yes — and this is an important part of the picture. Over the long term, improved blood sugar control dramatically reduces the risk of developing diabetic retinopathy in the first place. For people with type 2 diabetes, this is one of the most meaningful long-term benefits of GLP-1 treatment. The presence of GLP-1 receptors in retinal cells also suggests the medication may have direct protective effects on eye tissue. Some research points to anti-inflammatory properties of GLP-1 drugs that could benefit the retina over time. This area of research is still developing, but the early signals are encouraging. In short: GLP-1 medications carry both potential short-term eye risks (particularly for people with existing retinopathy or NAION risk factors) and meaningful long-term eye benefits (through better blood sugar control and possible direct protective effects). ## What should you do? The good news is that there are clear, practical steps you can take to protect yourself: - Get a baseline eye exam before starting treatment. Tell your eye doctor you are starting Wegovy, Ozempic, or Mounjaro. They can check for an at-risk optic disc and assess whether you have any existing retinopathy. This information helps your healthcare team make the best decisions for you. - Report any sudden vision changes immediately. If you notice sudden blurring, darkening, or loss of vision in one eye — even briefly — contact a doctor or eye specialist the same day. Time matters with NAION. Do not wait for a scheduled appointment. - Keep up with regular diabetic eye screening. If you have diabetes, annual eye checks should already be part of your care. Keep these appointments — and let your eye doctor know about your GLP-1 medication and any recent dose changes. ## Should you stop your medication? For most people, no. The overall benefit-risk profile of GLP-1 medications remains strongly positive. These medications reduce cardiovascular events, lower blood sugar, support significant weight loss, and may protect organs including the kidneys and liver. The absolute risk of NAION, while real and worth taking seriously, remains low for most users. However, if you have multiple risk factors for NAION — especially a confirmed at-risk optic disc or a prior NAION event in one eye — it is worth having an open conversation with your doctor about whether to continue, pause, or adjust your treatment. Do not make that decision alone or stop medication suddenly without medical advice. ## Conclusion GLP-1 medications and eye health is a topic that deserves attention — but not panic. The FDA warning about NAION is there for a reason, and the research linking semaglutide to increased NAION risk is real. At the same time, for most people taking Wegovy, Ozempic, or Mounjaro, the benefits of treatment are substantial and the absolute risk of serious eye complications is still low. The most important thing you can do is be informed: get an eye check before you start, keep your follow-up appointments, and seek help immediately if your vision changes suddenly. Working with your healthcare team — and knowing what to watch for — puts you in the best possible position. Always speak to your doctor if you have concerns about eye health during your treatment. ## Sources - Hathaway et al., JAMA Ophthalmology 2024 — Semaglutide Use and NAION - FDA safety communication — September 2024 labeling update for Ozempic and Wegovy - SUSTAIN-6 retinopathy data review — NIH/PMC - EMA — Ozempic product information --- Source: https://clickdose.io/en/articles/glp1-and-fatty-liver.html Fatty liver disease is one of the most common liver conditions in the world — and most people who have it don't know it. New research shows that GLP-1 medications like Wegovy, Ozempic, and Mounjaro don't just help with weight loss: they can directly treat fatty liver disease and prevent it from progressing into something far more serious. In this article, we explain what fatty liver disease is, why it matters, and what the latest clinical trials show about GLP-1 medications and liver health. ## What is fatty liver disease? Fatty liver disease — now officially called MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) — is a condition where fat builds up inside liver cells. It was previously known as NAFLD (Non-Alcoholic Fatty Liver Disease). It has nothing to do with alcohol; the cause is typically obesity, type 2 diabetes, elevated cholesterol, or metabolic syndrome. Fatty liver disease affects an estimated 25–30% of the Western population. Most people have no symptoms and discover it by chance during a blood test or scan. ## MASLD vs MASH — what's the difference? Fatty liver disease exists in two stages: - MASLD (simple fatty liver): Fat in liver cells but no significant inflammation. Relatively harmless, but can progress. - MASH (Metabolic Dysfunction-Associated Steatohepatitis): Fatty liver with inflammation and liver cell damage. This is the serious form, which over time can lead to scarring (fibrosis), cirrhosis, and in rare cases liver cancer. An estimated 20% of people with MASLD develop MASH, and of those, a significant proportion risk developing severe fibrosis. This makes early treatment of MASH important. ## How do GLP-1 medications affect the liver? GLP-1 receptors aren't only found in the pancreas and brain — they also exist in liver cells. When semaglutide or tirzepatide activates these receptors, several things happen at once: - Less fat accumulates in the liver — the medication reduces the amount of fat the liver receives from fat tissue and from food. - Better insulin sensitivity — improved insulin response reduces the liver's overproduction of fat (lipogenesis). - Reduced inflammation — GLP-1 medication directly lowers inflammatory markers in liver tissue. - Less scarring — studies suggest the medication can slow or partially reverse liver fibrosis. Crucially, a large part of these effects occur beyond weight loss — the medication appears to act on the liver directly. ## SYNERGY-NASH: tirzepatide and MASH In 2024, the New England Journal of Medicine published the results of the SYNERGY-NASH trial — a phase 2 study testing tirzepatide (Mounjaro) in adults with biopsy-confirmed MASH and moderate to severe fibrosis (stage F2–F3). The results were striking. After 52 weeks, MASH resolution was achieved by: - 51.8% in the tirzepatide 5 mg group - 62.8% in the tirzepatide 10 mg group - 73.3% in the tirzepatide 15 mg group - 13.2% in the placebo group In addition, approximately 51% of participants in the highest dose group achieved at least one stage of fibrosis improvement. These are remarkable numbers compared to most other available treatments. ## ESSENCE: semaglutide and MASH Semaglutide (the active ingredient in Wegovy and Ozempic) was also studied in the large phase 3 ESSENCE trial. The study followed patients with MASH and fibrosis (stage F2–F3) over 72 weeks using weekly injections of semaglutide 2.4 mg. For the first time in a phase 3 trial, semaglutide achieved a significant improvement in fibrosis — without worsening MASH. This breakthrough led the FDA to approve semaglutide for MASH with fibrosis in August 2025. Tirzepatide has likewise received FDA approval for MASH based on the SYNERGY-NASH results, making it the second approved medication — after resmetirom (Rezdiffra) — for this condition. ## Who benefits most? Those most likely to benefit from GLP-1 treatment for fatty liver include people with: - Confirmed MASLD or MASH (diagnosed by scan or biopsy) - Type 2 diabetes and fatty liver — a very common combination - Obesity with elevated liver enzymes (ALT, AST) - Metabolic syndrome (elevated blood sugar, blood pressure, cholesterol, and obesity) If your doctor has told you your liver enzymes are elevated, it's worth asking whether GLP-1 medication might be relevant for you. ## What GLP-1 medication cannot do It's important to have realistic expectations. GLP-1 medication is not a guarantee against developing cirrhosis or liver cancer. Studies show that treatment can reverse and slow the disease for many people — but not everyone responds, and the effect depends on disease stage, lifestyle, and other treatments. Alcohol significantly worsens fatty liver and should be minimised during treatment. Diet, exercise, and weight loss still play a central role. ## What does this mean for your treatment? Many people on Wegovy, Ozempic, or Mounjaro will find that liver fat decreases within the first few months — even before significant weight loss occurs. If you've been diagnosed with fatty liver disease, GLP-1 medication can therefore offer a double benefit: you lose weight and your liver improves. Talk to your doctor about whether your treatment is optimally structured for liver health — and use tools like ClickDose to ensure you're injecting exactly the dose you've been prescribed. ## Sources - Loomba R et al. — SYNERGY-NASH: Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. NEJM, 2024 - PMC Meta-analysis: GLP-1 Receptor Agonists Improve MASH and Liver Fibrosis (2025) - PMC: Outbreak of MASH pharmacotherapies in 2024 — from resmetirom to tirzepatide - PMC Review: GLP-1 Receptor Agonists — Mechanism of Action and Emerging Landscape in MASLD (2025) - VCU Health: What's new in treating MASH and liver fibrosis? --- Source: https://clickdose.io/en/articles/glp1-and-fertility.html Few side effects of GLP-1 medication have generated as much media attention as unexpected pregnancies — the so-called "Ozempic babies". Behind the headlines lies a more nuanced story about how these medications interact with reproductive health: sometimes improving it, sometimes requiring careful planning around it. Whether you are currently taking Wegovy, Ozempic or Mounjaro and want to understand what this means for your fertility, or whether you are planning a future pregnancy and wondering how to time things, here is a thorough and honest overview. ## Can GLP-1 medication improve fertility? Yes — particularly for women whose fertility challenges are linked to excess weight or PCOS (polycystic ovary syndrome). The connection works primarily through weight loss: adipose tissue (body fat) produces oestrogen-like compounds and disrupts insulin signalling, which can suppress ovulation. When significant weight is lost, this hormonal environment often normalises and ovulation can resume — sometimes for the first time in years. Beyond weight loss, GLP-1 receptors are also present directly in reproductive tissue, including the ovaries, endometrium (uterine lining), and testes. This raises the possibility that semaglutide and tirzepatide may have additional direct effects on reproductive biology, though research in this area is still emerging. What is well established is that women living with obesity and irregular cycles who begin GLP-1 treatment often experience restored menstrual regularity within months — which can come as a surprise if they had previously believed pregnancy was unlikely. ## What are "Ozempic babies"? "Ozempic babies" is the popular term for the unexpected pregnancies reported by women taking GLP-1 medication. Women who believed themselves to be infertile — or who were simply not focused on contraception — found themselves pregnant after starting Wegovy or Ozempic. There are at least two mechanisms that help explain this: - Restored ovulation: Weight loss from GLP-1 treatment can re-activate ovulation in women who had stopped ovulating due to obesity-related hormonal disruption. If a woman and her doctor were not expecting this, contraception may not have been in place. - Reduced contraceptive pill absorption: GLP-1 medication slows gastric emptying (the rate at which food and pills leave the stomach), which can reduce how much of an oral contraceptive pill is absorbed into the bloodstream. This effect appears to be most pronounced during the first weeks of treatment and may make hormonal contraception temporarily less reliable. If you take oral contraceptives and are starting GLP-1 treatment, it is worth discussing a backup contraceptive method with your doctor — at least for the first few months. ## GLP-1 and PCOS — a particularly important connection PCOS is the most common endocrine disorder in women of reproductive age and one of the leading causes of difficulty conceiving. Insulin resistance — present in the majority of women with PCOS — is a central driver of the hormonal imbalance that leads to irregular or absent ovulation. GLP-1 receptor agonists, particularly semaglutide, have shown promising results in clinical studies of women with PCOS. A study published in the Journal of Clinical Endocrinology & Metabolism found that semaglutide significantly reduced BMI, testosterone levels, and insulin resistance in women with PCOS, and improved menstrual regularity. Some participants experienced regular menstrual cycles restored for the first time in years. This does not mean GLP-1 drugs are a dedicated fertility treatment — but the metabolic improvements they produce can create a hormonal environment in which pregnancy becomes possible. For women with PCOS who are trying to conceive, GLP-1 treatment may be one piece of a broader care plan, ideally coordinated between an endocrinologist and a gynaecologist or fertility specialist. ## What about male fertility? Less research exists on GLP-1 and male reproductive health, but there are reasons to pay attention. GLP-1 receptors have been identified in testicular tissue in animal studies, suggesting a potential direct role in sperm production or function. Human clinical data in this area is still limited. What is well established is that obesity in men is associated with lower testosterone levels, reduced sperm quality, and impaired sperm motility. Weight loss — through GLP-1 medication or other means — has been shown in studies to improve these parameters. A large meta-analysis found that weight reduction in men with obesity led to significant improvements in testosterone levels and semen quality. If you are a man using GLP-1 medication and fertility is a consideration, it is worth discussing your individual situation with your doctor, as the data are still evolving. ## Should you stop GLP-1 before trying to conceive? Yes — this is a clear and consistent recommendation from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are contraindicated during pregnancy. Animal studies have demonstrated fetal harm at clinically relevant doses, including reduced fetal growth and skeletal malformations at high exposures. While no large human studies have confirmed these risks, the precautionary principle applies strongly here. Current guidance is: - Stop GLP-1 medication at least two months before attempting to conceive. Semaglutide has a half-life of approximately one week, but the two-month washout period gives ample time for the drug to fully clear your system. - If you become pregnant while taking GLP-1 medication, stop it immediately and contact your doctor or obstetrician. Early accidental exposure does not necessarily cause harm, but continuation is not recommended. - Plan ahead with your healthcare team. Stopping GLP-1 medication means the weight-related benefits pause, and some weight regain is possible. Your doctor can help you plan nutritional and lifestyle strategies to maintain progress during the period before and during pregnancy. ## Practical guidance by situation Here is a brief summary depending on where you are: - Taking GLP-1 and not planning pregnancy now: Ensure your contraception is reliable. If you use oral contraceptives, consider a backup method especially in the first months of treatment. Discuss with your doctor. - Taking GLP-1 and planning pregnancy in the future: Discuss timing with your doctor. Plan to stop GLP-1 at least two months before you start trying, and develop a plan for maintaining metabolic health during and after pregnancy. - Have PCOS and want to improve fertility: GLP-1 treatment may significantly help — but coordinate closely between your prescribing doctor and your gynaecologist or fertility specialist. - Have become pregnant while on GLP-1: Stop the medication immediately and contact your obstetrician. Most early exposures do not result in harm, but your doctor needs to know. ## Medical disclaimer This article is for general informational purposes only and does not constitute medical advice. Always consult your doctor or specialist before making any changes to your treatment. GLP-1 medications should only be used under medical supervision. Guidance on fertility and pregnancy is particularly individual — please work with your healthcare team to make the right decision for your specific situation. ## Sources - EMA — Ozempic Product Information (semaglutide), including pregnancy guidance - FDA — Wegovy prescribing information, pregnancy and lactation section - Jensterle et al. — Semaglutide in PCOS: effects on metabolic and reproductive parameters — PMC (2022) - GLP-1 receptors in the female reproductive system — review — PMC (2023) - Weight loss and male reproductive health: testosterone and semen quality — meta-analysis — PMC (2023) - "Ozempic babies" — unexpected pregnancies linked to weight loss medication — BMJ (2024) --- Source: https://clickdose.io/en/articles/glp1-and-food-noise.html If you have ever started treatment with a GLP-1 medication like Wegovy, Ozempic or Mounjaro, you may have noticed something unexpected: the constant chatter in your head about food — what will I eat next, should I have a snack, I keep thinking about that chocolate bar — simply goes quiet. For many people, this mental silence is one of the most profound and surprising effects of these medications. This phenomenon has been nicknamed "food noise" in patient communities, and it has become one of the most discussed topics among people on GLP-1 treatment. But what actually causes it — and is it backed by science? ## What is food noise? Food noise refers to the constant, intrusive mental preoccupation with food that many people with obesity or disordered eating patterns experience. It is more than just feeling hungry — it is the relentless background hum of food-related thoughts that makes it difficult to focus on anything else. People describe it differently: - "I'm always thinking about my next meal even while eating the current one." - "I fantasise about food constantly, even when I'm not hungry." - "Food is always on my mind — it's exhausting." This kind of persistent food-focused thinking is not simply a matter of willpower. Research suggests it is rooted in how the brain's reward and appetite systems are wired — and for some people, those systems are significantly more active than average, driving constant preoccupation with food regardless of actual caloric needs. ## How do GLP-1 medications affect the brain? GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals to the pancreas to release insulin, slows gastric emptying, and — crucially — travels to the brain where it activates GLP-1 receptors in areas controlling appetite, satiety and reward. These receptors are found in several key brain regions: - The hypothalamus: The brain's primary appetite-control centre, which regulates hunger and fullness signals - The brainstem: Processes signals from the stomach and gut about how full you are - The nucleus accumbens and ventral tegmental area: Core components of the brain's reward system, responsible for feelings of pleasure and motivation — including the motivational "pull" of food When GLP-1 receptor agonists like semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro) bind to these receptors, they dampen activity in the reward circuits associated with food craving. The result: food simply becomes less mentally compelling. The fridge loses its gravitational pull. A 2023 study published in Nature Metabolism (Farr et al.) confirmed that semaglutide reduced activity in the nucleus accumbens in response to food cues — the brain region most associated with food craving and addictive-like eating behaviour. Participants also reported significantly reduced "wanting" of high-fat, high-sugar foods, even though their "liking" of food (the pleasure of eating it) was less affected. ## What does the research say? The clinical evidence for food-noise reduction is growing. In the large STEP 1 trial of semaglutide (published in the New England Journal of Medicine, 2021), participants reported markedly reduced appetite and food cravings — effects that went beyond simple stomach fullness. A 2022 study in Diabetes, Obesity and Metabolism (Blundell et al.) examined appetite control during semaglutide treatment in detail. It found that semaglutide significantly reduced: - Hunger ratings - Food cravings (especially for sweet, salty, and fatty foods) - Prospective food consumption (thinking ahead about eating) - Eating disinhibition (the tendency to eat in response to emotions or external cues) Importantly, these reductions were observed independently of the amount of weight already lost — suggesting the medication acts directly on the appetite and reward brain circuits, not merely as a consequence of weight change. A 2024 study from the Journal of Clinical Endocrinology & Metabolism examining tirzepatide (Mounjaro) found similar patterns: participants reported a significant reduction in intrusive food thoughts, particularly for high-calorie foods, within the first weeks of treatment — often well before significant weight loss had occurred. ## What can you expect? If you are starting Wegovy, Ozempic or Mounjaro, it is worth knowing what people commonly report about food noise reduction: - Timing: Many people notice quieter food thoughts within 1–4 weeks of starting the medication, sometimes even at the lowest starting dose - Degree: The effect varies greatly between individuals — some describe it as dramatic and life-changing, others notice only a modest reduction - Nature: It is not that food becomes unpleasant — most people still enjoy meals. Rather, food simply stops dominating mental space between meals - Durability: For most people, the effect is sustained throughout treatment, although it may fluctuate with dose changes Many patients use words like "freedom" and "relief" to describe the experience. For people who have spent years — or decades — in a constant mental battle with food, this shift can feel profoundly liberating. ## Is the effect the same for everyone? No. Response to GLP-1 medications varies significantly between individuals, and food-noise reduction is no exception. Several factors may influence how pronounced this effect is for you: - Dose: Higher doses tend to produce stronger appetite and craving suppression - Individual neurobiology: People with more pronounced reward-driven eating patterns may notice a greater effect - Type of medication: Tirzepatide (Mounjaro), which acts on both GLP-1 and GIP receptors, may produce stronger effects for some individuals - Emotional eating: If your food noise is primarily driven by anxiety, stress or depression rather than hunger-related reward signals, the effect may be less pronounced — emotional eating often requires additional support such as therapy or psychological treatment ## What if your food noise doesn't quieten? Not everyone experiences a significant reduction in food noise on GLP-1 medication, and this is completely normal. If intrusive food thoughts remain a major challenge for you, there are several additional strategies worth discussing with your doctor or a therapist: - Cognitive behavioural therapy (CBT): CBT specifically targeting eating behaviours and food preoccupation has strong evidence behind it - Mindful eating practice: Learning to observe food thoughts without acting on them can reduce their grip over time - Treating underlying anxiety or depression: When food noise is primarily a coping mechanism for emotional distress, addressing that distress directly is often the most effective path - Dose review: In some cases, discussing your dose with your prescriber may help — the food-noise effect can be dose-dependent ## A note on losing joy in food While reduced food noise is welcome for many, some people find themselves missing the pleasure and excitement they used to feel around food. Meals that were once highlights of the day can feel more neutral. This is a real and valid experience that deserves acknowledgement. If this resonates with you, it may help to: - Focus on the quality rather than quantity of meals — savouring small portions of genuinely enjoyable food - Maintain the social rituals around food — cooking for others, eating together — even if your own appetite is reduced - Talk to your doctor about whether this aspect of the medication is acceptable to you in the long term It is worth remembering that the goal of treatment is an improved quality of life overall. Your relationship with food is part of that, and it deserves attention. ## Conclusion Food noise — the relentless mental preoccupation with food — is a real and often exhausting experience for many people managing their weight. GLP-1 medications like Wegovy, Ozempic and Mounjaro act directly on the brain's appetite and reward circuits to reduce this preoccupation, and for many people this is one of the most transformative aspects of treatment. The research supports what patients have been reporting: these medications genuinely change how the brain responds to food cues, not just how full the stomach feels. If you are curious about what to expect from your own treatment, speak to your doctor — they can help you understand what changes to look for and how to make the most of the medication's effects. This article is for informational purposes only and does not replace advice from your doctor or other qualified healthcare professional. Always consult your healthcare provider about questions regarding your medication and treatment. ## Sources - Wilding et al. (2021): Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine - Blundell et al. (2022): Effects of once-weekly semaglutide on appetite, energy intake, and weight loss — Diabetes, Obesity and Metabolism - Farr et al. (2023): GLP-1 receptor agonists and the brain — reward, cognition and body weight — NIH/PMC - Friedrichsen et al. (2022): The effect of semaglutide on food cravings in obesity — PubMed - Rajeev et al. (2024): Tirzepatide and food reward in obesity — PubMed --- Source: https://clickdose.io/en/articles/glp1-and-gallbladder.html GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) have helped millions of people lose weight and control their blood sugar. But like all medications, they can have side effects — and one of the more overlooked ones is an increased risk of gallstones and gallbladder inflammation. This isn't a one-in-a-million complication. Studies show a real, if modest, increase in risk. This article explains what happens in the body, what the research shows, and what you can practically do about it. ## What is the gallbladder? The gallbladder is a small, pear-shaped pouch that sits beneath your liver on the right side of your abdomen. Its job is simple: it collects and concentrates bile — a yellow-green fluid that the liver produces to help break down fat in the small intestine. When you eat a fatty meal, your intestine sends a signal to the gallbladder to contract and release bile into the duodenum. The key messenger in this process is the hormone cholecystokinin (CCK). Without sufficient CCK activity, the gallbladder empties more slowly — and that is where GLP-1 medications enter the picture. ## How do gallstones form? Gallstones form when the bile inside the gallbladder becomes unbalanced. The most common type — cholesterol gallstones — develop when bile contains too much cholesterol relative to the substances that keep it dissolved (bile salts and lecithin). Overly concentrated bile that sits too long gradually crystallises. Over time, the crystals grow into stones that can range from the size of a grain of sand to a golf ball. Many people have gallstones and never know it — they cause no symptoms at all. But if a stone blocks the gallbladder's outlet, it can cause severe pain and, in serious cases, inflammation (cholecystitis). ## Why does GLP-1 medication increase the risk? Research points to two interacting mechanisms: ### Mechanism 1: Slower gallbladder emptying GLP-1 receptors are found not just in the brain and pancreas — they also exist in the gastrointestinal tract, including in the nerve pathways that control gallbladder motility. When GLP-1 medications activate these receptors, they inhibit the release of cholecystokinin (CCK). The result is that the gallbladder contracts less frequently and empties more slowly. Bile that lingers too long in the gallbladder becomes concentrated and can crystallise. That is exactly the environment in which gallstones thrive. ### Mechanism 2: Rapid weight loss Rapid weight loss is itself a well-established risk factor for gallstones — regardless of whether it comes from dieting, bariatric surgery, or medication. When the body burns fat quickly, the liver secretes more cholesterol into bile, and the bile becomes supersaturated. This significantly increases the likelihood of crystal formation. GLP-1 medications are highly effective at promoting weight loss — and this is likely the single most important driver of the elevated gallstone risk, particularly for people who lose weight quickly in the first few months of treatment. ## What do the studies show? The research is clear: GLP-1 medications increase the risk of biliary events. A large meta-analysis published in JAMA Internal Medicine in 2022 reviewed data from multiple clinical trials and found that GLP-1 receptor agonists increased the risk of gallstones by approximately 27% (relative risk 1.27) and the risk of gallbladder inflammation by approximately 36% (relative risk 1.37) compared to placebo. In absolute terms, the picture is more reassuring. In semaglutide trials, approximately 1.6% of participants developed gallstones compared to about 0.7% in the placebo group over the study period. This means the vast majority — more than 98 out of 100 — did not develop gallstones. Based on this evidence, the FDA has included a formal warning about gallbladder events in the official prescribing information for Wegovy (semaglutide 2.4 mg). ## What are the symptoms? Gallstones don't always cause symptoms — many people discover them incidentally during an unrelated scan. When they do cause symptoms, these are typical: - Pain under the right ribs — often intense, cramping pain that comes on suddenly, especially after a fatty meal. - Pain that radiates — to the right shoulder or the back beneath the shoulder blade. - Nausea and vomiting — particularly during pain episodes. - Fever and chills — these symptoms suggest gallbladder inflammation (cholecystitis) and require prompt medical attention. - Yellowing of skin or eyes (jaundice) — occurs if a stone blocks the bile duct leading to the intestine. A pain episode typically lasts 30 minutes to a few hours. Fever and persistent pain are warning signs of a complication that needs urgent treatment. ## What can you do? You don't need to stop your medication out of fear of gallstones — but there are steps you can take to reduce your risk: - Avoid very high-fat meals. Fat is the strongest trigger for gallbladder contractions. A diet with moderate fat (not zero fat — the gallbladder still needs to empty regularly) reduces the burden. - Lose weight gradually. A weight loss rate of around 0.5–1 kg (1–2 lb) per week is considered safe from a gallstone perspective. Very rapid loss increases risk. Talk to your doctor if you are losing weight very quickly. - Stay well hydrated. Adequate fluid intake helps keep bile from becoming overly concentrated. - Ask your doctor about ursodiol. In specific circumstances — such as very rapid weight loss — bile acid medication (ursodeoxycholic acid) can be considered for prevention. This is not a standard recommendation but may be relevant for higher-risk individuals. If gallstones are already diagnosed, treatment ranges from watchful waiting (no symptoms, no intervention) to dietary adjustments to surgery. Laparoscopic removal of the gallbladder (cholecystectomy) is a routine procedure with a short recovery and good outcomes. ## Is the risk the same for all GLP-1 medications? Not necessarily. Some analyses suggest there may be differences between individual drugs. Tirzepatide (Mounjaro) — which activates both GIP and GLP-1 receptors — appears in certain analyses to carry a lower gallbladder risk than semaglutide. One possible explanation is that the GIP component influences gallbladder motility differently from pure GLP-1 stimulation. Research in this area is still ongoing, however, and head-to-head comparisons are difficult because the trials were not designed identically. What all GLP-1 medications share is that risk scales with the speed of weight loss. Regardless of which medication you take, a steady, controlled rate of weight loss is preferable to a very rapid one. ## When should you seek help? Contact your doctor if you experience: - Recurring pain on the right side of your abdomen, especially after fatty meals - Nausea and vomiting that is not explained by the usual GLP-1-related nausea (which is typically mild and fades over time) Seek urgent medical care if you develop: - Severe abdominal pain combined with fever - Yellowing of skin or eyes - Pain that persists for more than a few hours without easing Gallbladder inflammation can in rare cases escalate quickly — it is not something to wait out overnight. ## Sources - Association of GLP-1 RA Use With Risk of Gallbladder and Biliary Diseases: Meta-analysis — JAMA Internal Medicine - Relative risk of cholelithiasis among GLP-1 RAs — PMC - FDA prescribing information for Wegovy (semaglutide 2.4 mg) — FDA --- Source: https://clickdose.io/en/articles/glp1-and-gut-health.html If you have started Wegovy, Ozempic or Mounjaro, there is a good chance you have noticed it in your stomach. Nausea after an injection, feeling full after just a few bites, or unpredictable visits to the bathroom — these are some of the most commonly reported experiences among people taking GLP-1 medications. But why does this happen, and what can you do about it? The short answer is that GLP-1 receptors are found throughout the digestive tract — not just in the pancreas, where insulin regulation takes place. This means the medication actively changes how your gut works, which is part of why it is so effective at reducing appetite and causing weight loss. But it also means that digestive side effects are an expected and common part of the treatment. ## Why does GLP-1 affect the gut? GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally, primarily in the L-cells of the small intestine. In nature, it is released after a meal and sends signals to the brain that you are full, stimulates insulin secretion, and slows the movement of food through the digestive tract. Medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) mimic — or enhance — this hormone at far higher levels than the body would normally produce. GLP-1 receptors sit on cells throughout the digestive system: in the stomach, the small intestine, and even in the colon. When the medication activates these receptors, it slows the entire digestive process. This slowing is intentional — it is one of the mechanisms by which you feel full for longer — but it also brings side effects. ## Nausea — the most common side effect Nausea is the single most common side effect of GLP-1 medications. In the large STEP 1 clinical trial with semaglutide (Wegovy), approximately 44% of participants reported nausea at some point during treatment, compared to 16% in the placebo group. For tirzepatide (Mounjaro), the SURMOUNT-1 trial showed similar rates — around 30–45% depending on the dose. The nausea typically occurs within the first few hours after injection and tends to be worst in the early weeks of treatment and after each dose increase. Most people find it significantly improves over the first 4–8 weeks as the body adapts. Practical tips to reduce nausea: - Eat smaller, more frequent meals rather than large portions - Avoid high-fat, very spicy or very sweet foods right after injecting - Inject at a time of day that works for you — some people prefer evenings so they sleep through the worst of it - Stay hydrated, but sip water slowly rather than drinking large amounts at once - If nausea is severe, ask your doctor — anti-nausea medication can be used short-term ## Slowed gastric emptying — feeling full much faster One of the key effects of GLP-1 medication on the gut is delayed gastric emptying — the stomach empties its contents into the small intestine more slowly than usual. This is a significant reason why people on these medications feel full after much smaller amounts of food. Under normal circumstances, it takes the stomach roughly 2–4 hours to empty a mixed meal. On GLP-1 medication, this can be extended substantially. Radiological studies have confirmed measurably slower gastric emptying in patients taking semaglutide. This is generally a desired effect. However, it can also cause: - A feeling of fullness or bloating after even small meals - Belching or regurgitation - In rare cases, symptoms resembling gastroparesis (severe slowing of stomach emptying) If you develop persistent vomiting, inability to keep food down, or significant bloating, contact your doctor. True gastroparesis is a rare but serious complication that has been reported in connection with GLP-1 treatment. ## Constipation or diarrhea — why both can happen GLP-1 medications can cause both constipation and diarrhea, often at different stages of treatment. ### Constipation Constipation is one of the most common long-term GI complaints. When the entire digestive tract slows down, it takes longer for waste to move through the colon, and more water is reabsorbed — making stools harder and more difficult to pass. In the STEP 1 trial, approximately 24% of Wegovy users reported constipation. To prevent and manage constipation: - Drink plenty of water (at least 1.5–2 litres per day) - Increase dietary fibre (vegetables, legumes, whole grains) - Stay physically active — even short walks help gut motility - If needed, a gentle osmotic laxative (like macrogol/polyethylene glycol) is safe alongside GLP-1 treatment ### Diarrhea Diarrhea tends to occur more in the early weeks of treatment, particularly after a dose increase, as the gut adjusts. It typically resolves on its own. In some people, particularly with tirzepatide (Mounjaro), diarrhea can be quite pronounced initially. Staying hydrated and eating bland, low-fat foods during flare-ups helps considerably. ## GLP-1 medication and the gut microbiome One of the most exciting areas of current research is the effect of GLP-1 medications on the gut microbiome — the trillions of bacteria, viruses and fungi that live in the intestine. Early research suggests that GLP-1 treatment may beneficially shift the composition of gut bacteria. A 2024 study published in Cell Metabolism found that semaglutide treatment was associated with increases in bacteria associated with short-chain fatty acid production — compounds that support gut barrier integrity and reduce inflammation. The researchers noted that some of the weight-loss effect of semaglutide may be mediated in part through changes in the microbiome. This is an emerging field and much is still uncertain. However, it suggests that the gut effects of GLP-1 medication may extend beyond simple motility changes, potentially benefiting gut health in the longer term. ## Vomiting — when should you worry? Occasional vomiting, especially during the first few weeks of treatment or after a dose increase, is not unusual. However, you should contact your doctor if: - Vomiting is persistent (more than 24 hours) - You cannot keep food or fluids down - You notice blood in your vomit - You experience severe abdominal pain, especially in the upper abdomen or radiating to the back (this could indicate pancreatitis — a rare but serious complication) It is also important to know that persistent vomiting while on GLP-1 medication may affect medication absorption, particularly for oral medications you may be taking for other conditions. ## Practical tips for gut comfort on GLP-1 treatment Most people find that gut side effects improve significantly over the first 2–3 months of treatment. In the meantime, these strategies help: - Eat slowly and chew thoroughly — slower eating gives the digestive system more time to signal fullness and reduces the risk of overfilling a stomach that is already emptying slowly - Avoid trigger foods — very fatty, fried, or heavily spiced foods are harder for a slow-moving gut to manage - Eat at regular times — the gut thrives on routine, and regular meal times help stabilise digestive patterns - Don't lie down right after eating — staying upright for 30–60 minutes after meals reduces reflux and belching - Reduce alcohol and carbonated drinks — both can worsen bloating and nausea - Be patient with dose increases — if a dose increase causes severe GI symptoms, speak to your doctor about slowing the titration schedule ## What about long-term gut health? For most people, the most uncomfortable GI side effects are temporary. As the body adapts to the medication, nausea, diarrhea and vomiting typically lessen significantly. Constipation may persist longer but can be managed effectively with dietary changes and hydration. Importantly, there is no evidence that GLP-1 medications cause lasting damage to the gut lining or digestive organs in the vast majority of users. Ongoing research into the gut microbiome even suggests potential long-term benefits. The exception is the rare complication of gastroparesis, which can develop or worsen in susceptible individuals — another reason to discuss any persistent or worsening GI symptoms with your doctor. ## Conclusion GLP-1 medications are powerful because they engage with receptors throughout the gut — and that engagement comes with digestive side effects that are real but manageable. Nausea, constipation, diarrhea and fullness are expected parts of the treatment journey, especially early on. With the right strategies, most people adapt well and the side effects diminish over time. Always talk to your doctor before making changes to your medication or if you are concerned about persistent digestive symptoms during your treatment. ## Sources - STEP 1 Trial — Semaglutide 2.4 mg for Weight Reduction (NEJM, 2021) - SURMOUNT-1 Trial — Tirzepatide for Obesity (NEJM, 2022) - Wegovy (semaglutide) — European Medicines Agency product information - GLP-1 receptor agonists and the gut microbiome — PMC (2024) - Gastrointestinal effects of GLP-1 receptor agonists — PMC (2023) - Gastroparesis and GLP-1 receptor agonists — a review (PubMed, 2024) --- Source: https://clickdose.io/en/articles/glp1-and-hair-loss.html Hair loss is one of the side effects of GLP-1 treatment that catches many people off guard. You start Wegovy or Ozempic to lose weight and improve your health — and two to three months in, you suddenly notice more hair in the shower drain and on your brush. It can feel alarming. The good news is that for the vast majority it is a temporary condition with a clear biological explanation. ## How common is it? In the large STEP trials that supported the approval of Wegovy (semaglutide 2.4 mg), approximately 3% of participants reported hair loss — compared to about 1% in the placebo group. This gives a relative risk of 2.38 compared with no medication. A 2025 systematic review confirmed this pattern across the GLP-1 drug class. The numbers rise markedly with the degree of weight loss: among participants who lost more than 20% of their body weight, 5.3% reported hair loss — versus 2.5% among those who lost less than 20%. That detail points directly to the underlying mechanism. ## What is telogen effluvium? The hair loss most GLP-1 users experience has a name: telogen effluvium. It is a well-recognised, temporary form of hair shedding that occurs when the body is placed under physical or psychological stress — and rapid weight loss counts as physical stress, regardless of whether it is achieved through medication, caloric restriction or bariatric surgery. Normally, about 10–15% of hair follicles are in the resting phase (telogen phase) at any given time. Under stressful conditions, up to 30% or more can shift into the resting phase simultaneously. Months later, when they reactivate, the old hairs fall out and new ones grow in their place. The result is noticeable thinning — but rarely true baldness. Hair shedding typically begins 2–4 months after the triggering event. For GLP-1 users this often coincides with the period when weight loss is in full swing — making it easy to miss the connection between cause and effect. ## Is it the medication or the weight loss? This is probably the most important question. Research suggests it is primarily the weight loss — not semaglutide or tirzepatide itself — that triggers the hair loss. Evidence for this includes: - The degree of hair loss correlates with the amount of weight lost, not with the medication dose - The same type of hair loss occurs after bariatric surgery and intensive caloric restriction - Telogen effluvium is a well-established response to any significant weight loss That said, the medication's appetite-suppressing effect may contribute indirectly: eating substantially less raises the risk of insufficient protein and micronutrient intake — both of which are important for healthy hair production. ## Nutrients that play a role Research has identified several nutrients that are critical for hair health and may fall below optimal levels during intensive weight-loss treatment: - Protein: Hair is made largely of keratin — a protein. Insufficient protein intake is one of the most common causes of telogen effluvium. The recommendation during GLP-1 treatment is at least 1.2–1.6 g of protein per kg of body weight per day. - Iron: Iron deficiency is an independent risk factor for hair loss. Women are particularly vulnerable. Your doctor can check your iron stores (ferritin). - Zinc: Zinc is needed for cell division in hair follicles. Deficiency can develop during sustained caloric restriction. - Vitamin D: Low vitamin D levels are associated with several forms of hair loss and should be tested if you suspect a deficiency. - Biotin (vitamin B7): Heavily marketed for hair loss, but evidence is limited to people with genuine biotin deficiency, which is rare in healthy adults. ## What can you do? 1. Prioritise protein at every meal. This is the most evidence-backed step. Choose protein-rich foods such as eggs, chicken, fish, Greek yoghurt, cottage cheese and legumes. Many GLP-1 users supplement with protein shakes when appetite is low. 2. Get blood tests done. Ask your doctor to check ferritin (iron stores), vitamin D, thyroid hormones and possibly zinc. Treating a confirmed deficiency is the most effective thing you can do. 3. Be gentle with your hair. Avoid tight hairstyles, heat styling and chemical treatments during this period. Fragile hair tolerates less mechanical stress. 4. Be patient. Telogen effluvium is self-limiting. Once weight loss stabilises and the body adapts to its new energy level, normal hair growth typically returns — but it takes time. Do not expect visible improvement within the first 3–6 months. ## When is it normal, and when should you see a doctor? Diffuse thinning across the scalp — most noticeable when wearing a ponytail or at a centre parting — is classic for telogen effluvium and is generally harmless. You should contact your doctor if: - Hair loss is sudden and very heavy - You are losing hair in patches (could indicate alopecia areata — an autoimmune condition) - Hair loss is accompanied by fatigue, cold intolerance or weight fluctuations (may suggest a thyroid problem) - Hair loss continues beyond 12 months Isolated cases of alopecia areata have been reported in people using semaglutide, but a direct causal link has not been established. It is rare and should be assessed by a dermatologist. ## What about biotin and hair-loss products? The market is full of supplements promising to stop GLP-1-related hair loss. Clinical evidence is thin. Biotin works mainly in cases of genuine biotin deficiency, which is uncommon. "Hair vitamin" products typically contain a blend of nutrients that only help if you have a specific deficiency. Minoxidil (e.g. Rogaine) is approved for androgenetic alopecia (hereditary hair loss) and has limited evidence for telogen effluvium. It may be considered in consultation with a dermatologist if shedding is pronounced and prolonged — but it is not a standard recommendation for GLP-1-related hair loss. ## Is it permanent? For the vast majority: no. Telogen effluvium is a temporary condition. Even with significant thinning, hair growth typically returns once the body has adapted. Full regrowth can take 6–18 months from the point at which shedding peaks. Chronic telogen effluvium (lasting more than 6 months) does occur, but is rarely caused by GLP-1 treatment alone. If it happens, an underlying cause should be thoroughly investigated — most commonly iron deficiency, thyroid dysfunction or a persistent caloric deficit. ## Sources - Almohanna HM et al. "Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review." PMC / NLM, 2025. ncbi.nlm.nih.gov - Lipner SR et al. "Alopecia and Semaglutide: Connecting the Dots for Patient Safety." PMC, 2025. ncbi.nlm.nih.gov - "Risk of Hair Loss with Semaglutide for Weight Loss." medRxiv, 2025. medrxiv.org - "Alopecia as an Emerging Adverse Effect Associated With GLP-1 Receptor Agonists: A Scoping Review." PMC, 2025. ncbi.nlm.nih.gov - "Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review." PubMed, 2025. pubmed.ncbi.nlm.nih.gov - NHS. "Hair loss (alopecia)." nhs.uk - Mayo Clinic. "Hair loss: Symptoms and causes." mayoclinic.org --- Source: https://clickdose.io/en/articles/glp1-and-heart-health.html Most people know Wegovy and Ozempic as weight-loss medications. But research from recent years suggests that semaglutide and tirzepatide may have a far greater impact: they appear to protect the heart — regardless of how much weight you lose. In this article, we review what the most important studies show, why GLP-1 medications affect the heart, and what it means for you. ## What is GLP-1, and why does it affect the heart? GLP-1 receptors are not only found in the stomach and brain — they are also present in the heart and blood vessels. When medications like semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro) activate these receptors, several things happen at once: blood sugar drops, appetite is suppressed — and the heart is directly affected. This is why researchers began investigating whether GLP-1 medications could not only help with weight but actually prevent heart attacks and strokes. ## The SELECT trial: the major breakthrough In 2023, the New England Journal of Medicine published the results of the SELECT trial — one of the largest studies ever conducted on GLP-1 medications and heart health. The trial followed 17,604 adults with overweight or obesity and existing cardiovascular disease, but without diabetes. The result was striking: people who received semaglutide 2.4 mg weekly had a 20% lower risk of major adverse cardiovascular events — meaning heart attack, stroke, or death from cardiovascular causes — compared to those who received placebo. And the effect was present regardless of how much weight participants lost. This means that something beyond just weight loss is protecting the heart — the medication appears to have direct cardioprotective properties. ## SUSTAIN-6: semaglutide and type 2 diabetes Even before the SELECT trial, the SUSTAIN-6 study had shown that semaglutide reduced the risk of major cardiovascular events by 26% in patients with type 2 diabetes and high cardiovascular risk. This was a key step, as it showed that the benefit was not limited to one specific group. ## What about tirzepatide (Mounjaro)? Tirzepatide — the active ingredient in Mounjaro — is somewhat newer, but the results point in the same direction. A large real-world analysis presented at the American Heart Association's Scientific Sessions in 2025 compared semaglutide and tirzepatide. Both medications significantly reduced the risk of heart attack, stroke, and death in people with obesity and diabetes. Specifically, tirzepatide reduced the combined risk of heart attack, stroke, and death by 13% compared to another diabetes medication (dulaglutide), while semaglutide reduced the risk of stroke and heart attack by 18% compared to sitagliptin. ## How do GLP-1 medications protect the heart? Researchers don't fully agree on all the mechanisms, but several factors are at play: ### 1. Lower blood pressure GLP-1 medications lower systolic blood pressure by an average of 2–4 mmHg. That may sound modest, but even small reductions in blood pressure reduce the risk of heart disease over time. ### 2. Improved cholesterol and blood fats Treatment leads to modest reductions in LDL cholesterol (the "bad" cholesterol), total cholesterol, and triglycerides. These improvements contribute to a healthier cardiovascular system. ### 3. Reduced inflammation Chronic low-grade inflammation is one of the most important risk factors for cardiovascular disease. GLP-1 medications dampen inflammatory markers such as CRP (C-reactive protein), TNF-α, and interleukin-6. These improvements occur partly independently of weight loss. ### 4. Direct effects on the heart and vessels GLP-1 receptors in the heart muscle and blood vessels can be directly activated by the medication, improving the heart's pumping function and promoting a healthier vascular tone. Research suggests these direct effects contribute to the overall cardioprotective picture. ### 5. Weight loss and improved insulin sensitivity Finally, weight loss still plays a role. While the direct cardiac effects are important, a reduction in body weight improves insulin sensitivity and reduces the workload on the heart. ## Who benefits most? Research suggests that those who already have cardiovascular disease gain the greatest benefit from GLP-1 treatment from a cardiac perspective. But even in people without existing heart disease, the risk profile improves with weight loss, lower blood pressure, and better blood lipids. If you have high blood pressure, high cholesterol, type 2 diabetes, or have previously had a heart attack or stroke, GLP-1 medications may be particularly relevant — talk to your doctor about what applies to you. ## What GLP-1 medications are not It is important to emphasise that GLP-1 medications are not a guarantee against heart disease. They reduce risk statistically — but they do not replace a healthy diet, exercise, quitting smoking, and other lifestyle changes. They are also not the right choice for everyone: pregnancy, certain past cancers, and other conditions may mean the medication is not suitable. The decision to start, continue, or stop treatment should always be made in consultation with your doctor. ## What does this mean for your treatment? Many people start Wegovy or Ozempic primarily to lose weight. That is a perfectly valid goal — but it is worth knowing that you may also be giving your heart a helping hand. This is one of the reasons GLP-1 medications are increasingly recommended for people with obesity and cardiovascular risk factors, even when weight loss is not the primary goal. Whatever your reason for treatment: use the medication correctly, follow your doctor's dosing instructions — and use tools like ClickDose to ensure you inject exactly the amount you should. ## Sources - Lincoff AM et al. — SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM, 2023 - PMC: The benefits of GLP-1 receptors in cardiovascular diseases - Mass General Brigham: Tirzepatide and Semaglutide Provide Heart Protection (2025) - AHA Circulation: GLP-1 Receptor Agonists for Reduction of Atherosclerotic Cardiovascular Risk - Minneapolis Heart Institute Foundation: How do GLP-1 medications impact heart health? --- Source: https://clickdose.io/en/articles/glp1-and-hydration.html Most people expect nausea, an early feeling of fullness or a smaller appetite when they start Wegovy, Ozempic or Mounjaro. What surprises many is how easy it becomes to forget to drink. You are not imagining it — GLP-1 medications change how your body signals thirst, how quickly your stomach empties and how much water arrives with your meals. All three shifts pull in the same direction: less fluid in. For most people this is a mild inconvenience. For some, it becomes a real problem — dry mouth, headaches, constipation, dizziness and, in the worst case, extra stress on the kidneys. Here is what is happening and what you can do about it. ## Why does hydration change on GLP-1 medication? Three separate mechanisms overlap during GLP-1 treatment, and together they explain almost every hydration complaint people report. ### 1. A quieter thirst signal GLP-1 receptors sit not only in the pancreas and gut but also in areas of the brain that regulate hunger — and thirst. Animal studies and clinical observations suggest that activating these receptors dampens the drive to drink, similar to how it dampens the drive to eat. The result is a very specific problem: your body may already be running low on water, but your brain does not raise the alarm as loudly as it used to. ### 2. A slower stomach Semaglutide and tirzepatide slow gastric emptying — food and fluid leave your stomach more gradually. That is part of the medicine's benefit (you feel full for longer), but it also means a big glass of water can sit and make you feel heavy, so you stop drinking earlier in a meal. Many people cope by drinking less at once, which is fine — but they forget to make up the volume between meals. ### 3. Less water coming in with food People often underestimate how much of their daily water comes from food. Fruit, vegetables, soup, yogurt, porridge and even bread all contribute. On GLP-1 treatment, portions shrink and meals are skipped, so a significant "invisible" fluid source disappears — sometimes 500–1000 ml a day — without you noticing. ### 4. Gut side effects that cost fluid Nausea, vomiting and diarrhoea are the most common side effects during the first weeks and after each dose increase. All three cause direct fluid loss. Clinical trials of high-dose semaglutide have reported nausea in roughly 4 in 10 users, diarrhoea in about 3 in 10, and vomiting in around a quarter — most cases are mild, but every episode moves you closer to dehydration. ## What are the warning signs of dehydration? Learn to spot the early signs before they turn into anything serious: - Dry mouth and sticky lips — often the very first clue. - Dark, strong-smelling urine — pale straw colour is the target. - Passing urine less often — fewer than 4–5 times a day is a signal. - Headache, difficulty concentrating, or feeling "foggy". - Dizziness when standing up — a classic sign of low blood volume. - Constipation — the colon reabsorbs water when supply is low. - Muscle cramps or unusual fatigue. If you also have persistent vomiting, diarrhoea, a racing heartbeat, or you cannot keep fluids down, contact your doctor — that is a medical situation, not just poor hydration. ## How much should you actually drink? A reasonable target for most adults on GLP-1 treatment is 2–3 litres of fluid a day (about 8–12 cups). Aim for the higher end during dose increases, in hot weather, when you exercise, or when you have any gut side effects. Small, frequent sips work far better than trying to down a big glass at once — a slow stomach does not appreciate volume. Water is best, but coffee, tea, sparkling water, broth and low-sugar drinks all count. If you sweat a lot or have had a bout of diarrhoea, an oral rehydration solution (available from any pharmacy) restores water and electrolytes faster than plain water. ## Practical tips that actually work - Drink on a schedule, not on thirst. Fill a marked 500 ml bottle and finish one before mid-morning, one before lunch, one before mid-afternoon, and one during the evening. - Front-load your fluid. Because a slower stomach fills up quickly, drink most of your water between meals, not with them. - Use flavour if plain water feels heavy. A slice of lemon, cucumber, mint or a splash of squash makes it easier to keep going. - Choose water-rich foods. Soup, watermelon, cucumber, tomato, oranges and yogurt all put a surprising amount of fluid back on the plate. - Watch your urine colour. The most reliable, free hydration test you have — aim for pale straw. - Treat every dose step-up as a hydration event. Add an extra 500 ml the day before and for a few days after. - Do not rely on alcohol, energy drinks or lots of caffeine. They can worsen fluid loss and interact with GLP-1 side effects. ## Why hydration matters for your kidneys Your kidneys need a steady flow of blood to work properly. If you become dehydrated because of vomiting, diarrhoea or simply not drinking enough, the volume of blood reaching them can fall. Reviews in the medical literature and post-marketing reports have identified acute kidney injury linked to volume depletion as one of the more serious risks of GLP-1 treatment — almost always in people who had significant gut side effects and did not replace the lost fluid. The good news: this is very preventable. If you keep up with fluids during side-effect days, tell your doctor about persistent vomiting or diarrhoea, and continue your usual blood tests, your kidneys are unlikely to run into trouble. If you already have kidney disease, discuss a specific hydration plan with your care team before starting or increasing the dose. ## Dry mouth, bad breath and dental care A common but rarely discussed side effect is dry mouth — partly from lower fluid intake, partly from changes in saliva and, in some people, from acid reflux caused by slower gastric emptying. Dry mouth encourages tooth decay and gum problems. Sipping water, chewing sugar-free gum, using a fluoride mouthwash and keeping up with your dentist all help. ## Special situations to think about - Hot weather and travel. Aim closer to 3 litres and carry a bottle everywhere. - Exercise. Add roughly 500 ml for every hour of moderate activity — more if you sweat heavily. - Illness with fever, vomiting or diarrhoea. Use an oral rehydration solution and pause any dose increase until you have recovered — discuss with your doctor. - Older adults. Thirst signals are already weaker with age; a fixed drinking schedule matters even more. - Kidney disease, heart failure or diuretics. Your fluid target may be different — always personalise this with your doctor. ## The bottom line Hydration is one of the most overlooked but easiest things to get right on Wegovy, Ozempic or Mounjaro. Because the medication quietly turns down your thirst and cuts water intake from food, you have to be a little more deliberate — a bottle by the desk, a glass with every routine, and extra care during side-effect days and dose increases. Do that, and you dodge headaches, constipation and dry mouth, and you keep your kidneys safe while the medicine does its work. This article is for general information only. Always speak to your doctor or pharmacist about your treatment, particularly if you have kidney or heart problems, take diuretics, or feel unwell. ## Sources - Semaglutide — StatPearls, NCBI Bookshelf (NIH, 2024) - Semaglutide-associated kidney injury — PMC (2024) - GLP-1 receptor agonists comparison — StatPearls, NCBI Bookshelf - The multifaceted effects of semaglutide — PMC (2025) - Side effects of Wegovy (semaglutide) — NHS - Dehydration — Symptoms and causes — Mayo Clinic --- Source: https://clickdose.io/en/articles/glp1-and-immune-system.html Most people starting Wegovy, Ozempic or Mounjaro are focused on weight loss. But researchers have increasingly discovered that GLP-1 medications do far more than suppress appetite. One of the more surprising areas of research concerns the immune system — how these medications interact with immune cells, reduce chronic inflammation, and may have a role in autoimmune and infectious conditions. Here is what the current science tells us. ## Do GLP-1 receptors exist on immune cells? Yes — and this is the key to understanding why GLP-1 medications affect immunity at all. GLP-1 receptors (GLP-1R) have been identified on a range of immune cell types, including: - Macrophages — the front-line cells that engulf pathogens and coordinate the inflammatory response - Dendritic cells — which present antigens to T cells and shape adaptive immunity - T lymphocytes — both helper (CD4+) and cytotoxic (CD8+) T cells - B lymphocytes — responsible for antibody production - Natural killer (NK) cells — part of the innate immune response This means GLP-1 medications are not acting purely through the nervous system and pancreas. They are capable of directly modulating how your immune cells behave. ## How do GLP-1 medications reduce inflammation? Chronic low-grade inflammation is a hallmark of obesity and is tightly linked to insulin resistance, cardiovascular disease, and many other conditions. GLP-1 medications appear to fight this inflammation through multiple mechanisms: ### Shifting macrophage behaviour Macrophages exist in two broad states: the inflammatory M1 state and the anti-inflammatory M2 state. In obesity, macrophages — particularly in fatty tissue — tend towards M1, driving chronic inflammation. Research published in Nature Communications (2023) and subsequent studies have shown that GLP-1 receptor activation shifts macrophages towards the M2 phenotype, reducing the release of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β. ### Lowering C-reactive protein (CRP) The landmark SELECT cardiovascular trial, which enrolled over 17,500 people, found that semaglutide (the active ingredient in Wegovy and Ozempic) reduced high-sensitivity CRP — a key marker of systemic inflammation — by approximately 40%. Crucially, this reduction occurred partly independent of weight loss, suggesting a direct anti-inflammatory action of the drug itself. ### Suppressing the NF-κB pathway NF-κB is a molecular "master switch" for inflammation — when activated, it triggers a cascade of pro-inflammatory gene expression. Studies in animal models and in vitro (cell culture) have shown GLP-1 receptor activation can suppress NF-κB signalling in immune cells, dampening the overall inflammatory response. ## What about autoimmune conditions? People living with autoimmune diseases — conditions where the immune system attacks the body's own tissues — are often curious about what GLP-1 medications do to immune function. This is an area of active research with promising, if still early, findings. ### Rheumatoid arthritis Several observational studies have found that people with rheumatoid arthritis (RA) who take GLP-1 medications report reduced joint pain and lower disease activity scores. A 2024 register-based study from Denmark found lower rates of RA flares among GLP-1 users compared to matched controls. Researchers attribute this partly to weight loss — which reduces mechanical load on joints — and partly to the direct anti-inflammatory effects described above. ### Multiple sclerosis Intriguingly, GLP-1 receptors are also found on microglia, the immune cells of the central nervous system. Early-phase clinical trials and animal studies suggest that GLP-1 receptor agonists may reduce neuroinflammation and protect nerve tissue. However, evidence in humans with multiple sclerosis is still limited and large trials are ongoing. This remains a developing area. ### Inflammatory bowel disease The gut is home to a large proportion of the immune system, and GLP-1 is naturally produced in the gut lining (L-cells). Some small studies suggest GLP-1 agonists may have beneficial effects in Crohn's disease and ulcerative colitis, likely through modulation of gut macrophages and reduced intestinal inflammation. Clinical use in IBD is not yet established, but research is underway. ## Does GLP-1 medication affect your ability to fight infections? This is an important and nuanced question. The short answer is: for most people, GLP-1 medications do not impair the ability to fight infections, and may actually improve it in some cases. ### COVID-19 outcomes Multiple large-scale analyses during the COVID-19 pandemic found that people with diabetes or obesity who were taking GLP-1 medications had better outcomes from COVID-19 infection compared to those on other diabetes treatments. This included lower rates of severe disease, hospitalisation, and mechanical ventilation. The reasons are likely multifactorial: better glycaemic control, weight reduction, and direct immune-modulating effects. ### Upper respiratory infections Some clinical trial data suggest a modest increase in upper respiratory tract infections (common colds, sinusitis) in people taking semaglutide, though this was not consistently observed across all trials. If you do notice you are getting more colds, it is worth discussing with your doctor — though in most cases this is unrelated to immune suppression. ### Injection site reactions A small proportion of people develop redness, itching or swelling at the injection site — this is a local immune reaction, not a sign of impaired immunity. Rotating injection sites and ensuring good injection technique resolves this in most cases. ## GLP-1, the gut microbiome, and immunity The connection between GLP-1 and immunity extends to the gut microbiome. GLP-1 is produced by intestinal L-cells in response to food, and these same cells interact closely with the gut's immune environment. Research has shown that GLP-1 medications can alter the composition of the gut microbiome, generally shifting it towards bacteria associated with lower inflammation and better metabolic health. Since up to 70% of immune cells reside in the gut, this microbiome shift may represent an additional pathway through which GLP-1 medications modulate immunity. ## What does this mean in practice? If you are taking Wegovy, Ozempic or Mounjaro, here is what the current evidence suggests: - You are unlikely to become immunocompromised. Unlike corticosteroids or chemotherapy, GLP-1 medications do not broadly suppress the immune system — they modulate it in a generally anti-inflammatory direction. - If you have a chronic inflammatory condition, you may notice benefits beyond weight loss — though you should not adjust your existing treatment without speaking to your specialist. - Stay up to date with vaccinations. There is no evidence that GLP-1 medications reduce vaccine efficacy, but annual flu and COVID-19 boosters remain important, especially if you have obesity or diabetes. - Report unusual infections to your doctor. If you experience recurrent or severe infections, mention your GLP-1 medication — though it is rarely the cause. ## Conclusion GLP-1 medications are far more than appetite suppressants. Through direct action on immune cells and indirect effects via weight loss, reduced blood sugar, and microbiome changes, they exert a meaningful anti-inflammatory effect. For many people — particularly those with obesity-related chronic inflammation, cardiovascular disease, or autoimmune conditions — this may represent an additional benefit of treatment. Research in this field is moving quickly, and the full immunological story of GLP-1 is still being written. Always talk to your doctor before starting or adjusting any treatment related to immune function. ## Sources - SELECT Trial — Semaglutide and Cardiovascular Outcomes (NEJM, 2023) - GLP-1 Receptor Agonists and the Immune System — PMC Review (2023) - GLP-1 and Macrophage Polarisation — PMC (2022) - Semaglutide and Inflammation Biomarkers — The Lancet Diabetes & Endocrinology (2024) - GLP-1 Agonists, COVID-19 Outcomes and Immune Modulation — PMC (2024) - GLP-1 Receptor Agonists and Autoimmune Diseases — PMC Review (2024) --- Source: https://clickdose.io/en/articles/glp1-and-inflammation.html When most people think about Wegovy or Ozempic, they think about weight loss, blood sugar control, or heart health. But there is a growing body of research pointing to a less discussed benefit: these medications appear to actively reduce chronic inflammation in the body — and this may be part of the reason they help with so many different conditions. Chronic low-grade inflammation is increasingly recognised as a driver of some of the most common and serious diseases of our time: cardiovascular disease, type 2 diabetes, fatty liver disease, and possibly even depression and cognitive decline. Understanding how GLP-1 medications interact with the immune system opens up new possibilities — and a more complete picture of why these drugs are proving so remarkably versatile. ## What is chronic inflammation? Inflammation is the body's natural response to injury, infection or other threats. In the short term, it is protective and essential. The problem arises when inflammation becomes chronic — a persistent, low-level state where the immune system remains activated even when there is no acute threat. This is often referred to as "silent" inflammation because it typically causes no obvious symptoms in the early stages. Over time, however, it can quietly damage blood vessels, organs and tissues. Excess body fat — particularly visceral fat around the abdomen — is one of the main drivers of this chronic inflammatory state, as fat cells release pro-inflammatory substances continuously. Key biomarkers used to measure systemic inflammation include: - CRP (C-reactive protein): A protein produced by the liver in response to inflammation; elevated levels are strongly associated with cardiovascular risk - TNF-α (tumour necrosis factor alpha): A cytokine that promotes inflammation and plays a role in insulin resistance - IL-6 (interleukin-6): A signalling protein that amplifies the inflammatory response - IL-1β (interleukin-1 beta): A cytokine associated with metabolic inflammation and cardiovascular disease ## How do GLP-1 medications affect inflammation? The anti-inflammatory effects of GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) come from several mechanisms working together. ### GLP-1 receptors on immune cells GLP-1 receptors are not only found in the pancreas and brain — they are also expressed on various immune cells, including macrophages, T lymphocytes and dendritic cells. When GLP-1 medications activate these receptors, they appear to shift macrophages from a pro-inflammatory state (M1) toward an anti-inflammatory state (M2). This is significant because macrophages are key orchestrators of the inflammatory response throughout the body. A review published in PMC (2022) demonstrated that GLP-1 receptor activation on macrophages reduces the production of pro-inflammatory cytokines while increasing the release of anti-inflammatory mediators. This mechanism appears to be direct and does not simply result from weight loss itself. ### Reduced inflammatory markers in studies Multiple clinical trials have documented significant reductions in inflammatory biomarkers in people taking GLP-1 medications: - CRP: Studies consistently show reductions of 30–50% in high-sensitivity CRP with semaglutide treatment, even when controlling for weight loss - TNF-α and IL-6: Both cytokines are significantly reduced in people treated with GLP-1 RAs; this correlates with improvements in insulin sensitivity - IL-1β: Reductions have been observed particularly in people with type 2 diabetes and metabolic syndrome Importantly, several studies have found that a portion of these anti-inflammatory effects remain even after accounting for weight reduction, suggesting a direct mechanism of action beyond simply being thinner. ## Are the effects independent of weight loss? This is a crucial question — and the answer appears to be: partly yes. While a significant proportion of the anti-inflammatory effect in clinical trials can be explained by the weight that was lost (since excess fat is itself inflammatory), researchers have identified anti-inflammatory effects that seem to operate through other pathways. Animal studies and mechanistic research have shown that semaglutide reduces markers of vascular inflammation independently of body weight. In the landmark SELECT trial — which enrolled over 17,000 adults with cardiovascular disease and overweight or obesity — semaglutide reduced the risk of major cardiovascular events by 20%. Researchers believe that reducing vascular inflammation may have contributed to this benefit alongside the cardiovascular effects of weight loss. A 2023 analysis published in PubMed found that in people with type 2 diabetes, CRP reductions with GLP-1 treatment were partly independent of changes in BMI and HbA1c, suggesting a direct anti-inflammatory action. ## Which conditions might benefit? The anti-inflammatory properties of GLP-1 medications have prompted researchers to study their potential in conditions where chronic inflammation plays a central role: ### Cardiovascular disease Atherosclerosis — the buildup of plaque in arteries that leads to heart attacks and strokes — is fundamentally an inflammatory process. By reducing vascular inflammation, GLP-1 medications may slow plaque progression. The SELECT trial results support this hypothesis, as the cardiovascular benefit was seen even in people without diabetes. ### Inflammatory arthritis Early observational studies and case reports have noted improvements in rheumatoid arthritis symptoms in people taking GLP-1 medications. A large retrospective study published in 2024 found that people with obesity and rheumatoid arthritis who were treated with GLP-1 RAs had fewer disease flares and lower inflammatory marker levels compared to those not taking the medications. Formal clinical trials are ongoing. ### Inflammatory bowel disease GLP-1 receptors are expressed in the gut, and there is preclinical evidence that GLP-1 agonists can reduce intestinal inflammation. Small clinical studies in people with Crohn's disease and ulcerative colitis have shown promising results, though this area of research is still in its early stages. ### Neuroinflammation and brain health There is growing interest in GLP-1 medications for neurological conditions. GLP-1 receptors exist in the brain, and semaglutide has been shown to reduce microglial activation — the brain's immune cell response — in animal models of neurodegeneration. Large clinical trials are now underway investigating semaglutide in Alzheimer's disease and Parkinson's disease, with results expected in the coming years. ### Psoriasis and skin inflammation Several case series and observational studies have reported improvements in psoriasis severity in people taking GLP-1 medications. Since psoriasis is an inflammatory skin condition closely linked with metabolic syndrome, the anti-inflammatory effects — together with weight loss — may contribute to these improvements. ## What does this mean for you in practice? If you are taking Wegovy, Ozempic or Mounjaro for weight management or type 2 diabetes, the anti-inflammatory benefits are largely an additional bonus that comes with the treatment — you do not need to do anything differently to benefit from them. However, a few practical points are worth noting: - The medication is not approved to treat inflammation or autoimmune conditions specifically. Always use it as prescribed by your doctor, and do not adjust your dose based on inflammatory conditions without medical guidance. - Diet reinforces the effect. An anti-inflammatory diet rich in vegetables, oily fish, whole grains and nuts — while limiting processed foods and sugar — works in the same direction as your medication and amplifies the benefits. - Exercise also reduces inflammation. Regular physical activity, particularly strength training and moderate aerobic exercise, lowers inflammatory markers independently of GLP-1 medication. Combining them produces stronger effects. - Smoking increases inflammation. If you smoke, quitting is the single most powerful additional step you can take to reduce systemic inflammation alongside your medication. - If you have an autoimmune condition, speak to your rheumatologist or specialist before starting GLP-1 treatment. While the overall evidence is encouraging, individual cases may vary, and potential interactions with immunosuppressive drugs need to be considered. ## Medical disclaimer This article is for general information only and does not constitute medical advice. The research cited reflects the state of knowledge as of mid-2026 and may continue to evolve. Always consult your doctor or specialist before making any changes to your treatment. GLP-1 medications should be used under medical supervision only. ## Sources - GLP-1 receptor agonists and anti-inflammatory mechanisms — NIH/PMC (2023) - Anti-inflammatory effects of GLP-1 agonists beyond glycaemic control — NIH/PMC (2022) - GLP-1 and systemic inflammation in type 2 diabetes — PubMed (2023) - SELECT trial: Semaglutide and cardiovascular outcomes — NEJM (2023) - Wegovy — European Medicines Agency (EMA) --- Source: https://clickdose.io/en/articles/glp1-and-joint-pain.html Many people taking Wegovy, Ozempic or Mounjaro notice an unexpected benefit: their joint pain improves. For some, it is the first time in years they can walk comfortably. But can GLP-1 medications really help your joints — and if so, how? Here is what the research shows. ## Why does weight affect joints so much? The link between body weight and joint pain is well-established. When you walk, the forces passing through your knee joint are several times your body weight. Research by Messier et al. (published in Arthritis & Rheumatism, 2005) found that each kilogram of body weight lost results in approximately 4 kilograms less compressive force on the knee joint per step. Over a full day of walking, this amounts to thousands of tonnes less cumulative load on the knees. This is why weight loss is one of the most effective treatments for osteoarthritis (OA) — the most common form of joint disease. Joints that have been subjected to years of excess loading often show significant pain reduction once that load begins to decrease. The effect can be felt relatively quickly, sometimes within weeks of starting weight loss. ## What do the clinical trials show? In 2024, a landmark randomized controlled trial published in the New England Journal of Medicine (NEJMoa2403664) tested once-weekly semaglutide specifically in people with obesity and knee osteoarthritis. After 68 weeks, the results were striking: - The semaglutide group lost an average of 13.7% of body weight vs. 3.2% in the placebo group - WOMAC knee pain scores fell by 41.7 points vs. 27.5 points (p<0.001) - Physical function (SF-36) improved significantly in the semaglutide group In other words, people taking semaglutide experienced roughly 50% more pain reduction than those taking a placebo — even after accounting for the weight loss difference. For tirzepatide (Mounjaro), analysis of the SURMOUNT-1 trial (PMC12724063, 2025) found that people with the lowest physical functioning at baseline gained the greatest benefit — an average improvement of +12.5 points in physical function in the most impaired quartile. This is particularly encouraging for people who have been significantly limited by their joint pain. ## Is it just the weight loss — or is there something more? This is an important question. The weight-loss effect alone is substantial, but research strongly suggests there is more to it than kilograms on the scale. A 2025 systematic review (PMC11849622) examined 11 studies — 7 pre-clinical and 4 human — and confirmed that GLP-1 receptors are expressed directly in synovial tissue and cartilage. These are the tissues that line and cushion your joints. Activation of these receptors appears to: - Reduce pro-inflammatory cytokines (chemical messengers that drive joint inflammation) - Inhibit chondrocyte apoptosis — the programmed death of cartilage cells - Reduce oxidative stress in articular cartilage A separate study on liraglutide (PMC6554939) confirmed these effects in a dose-dependent manner in joint tissue. In other words, GLP-1 medications may protect joints through a dual mechanism: first, by reducing mechanical load through weight loss, and second, by directly reducing inflammation in joint tissue — independent of the number on the scale. A further study published in 2025 (PMC11729447) looked at whether GLP-1 treatment reduced the need for hip and knee replacement surgery and found encouraging early signals, though longer follow-up data is still needed to confirm this. ## Who benefits the most? Based on current evidence, people who tend to benefit most are those with: - Knee or hip osteoarthritis combined with obesity - Limited physical mobility at baseline — the more restricted you are, the more room there is to improve - High inflammatory markers such as C-reactive protein (CRP) or ESR The evidence is strongest for knee OA. Effects on hip OA, ankle joints and inflammatory forms of arthritis (such as rheumatoid arthritis) are plausible given the mechanism, but less thoroughly studied to date. If you have rheumatoid or psoriatic arthritis, speak to your rheumatologist about what the research currently supports for your specific condition. ## What can you do alongside your medication? You don't have to rely on medication alone. Several lifestyle measures have strong evidence for reducing joint pain and protecting joint health during GLP-1 treatment: - Low-impact exercise: Swimming, cycling and water aerobics place minimal stress on joints while strengthening surrounding muscles. Aim for at least 150 minutes of moderate activity per week. Water-based exercise is particularly useful when pain limits land-based activity. - Strength training: Muscles support and stabilize joints. Strengthening the quadriceps (for knees) and hip abductors is particularly beneficial. Even 2 sessions per week make a meaningful difference. You do not need a gym — resistance bands at home work well. - Anti-inflammatory diet: Emphasize omega-3-rich foods (oily fish, flaxseed, walnuts), vegetables, whole grains and legumes, and limit processed food and added sugar. These changes complement the anti-inflammatory effects of GLP-1 medication itself. - Physiotherapy: Targeted exercises from a physiotherapist addressing specific muscle groups around the affected joints are among the most evidence-based interventions for osteoarthritis. A physiotherapist can also advise on movement strategies that protect your joints during daily activities. - Adequate protein: This is critical during weight loss on GLP-1 medication. Preserving muscle mass is essential for joint stability — see the companion article on muscle preservation with GLP-1 for detailed guidance. ## When should you speak to your doctor? If you have joint pain and are taking GLP-1 medication, it is worth raising this with your doctor at your next appointment. They can: - Assess whether further investigation is needed, such as imaging or blood tests for inflammation markers - Refer you to physiotherapy or a rheumatologist if appropriate - Help optimize your dose titration in the context of any pain improvements Importantly, do not reduce or change your medication doses because your joint pain is improving without first speaking to your doctor. Pain improvement is a positive sign of the treatment working, not a reason to stop. This article provides general information only and does not constitute medical advice. Always consult your doctor about your treatment plan and joint health. ## Sources - Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis — NEJM (2024) - Weight Loss Reduces Knee-Joint Loads — Messier et al. (2005) - Effect of GLP-1 Receptor Agonists in Osteoarthritis: Systematic Review — PMC (2025) - Physical Function Improvements with Tirzepatide — SURMOUNT-1 (2025) - Liraglutide Reduces Inflammation in Knee Osteoarthritis — PMC - GLP-1 Receptor Agonists and Arthroplasty Conversion in Hip and Knee OA — PMC (2025) --- Source: https://clickdose.io/en/articles/glp1-and-kidneys.html Your kidneys are two of the hardest-working organs in your body. They filter your blood, regulate blood pressure, and remove waste products. But in many people with type 2 diabetes and obesity, the kidneys are under constant stress — and kidney disease is one of the most feared long-term complications of diabetes. The good news: new research shows that GLP-1 medications like semaglutide (Wegovy, Ozempic) don't just help with weight loss and blood sugar control — they may also actively protect the kidneys from getting worse. ## What is chronic kidney disease? Chronic kidney disease (CKD) happens when the kidneys gradually lose their ability to filter blood. It develops slowly over months or years and often causes no symptoms in the early stages. The two most common causes are type 2 diabetes and high blood pressure. Doctors track kidney health with two key numbers: - eGFR (estimated glomerular filtration rate) — how well the kidneys are filtering, expressed as a percentage of normal function. - Albumin in urine — when kidneys are damaged, protein leaks into the urine. Elevated albumin is an early warning sign. An estimated 37 million Americans live with CKD, and globally the number exceeds 800 million. Many don't know they have it because symptoms only appear at advanced stages. ## The FLOW trial: a landmark result In 2024, researchers published the results of the FLOW trial (Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes). It is the first major clinical trial specifically designed to test whether a GLP-1 medication can slow the progression of kidney disease. The study enrolled 3,533 patients with type 2 diabetes and CKD. Half received once-weekly semaglutide 1.0 mg; the other half received placebo. Patients were followed for a median of 3.4 years. The results were so compelling that the trial was stopped early in October 2023 — it would have been unethical to keep giving half the participants placebo. Semaglutide showed: - 24% reduction in the risk of serious kidney events (kidney failure, sustained eGFR decline, kidney-related death) - 32% reduction in urinary albumin — meaning the kidneys' filters were working better - 18% reduction in cardiovascular events (heart death, heart attack, stroke) These are striking numbers. As a result, semaglutide is now the only GLP-1 medication with a specific approved indication for slowing CKD progression in people with type 2 diabetes. ## How does GLP-1 protect the kidneys? Researchers believe the protection works through several pathways simultaneously: ### Weight loss and lower blood pressure Excess body fat puts direct pressure on the kidneys — fat tissue produces inflammatory signals that raise blood pressure and damage kidney filters over time. When GLP-1 medications reduce body weight, this burden lessens. Semaglutide also lowers blood pressure independently of weight loss, which matters because hypertension is one of the primary drivers of CKD progression. ### Better blood sugar control Persistently high blood sugar damages the tiny blood vessels inside the kidneys. GLP-1 medications lower blood sugar steadily across the entire day — not just in the short term after meals. This reduces the cumulative damage to kidney blood vessels over years of treatment. ### Direct effects on kidney tissue GLP-1 receptors are found not just in the brain and pancreas — they also exist in the kidneys. Animal and human studies suggest that activating these receptors directly reduces inflammation and oxidative stress inside kidney tissue. This is a separate mechanism that partly explains why the protective effect is larger than what weight loss and blood pressure improvements alone would predict. ## What about tirzepatide (Mounjaro/Zepbound)? Tirzepatide (Mounjaro, Zepbound) is a newer medication that activates two receptors — GIP and GLP-1. The TREASURE-CKD trial showed that tirzepatide significantly reduces albumin in urine, suggesting kidney protection. However, a dedicated kidney outcomes trial comparable to FLOW has not yet been completed, so tirzepatide does not yet have the same specific CKD indication as semaglutide. Early data is promising. ## Who benefits most from kidney protection? The documented kidney benefit applies most clearly to people with: - Type 2 diabetes and chronic kidney disease (CKD stages 2–4) - Elevated albumin in urine (albuminuria) - High blood pressure If you're taking GLP-1 medication primarily for weight loss and have no signs of kidney disease, the direct kidney-protective effect is less relevant for you — but the weight loss and blood pressure improvements are still good for your kidneys long-term. ## Should I talk to my doctor about my kidneys? Yes — if you're taking Wegovy, Ozempic, or Mounjaro and have diabetes, it's worth asking your doctor to check your eGFR and urine albumin regularly if they're not already doing so. These are simple blood and urine tests that can catch early kidney damage before it becomes serious. Conversely, if you already have kidney disease and aren't on a GLP-1 medication, the FLOW results give you a strong reason to discuss semaglutide with your doctor. ## A note on dosing with kidney disease For most GLP-1 medications, no dose reduction is needed for mild to moderate kidney impairment. Semaglutide is primarily metabolised by the liver, not the kidneys, and is generally well tolerated even at reduced kidney function. That said, always consult your doctor — other medications, dehydration risk, and electrolyte levels can all influence what's right for you. ## Sources - FLOW Trial: Semaglutide in Patients with CKD and Type 2 Diabetes — PubMed Central - GLP-1 Receptor Agonists — National Kidney Foundation - Semaglutide's Role in CKD Management — Cleveland Clinic - GLP-1 RAs in Diabetic Kidney Disease: Kidney and Heart Protection — PubMed Central --- Source: https://clickdose.io/en/articles/glp1-and-menopause.html For many women, menopause brings an unwelcome surprise: weight gain that seems to arrive despite no obvious change in diet or exercise habits. This is not just about calories — it reflects hormonal changes that fundamentally alter how the body stores fat. GLP-1 medications like Wegovy, Ozempic, and Mounjaro offer a clinically proven approach to managing this. But how do they interact with menopause? And what should you know before starting? ## Why do women gain weight during menopause? When estrogen levels decline during perimenopause and menopause, several metabolic changes occur: - The body stores more fat — particularly visceral fat in the abdomen - Metabolism slows slightly - Muscle mass decreases (sarcopenia accelerates) - Insulin sensitivity declines Research shows the average woman gains 2–3 kg during the menopause transition, though individual variation is wide. Equally important is redistribution: even women who don't gain overall weight often see fat shift from hips and thighs to the abdomen. This visceral fat is more metabolically active and more closely linked to cardiovascular risk than fat in other locations. ## How do GLP-1 medications help during menopause? GLP-1 receptor agonists — semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) — work through several mechanisms that are particularly relevant during the menopause transition: - Reduce appetite: they signal satiety to the brain, lowering hunger and calorie intake - Target visceral fat: clinical trials consistently show GLP-1 medications are especially effective at reducing abdominal visceral fat — exactly what accumulates during menopause - Improve insulin sensitivity: this directly counters the insulin resistance that worsens with declining estrogen - Support weight maintenance: for women who have gained weight during the menopause transition, these medications help reverse that gain The landmark STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) enrolled large proportions of women of menopausal age and demonstrated consistent effectiveness in this group. ## Does menopause affect how GLP-1 medications work? Research suggests that estrogen levels modulate GLP-1 receptor expression in the hypothalamus — the brain region responsible for appetite regulation. In animal models, estrogen appears to enhance GLP-1 receptor sensitivity, which would theoretically mean postmenopausal women have slightly lower receptor sensitivity. What this means in practice: GLP-1 medications work well in menopausal and postmenopausal women, as confirmed by the major clinical trials. However, some women may need to titrate to the higher dose ranges to achieve the same appetite suppression as younger women. Individual responses vary considerably, and there's no reason to assume the medication won't work. ## Can GLP-1 medications help with menopause symptoms beyond weight? This is an active area of research with some promising early signals: - Hot flashes: Observational reports suggest some women notice a reduction in hot flash frequency and severity after starting GLP-1 medications. The proposed mechanism involves reduced systemic inflammation and possible effects on temperature regulation in the hypothalamus. This has not yet been confirmed in large randomised controlled trials. - Sleep quality: Weight loss itself improves sleep and can reduce obstructive sleep apnea — a condition that worsens during menopause. GLP-1-mediated weight loss may therefore provide indirect but meaningful sleep benefits. - Mood and energy: Some women report improved mood and energy on GLP-1 medications. Whether this is from weight-related improvements in self-esteem, reduced inflammatory burden, or direct neurological effects of GLP-1 receptors in the brain is still being investigated. It is important to be clear: GLP-1 medications are not approved treatments for menopause symptoms. These are potential secondary benefits observed incidentally — not established or licensed effects. ## Can you take GLP-1 medication and HRT together? Yes. There are no known pharmacological interactions between GLP-1 receptor agonists (semaglutide, tirzepatide) and hormone replacement therapy (HRT — also called menopausal hormone therapy, MHT). The two treatments work through entirely different pathways and can safely be used simultaneously. Combining them may offer complementary benefits: - HRT addresses the root hormonal cause of menopausal symptoms (hot flashes, mood changes, bone loss, vaginal dryness) - GLP-1 medication manages weight and metabolic health (insulin resistance, cardiovascular risk, visceral fat) - Some preliminary research suggests estrogen therapy may slightly improve GLP-1 receptor sensitivity — a potential positive interaction Always discuss both treatments with your doctor. HRT has its own individual considerations — personal and family history of breast cancer, cardiovascular history, duration of use, type of HRT — that are separate from GLP-1 medication decisions. ## Practical tips for women using GLP-1 during menopause To get the most out of GLP-1 medication during menopause, these steps have strong evidence behind them: - Strength train regularly: Menopause already accelerates muscle loss; GLP-1-mediated weight loss can exacerbate this. Aim for at least 2–3 strength training sessions per week. Even bodyweight exercises (squats, lunges, resistance bands) make a real difference. - Prioritise protein: Aim for at least 1.2–1.6 g of protein per kg of body weight daily. This protects muscle mass during weight loss and supports bone health. - Monitor bone density: Both the hormonal changes of menopause and rapid weight loss can reduce bone density. Discuss whether a DEXA scan is appropriate for you with your doctor, especially if you have other risk factors. - Don't neglect HRT: GLP-1 medication addresses weight and metabolism but not the hormonal symptoms of menopause. If you are experiencing significant hot flashes, sleep disturbance, or other menopause symptoms, discuss HRT separately with your doctor. - Be patient with the timeline: The typical onset of meaningful weight loss is 4–8 weeks. This timeline is similar in menopausal women as in the general population. ## When should you speak to your doctor? Speak to your doctor before starting GLP-1 medication if: - You are currently on HRT or other hormone treatments (not a contraindication — just worth discussing) - You have a personal or family history of thyroid cancer or MEN2 syndrome (a contraindication for GLP-1 medications) - You are experiencing severe menopause symptoms that may need dedicated treatment - You have type 2 diabetes (GLP-1 medication dosing for weight management differs from diabetes management) Also contact your doctor if you notice unexpected changes in your menstrual pattern while still in perimenopause after starting GLP-1 medication. ## Conclusion For women navigating the metabolic challenges of menopause, GLP-1 medications offer a well-studied, effective tool — particularly for the visceral abdominal fat that accumulates during the hormonal transition. They can safely be combined with HRT, work effectively in menopausal women, and may offer additional benefits beyond weight management. With the right lifestyle support — strength training, adequate protein, bone health monitoring — they can be a valuable part of a comprehensive menopause management strategy. Always speak to your doctor or menopause specialist to find the right combination of treatments for your individual situation. Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any treatment. ## Sources - The Menopause Society (NAMS): Menopause 101 - NHS: Menopause - Mayo Clinic: Menopause weight gain - Wilding JPH et al. — STEP 1 trial: Semaglutide and weight — NEJM (2021) - NAMS Position Statement on Obesity Management in Menopause (2022) --- Source: https://clickdose.io/en/articles/glp1-and-mental-health.html When people start Wegovy, Ozempic or Mounjaro, the focus is usually on weight loss and blood sugar control. But many users notice something unexpected: a shift in mood, reduced cravings for alcohol or sugar, and for some, a relief from symptoms of anxiety and depression. Is this coincidence? Not at all — there is now solid research showing that GLP-1 medications affect the brain in ways that go far beyond the digestive system. ## What are GLP-1 receptors in the brain? GLP-1 is a natural hormone primarily produced in the gut in response to eating. But GLP-1 receptors are not found only in the pancreas and gastrointestinal tract — they are also present in the brain, particularly in areas that govern reward, motivation, stress and mood. When GLP-1 medications (such as semaglutide or tirzepatide) bind to these receptors in the brain, they influence the dopamine system — the so-called reward system. This is the same system activated by food, alcohol and other substances. It explains why many users report reduced cravings for sweets and alcohol — not just because they are less hungry, but because the brain's reward signal is dampened. ## GLP-1 and depression: promising results A large Scandinavian register study published in The Lancet Psychiatry in 2026 followed more than 200,000 patients with depression or anxiety across Denmark, Norway and Sweden. The study found that patients treated with GLP-1 receptor agonists (primarily semaglutide) had significantly lower risk of worsening depression (hazard ratio 0.56) and anxiety (HR 0.62) compared to the control group. This means the risk of depression getting worse was nearly halved in those taking GLP-1 medication. That is a remarkable finding — and it is corroborated from other angles. A post-hoc analysis of the large STEP trials (published in JAMA Internal Medicine, 2024) investigated psychiatric safety in participants without known mental health conditions. Researchers found no increased risk of depression, anxiety or suicidal behaviour — in fact, data showed a slight positive trend in mood among those who lost the most weight. ## Is the effect through weight loss — or directly in the brain? This is an important question. It is well established that weight loss itself improves mental health: better self-image, more energy, less pain, better sleep. But research suggests GLP-1 medications also have direct neural effects, independent of weight loss. A review published in Nature Mental Health (2025) examined 47 studies and concluded that GLP-1 receptor activation in the brain reduces neuroinflammation, influences stress hormone regulation and modulates dopamine pathways — all mechanisms relevant to depression and anxiety. These effects were also seen in animal studies, where GLP-1 agonists reduced anxiety-like and depression-like behaviour independent of body weight changes. ## GLP-1 and cravings: alcohol, sugar and other habits One of the most surprising findings in recent years is that GLP-1 medication reduces the desire for alcohol. A systematic review and meta-analysis published in eClinicalMedicine (The Lancet, 2025) analysed 14 studies with over 900,000 patients and found a significant reduction in alcohol consumption among GLP-1 agonist users. In one randomised trial, participants taking dulaglutide (another GLP-1 agonist) were 29% more likely to reduce their alcohol intake compared to placebo. The effect is thought to stem from the medication dampening the brain's reward response to alcohol in the same way as to food. Research also suggests similar effects on nicotine, and in animal studies on cocaine. Clinical trials of semaglutide for alcohol and substance use disorder are underway — this could prove to be one of the most significant future applications of the GLP-1 class. ## Important caveats: what we don't know yet The picture is not unambiguously positive. There are individual case reports of patients experiencing worsening depression, increased anxiety or mood swings — particularly during the start-up phase, when side effects such as nausea and sleep disturbances are most pronounced. In 2023, the European Medicines Agency (EMA) and the FDA launched a review of possible risks of self-harm and suicidal thoughts in GLP-1 medication users, based on spontaneous reports. Subsequent large register studies have not confirmed a causal link, but this underscores the importance of vigilance — particularly in people with a psychiatric history. It is also important to note that most studies have been conducted in people without serious mental illness. Research in patients with schizophrenia, bipolar disorder or severe depression is still limited, and findings cannot be directly extrapolated. ## What if you already have anxiety or depression? Many people who take GLP-1 medication already have a mental health condition — obesity and mental health disorders frequently co-occur. The question is whether the medication is safe, and perhaps even beneficial, for this group. The Scandinavian Lancet study gives grounds for cautious optimism: it specifically included patients with existing depression and anxiety and still found a protective effect. But it is crucial that — before starting and throughout treatment — you talk openly with your doctor about your mental health, any changes in symptoms and any other medications you are taking. GLP-1 medications are not approved for treating depression or anxiety, and they should not replace psychiatric treatment. But the evidence suggests that for many people they do not worsen mental health — and for some may even help. ## Practical advice: what to watch for - Note your baseline. Pay attention to your mood, sleep and energy levels before you start — so you can detect changes along the way. - Contact your doctor if symptoms worsen. If you experience increased sadness, anxiety, irritability or thoughts of self-harm, contact your doctor promptly. - Start-up side effects. Nausea and sleep disturbances in the first weeks can temporarily affect mood — this is not necessarily a psychiatric problem, but part of the body's adjustment. - Share your mental health history. Make sure the prescribing doctor knows about any psychiatric history and current medications — including antidepressants. ## The future: GLP-1 as psychiatric medication? The research community is increasingly excited about the potential of GLP-1 receptor agonists in psychiatry and neurology. Clinical trials are underway with semaglutide for alcohol use disorder, Alzheimer's disease, depression and even schizophrenia. It is too early to conclude that Wegovy is an antidepressant — but it is not too early to say that the medication influences the brain in biologically relevant ways, and that the research is promising. ## Sources - Ludvigsson JF et al. "Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden." The Lancet Psychiatry, 2026. thelancet.com - Blanco C et al. "Psychiatric Safety of Semaglutide for Weight Management: Post Hoc Analysis of STEP 1, 2, 3, and 5 Trials." JAMA Internal Medicine, 2024. jamanetwork.com - Guo Z et al. "An analysis on the role of GLP-1 receptor agonists in cognitive and mental health disorders." Nature Mental Health, 2025. nature.com - Quddos F et al. "Association between GLP-1 receptor agonists use and change in alcohol consumption: a systematic review." eClinicalMedicine, 2024. thelancet.com - "Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity." Scientific Reports, 2023. nature.com - Svensson E et al. "12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes." eClinicalMedicine, 2024. thelancet.com - EMA. "Wegovy — European Public Assessment Report." ema.europa.eu --- Source: https://clickdose.io/en/articles/glp1-and-muscle-preservation.html Wegovy, Ozempic, and Mounjaro are remarkably effective for weight loss. But like all forms of weight loss, there is an important caveat: some of what you lose may be muscle mass — not just fat. This surprises many users and is something research is only beginning to fully understand. In this article we explain what actually happens to your muscles during GLP-1 treatment, what the latest studies show, and what you can do to protect yourself. ## What happens to muscles during weight loss? When you lose weight — by any method — you always lose a mix of fat and muscle mass. This is normal. The body cannot exclusively burn fat. The question is how large a proportion comes from muscle, and whether it can be minimised. With traditional calorie restriction (diet alone), typically 20–30% of weight loss comes from lean mass (muscle, bone, water). With GLP-1 medications — which produce larger and faster weight loss — the picture is somewhat more complex. ## What does the research show? Studies indicate that the proportion of muscle loss varies depending on which medication you take: - Semaglutide (Wegovy/Ozempic): In the SEMALEAN study, participants lost an average of approximately 3 kg of lean mass over the first 7 months — but muscle loss stabilised thereafter. Grip strength (a measure of muscle function) actually improved by an average of +4.5 kg by month 12, suggesting that muscle quality can improve even during treatment. - Tirzepatide (Mounjaro): In the SURMOUNT-1 trial, participants lost an average of 5.67 kg of lean mass out of a total weight loss of 22.1 kg — roughly 26% of total weight lost. A 2025 systematic review confirmed that tirzepatide appears to preserve a relatively greater proportion of lean mass compared to semaglutide. Overall, research suggests that 25–45% of total weight loss with GLP-1 medications may come from lean mass, depending on diet, exercise, and the specific medication used. ## Why is preserving muscle mass important? Muscle mass is not just about appearance or strength. It matters for your overall health — now and in the future: - Metabolism: Muscles burn energy even at rest. If you lose too much muscle, your resting metabolic rate drops, making it harder to maintain your weight if you stop the medication. - Insulin sensitivity: Muscles are the body's primary engine for burning blood sugar. More muscle mass means better blood sugar control. - Strength and function: Especially for older adults, muscle mass is critical for balance, mobility, and the ability to manage daily life independently. - Bone health: Strength training and muscle loading protect bones against brittleness (osteoporosis). ## Protein: the key nutrient for muscle preservation The most important nutritional step to preserve muscle mass during weight loss is eating enough protein. Many people on GLP-1 medications experience a markedly reduced appetite — and risk eating too little protein even when eating as much as they can manage. Most experts and clinical guidelines recommend: - At least 1.2–1.6 g of protein per kg of body weight per day during active weight loss - Spread protein evenly across 3–4 meals (20–40 g per meal) - Prioritise protein-rich foods over carbohydrates when appetite is limited Good protein sources include: eggs, chicken, fish, lean beef, dairy (Greek yogurt, cottage cheese), legumes, and tofu. Protein powder can supplement if it is difficult to meet requirements through food alone. Quality matters: complete proteins (from animal sources or complementary plant protein combinations) contain all essential amino acids, including leucine — the most important trigger for muscle protein synthesis. ## Resistance training: the other half of the solution Protein alone is not enough. To preserve — and potentially build — muscle mass during weight loss, resistance training is essential. Aerobic exercise like walking and cycling is excellent for heart health, but only strength training effectively stimulates muscles to maintain their mass. Recommendations from WHO and clinical experts: - 2–3 resistance training sessions per week covering all major muscle groups - Use free weights, machines, or bodyweight exercises (squats, lunges, push-ups) - Progressive overload: gradually increase weight or repetitions over time - Even 20–30 minutes per session has documented benefits Studies show that combining GLP-1 medication with a high-protein diet and resistance training produces the best outcome: more fat loss, less muscle loss, and better long-term weight maintenance. ## Signs you may be losing too much muscle Muscle loss can be difficult to notice directly — the scale drops regardless. But watch out for these signs: - You feel weaker in daily activities (climbing stairs, carrying shopping) - You fatigue quickly during light physical activity - Your grip strength (e.g. opening lids) is noticeably weaker than before - You are losing weight rapidly, but your body feels "soft" rather than toned Talk to your doctor if you are concerned. A bioimpedance analysis (body composition scan) can give a precise picture of what you are losing. ## Is tirzepatide better for muscles than semaglutide? Research suggests that tirzepatide (Mounjaro) may preserve a slightly higher proportion of muscle mass than semaglutide (Wegovy/Ozempic) during weight loss. This is likely because tirzepatide also activates the GIP receptor — in addition to the GLP-1 receptor — which appears to have a positive effect on muscle composition. However, the difference is not dramatic, and diet and exercise are far more important factors in practice. This alone is not a reason to choose one medication over the other — discuss it with your doctor based on your overall health profile. ## Practical tips — a summary - Eat at least 1.2 g of protein per kg of body weight daily — prioritise protein at every meal - Strength train 2–3 times per week, even with short sessions - Avoid eating too little — an excessive calorie deficit accelerates muscle loss - Get enough sleep — sleep is critical for muscle repair and hormonal balance - Consider a body composition scan to track your progress ## Sources - Rondanelli M et al. — SEMALEAN: Impact of Semaglutide on fat mass, lean mass and muscle function in obesity. PMC, 2025 - Tirzepatide and muscle composition changes — SURPASS-3 MRI. The Lancet Diabetes & Endocrinology, 2025 - Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review. PMC, 2025 - Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists. PubMed, 2025 - New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? PubMed, 2025 --- Source: https://clickdose.io/en/articles/glp1-and-nausea.html Starting Wegovy, Ozempic, or Mounjaro is an exciting step — but for close to half of all new users, it comes with an unwelcome companion: nausea. Some describe it as a persistent background queasiness, others experience actual vomiting, and for some it becomes the main reason they consider stopping treatment before it has had a chance to work. The good news is that nausea from GLP-1 medications is well understood, almost always temporary, and there are several practical things you can do to make it far more manageable. ## Why does GLP-1 medication cause nausea? GLP-1 (glucagon-like peptide-1) receptors are found throughout your body — not just in the pancreas and brain, but also lining your gastrointestinal tract. When these receptors are activated by semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro), they slow down the movement of food through your stomach and intestines — an effect called delayed gastric emptying. This slower digestion is actually part of how these medications work: it helps you feel full for longer and reduces hunger signals to the brain. But it also means food sits in the stomach longer than usual, which can trigger nausea — particularly when starting treatment or increasing the dose. GLP-1 receptors also exist in the brainstem's area postrema — the body's "nausea centre" — where the medication can directly trigger feelings of sickness, independent of what is happening in the stomach. ## When is nausea most common? Nausea with GLP-1 medications follows a recognisable pattern that most patients experience: - Strongest in the first 2–4 weeks of starting treatment - Returns briefly with each dose increase (Wegovy and Ozempic follow a titration schedule, typically stepping up every 4 weeks) - Usually eases substantially after staying on the same dose for 4–8 weeks, as the body adapts In the SCALE Obesity trial for semaglutide, nausea affected approximately 44% of participants — but for most, it was mild to moderate and temporary. In the SURMOUNT-1 trial for tirzepatide (Mounjaro), nausea was reported in around 28–33% of patients, depending on dose. ## How long does it last? For most people, nausea is self-limiting. Once you have been on the same dose for several weeks, your body adapts and the symptoms subside. Many patients report that they barely notice nausea anymore by week 8–12 at any given dose level. However, expect a brief return of nausea each time your dose is increased — this is completely normal and part of the titration process. If nausea remains severe or persistent for more than 2–3 weeks at a stable dose, it is worth speaking to your doctor. A temporary dose pause or reduction is sometimes a better option than stopping treatment entirely. ## What can you do to reduce nausea? ### 1. Eat smaller, more frequent portions Your stomach now empties more slowly than before. Overloading it with a large meal is one of the most reliable triggers for nausea on GLP-1 therapy. Try eating 4–5 small meals a day instead of 2–3 large ones. A portion the size of your cupped hand is a useful guide. Stop eating as soon as you feel comfortably full — the medication means satiety signals arrive sooner, and ignoring them often leads to nausea. ### 2. Avoid fatty, fried, and spicy foods High-fat foods take the longest to digest. When gastric emptying is already slowed by the medication, fatty meals can make nausea significantly worse. During the first weeks of treatment, stick to easily digestible foods: plain rice or pasta, boiled potatoes, chicken, white fish, plain yogurt, bananas, and cooked vegetables. Avoid fast food, fried dishes, very spicy food, and heavy cream sauces. ### 3. Eat slowly and chew thoroughly Eating quickly overloads a stomach that is already working at a slower pace. Eat calmly, put your utensils down between bites, and aim to chew each mouthful well before swallowing. Try to make meals last at least 20 minutes. Eating while distracted — watching television, working at a desk — tends to lead to faster eating and larger portions than you realise. ### 4. Time your injection wisely Some people find that injecting at bedtime helps them sleep through the worst of the nausea. Others prefer morning injections. Experiment to find what works best for you — consistency is the most important thing, but a small timing adjustment can make a real difference for some people. ### 5. Stay hydrated Nausea can make you reluctant to drink, but dehydration makes nausea worse — a vicious cycle. Sip water or clear fluids steadily throughout the day rather than drinking large amounts at once. Still or sparkling water works well. Avoid sugary drinks and large quantities of coffee, as these can worsen nausea for some people. ### 6. Try ginger Ginger has well-documented anti-nausea properties and is widely used in chemotherapy-related and pregnancy nausea. It has not been studied specifically in GLP-1 nausea, but many patients report it helpful. Options include ginger tea, crystallised ginger, or ginger capsules (follow the package instructions). Ginger is generally safe, but check with your pharmacist if you take blood-thinning medication. ### 7. Stay upright after eating Lying flat immediately after a meal can worsen nausea and reflux. Try to stay upright for at least 30–60 minutes after eating. If nausea strikes, sitting comfortably or going for a gentle walk is usually better than lying down. ## Can a slower dose increase help? Yes. The standard titration schedule for Wegovy, Ozempic, and Mounjaro is designed to minimise side effects, but you and your doctor can choose to move more slowly if nausea is troublesome. Some clinicians recommend staying at the starting dose for 8 weeks instead of 4. A slower titration is not associated with reduced long-term effectiveness and often leads to better overall tolerability — meaning fewer people stopping treatment early. ## When should you contact your doctor? Mild nausea is expected and does not require medical attention. However, contact your doctor or seek medical care if: - You are vomiting repeatedly and cannot keep food or fluids down - You show signs of dehydration (dark urine, dizziness, dry mouth, confusion) - Nausea remains severe at full intensity for more than 2–3 weeks at a stable dose - You experience severe abdominal pain — this may indicate pancreatitis and requires immediate assessment Never stop your GLP-1 medication abruptly without speaking to your doctor. If nausea is severe, a temporary dose reduction is usually the safer and more effective solution. ## Conclusion Nausea is one of the most common side effects of GLP-1 medications — but also one of the most temporary. With the right strategies (smaller meals, avoiding fatty foods, eating slowly, staying hydrated, and being patient through the adjustment period), the vast majority of people find that nausea improves significantly within the first few weeks at any given dose. If you are struggling, don't give up without speaking to your doctor first. A few practical changes can often make the difference between stopping and succeeding. Always discuss any persistent side effects with your prescribing doctor. ## Sources - Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384:989–1002. - Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387:205–216. - Wegovy (semaglutide) Prescribing Information. FDA / Novo Nordisk. 2021. - Mounjaro (tirzepatide) Prescribing Information. FDA / Eli Lilly. 2022. - NHS: Semaglutide for weight management — side effects and how to cope. --- Source: https://clickdose.io/en/articles/glp1-and-pancreatitis.html When you start a GLP-1 medication like semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro), your prescribing doctor or the medication leaflet may mention pancreatitis as a potential risk. This can feel alarming — especially if you have had stomach trouble before. But what does the evidence actually say, and should you be worried? Here is a thorough look at what pancreatitis is, what the science shows, and what you should do if warning symptoms appear. ## What is pancreatitis? The pancreas is a gland located behind the stomach that plays two vital roles: it produces digestive enzymes that break down food in the intestine, and it releases the hormones insulin and glucagon that regulate blood sugar. Pancreatitis is inflammation of the pancreas. There are two main types: - Acute pancreatitis: A sudden episode of inflammation that comes on quickly and can range from mild discomfort to a severe, life-threatening condition. Most people recover fully with treatment, but it can be serious. - Chronic pancreatitis: Long-lasting inflammation that permanently damages pancreatic tissue over time, affecting both digestion and blood sugar regulation. The most common causes of pancreatitis are gallstones and heavy alcohol use. High triglycerides, certain medications, and genetic factors also play a role. ## What does the prescribing information say? The US prescribing information for semaglutide (Ozempic) states that cases of acute pancreatitis, including fatal and non-fatal cases, have been reported during post-marketing use. The label advises that GLP-1 medications should be discontinued if pancreatitis is suspected and not restarted if pancreatitis is confirmed. The NHS information for semaglutide injection similarly lists severe stomach pain as a symptom that requires urgent medical attention, as it may be a sign of pancreatitis. This caution is standard practice for a class of medications where a biological signal was observed in early studies — even if the overall risk in large trials has been more reassuring. It is there to protect you, not to alarm you unnecessarily. ## What are the warning signs of pancreatitis? Knowing what to look for is the most important practical step. The classic symptoms of acute pancreatitis include: - Severe abdominal pain: Typically in the upper abdomen, often described as a deep, constant ache that may radiate through to the back - Pain that worsens after eating - Nausea and vomiting - Fever - Rapid heart rate - Tenderness when you touch your abdomen It is important to note that mild nausea is a very common and expected side effect of GLP-1 medications — particularly in the early weeks. Mild nausea alone is not a sign of pancreatitis. The hallmark of pancreatitis is severe abdominal pain, especially pain radiating to the back. ## What should you do if these symptoms appear? If you experience severe abdominal pain — with or without nausea, vomiting or fever — while taking a GLP-1 medication: - Stop taking the medication and do not take the next scheduled dose. - Seek medical help immediately — either contact your doctor urgently or go to an emergency department, depending on the severity. - Do not restart the medication until you have spoken to your doctor and pancreatitis has been ruled out or fully resolved. Pancreatitis is diagnosed with blood tests (elevated pancreatic enzymes) and sometimes imaging. If confirmed, your doctor will decide whether it is safe to continue GLP-1 treatment or whether an alternative approach is needed. ## Who is at higher risk? Certain people may be more vulnerable to pancreatitis in general, and should discuss their history carefully with their doctor before starting a GLP-1 medication: - Prior history of pancreatitis: If you have had pancreatitis before, you are at higher risk of recurrence regardless of medication. Many guidelines advise caution or avoidance of GLP-1 medications in this group. - Gallstones: Gallstones are a leading cause of pancreatitis, and GLP-1 medications can, in some cases, affect gallbladder motility. Weight loss itself also increases the risk of gallstone formation. - High triglycerides (hypertriglyceridaemia): Very high triglyceride levels are a well-known trigger for pancreatitis. If your triglycerides are elevated, this should be managed alongside your GLP-1 treatment. - Heavy alcohol use: Alcohol is one of the most common causes of pancreatitis. If alcohol use is a factor in your life, discuss this openly with your doctor. - Family history of pancreatitis or pancreatic disease ## What does the evidence show? The scientific picture is more reassuring than the prescribing warnings might initially suggest. The LEADER trial (Marso et al., 2016, NEJM) was a large cardiovascular outcomes trial involving over 9,000 people with type 2 diabetes taking liraglutide. The rate of acute pancreatitis was 0.4% in the liraglutide group versus 0.5% in the placebo group — a non-significant difference. The SUSTAIN-6 trial (Marso et al., 2016, NEJM), which studied semaglutide in over 3,000 people, similarly found no statistically significant increase in pancreatitis compared to placebo. A 2023 meta-analysis (PubMed: 37982580) pooling data from multiple randomised controlled trials found no significant increase in the risk of pancreatitis with GLP-1 receptor agonists overall. The authors noted that while isolated cases have been reported, the absolute risk remains low. In summary: the biological mechanism raises a question worth monitoring, the prescribing information reflects appropriate caution, and the large trial data is broadly reassuring. The absolute risk of pancreatitis on a GLP-1 medication, for most people, is low. ## Should you avoid GLP-1 medications if you have had pancreatitis before? This is genuinely a question to discuss with your doctor, as guidance varies. Many clinicians and prescribing guidelines advise avoiding GLP-1 medications if you have a history of pancreatitis, particularly if the cause was never fully identified or if you have had recurrent episodes. However, some doctors may consider GLP-1 treatment even in people with a past episode, especially if the pancreatitis was mild, fully resolved, and a clear and avoidable cause was identified (such as a gallstone that has since been treated). The decision involves weighing the potential benefits — significant improvement in blood sugar, weight and cardiovascular risk — against the uncertainty of risk in an individual who is already predisposed. If you have a history of pancreatitis and are being considered for a GLP-1 medication, make sure your full medical history is shared with the prescribing clinician before you start. ## Keeping the risk in perspective It is natural to feel unsettled when a medication leaflet lists a serious condition as a possible risk. But context matters. Pancreatitis is listed as a warning because isolated cases have been observed, not because GLP-1 medications are strongly associated with the condition at a population level. For the vast majority of people taking Wegovy, Ozempic or Mounjaro, pancreatitis will never occur. The clinical trials — which collectively involved tens of thousands of participants — have not found a statistically significant increase in risk compared to placebo. Knowing the warning signs and acting quickly if they appear is the best practical protection you have. ## Conclusion GLP-1 medications carry a label warning about pancreatitis, and it is right to take that seriously. But the large body of clinical evidence, including major cardiovascular outcome trials, has not demonstrated a meaningful increase in risk for most people. The most important things you can do are: be aware of the warning signs, let your doctor know about any relevant risk factors in your history, and seek prompt medical attention if you develop severe abdominal pain. Always speak to your doctor or pharmacist if you have concerns about pancreatitis and your GLP-1 treatment. Do not stop or change your medication without medical advice. ## Medical disclaimer This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any decisions about your medication or treatment. ## Sources - Ozempic US Prescribing Information — FDA (2021) - Semaglutide injection — NHS - LEADER Trial: Liraglutide and Cardiovascular Outcomes — Marso et al., NEJM (2016) - SUSTAIN-6 Trial: Semaglutide and Cardiovascular Outcomes — Marso et al., NEJM (2016) - Meta-analysis: GLP-1 Receptor Agonists and Risk of Pancreatitis — PubMed (2023) --- Source: https://clickdose.io/en/articles/glp1-and-pcos.html ## What is PCOS? Polycystic ovary syndrome — PCOS — is the most common hormonal disorder in women of reproductive age, affecting approximately 8–13% of all women. It is one of the leading causes of reduced fertility. Despite the name, PCOS is not just about the ovaries — it is a complex metabolic condition that affects the whole body. The three hallmarks of PCOS are: - Irregular or absent ovulation — causing unpredictable or absent periods - Elevated male sex hormones (androgens) — which can cause excess facial hair, acne, and scalp hair thinning - Polycystic ovaries — many small follicles clustered on the ovary surface, visible on ultrasound For many women with PCOS, the underlying engine is insulin resistance — the body's cells do not respond normally to insulin. This pushes the body to produce more insulin, which in turn stimulates the ovaries to make excess androgens. This is exactly where GLP-1 medications become relevant. ## What is GLP-1 — and what does it do? GLP-1 (glucagon-like peptide-1) is a natural gut hormone released after eating. It signals the pancreas to produce insulin, reduces appetite, and blunts blood sugar spikes after meals. Medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) mimic and amplify this hormonal signal. This makes GLP-1 medications relevant for PCOS for two reasons: they directly lower insulin levels, and they promote weight loss — and weight loss itself improves insulin sensitivity. It is like attacking PCOS from two angles at once. ## What does the research show? Research into GLP-1 medications and PCOS is still relatively new, but the results are promising. A 2023 clinical study published in the Journal of Clinical Medicine treated obese women with PCOS who had not responded adequately to lifestyle changes with semaglutide 0.5 mg weekly. After 6 months: - 80% experienced normalisation of their menstrual cycle - Average weight loss of 11.5 kg, with BMI dropping from 34.4 to 29.4 - Significant improvements in insulin resistance and blood glucose levels - Very few side effects reported A randomised controlled trial from 2025 compared metformin alone with a combination of metformin and semaglutide in overweight/obese women with PCOS. The combination group achieved significantly greater weight loss, improved insulin sensitivity, lower inflammatory markers, menstrual normalisation — and higher natural pregnancy rates. A 2024 review concluded that all three classes of incretin mimetics — GLP-1 agonists, dual agonists (GLP-1/GIP), and triple agonists — showed significant improvements in weight loss and insulin sensitivity compared with traditional PCOS management. ## What happens to hormones? One of the most interesting effects is the reduction in androgen levels. As insulin levels fall, the ovaries produce fewer male sex hormones. This can mean: - Reduced unwanted hair growth (hirsutism) - Improved acne - Better regulation of the menstrual cycle - Increased chance of spontaneous ovulation It is important to note that the effect is not the same for everyone. Women with predominantly insulin-resistant PCOS tend to benefit the most, while the effect may be more limited in women with a lean PCOS phenotype. ## What about fertility? PCOS is one of the most common causes of infertility, because irregular ovulation makes it difficult to conceive. The improvement in insulin sensitivity and normalisation of the menstrual cycle can in itself increase the chances of pregnancy. However, there is an important safety rule: semaglutide is not recommended during pregnancy. The manufacturer Novo Nordisk advises stopping semaglutide at least 2 months (8 weeks) before attempting to conceive. For tirzepatide (Mounjaro), the recommendation is at least 1 month (4 weeks) before trying. Animal studies have shown a risk of foetal malformations when used during pregnancy. If you are on GLP-1 medication and planning a pregnancy, it is essential to discuss this with your doctor well in advance. Treatment with metformin or ovulation induction may be more appropriate when pregnancy is the immediate goal. ## Is GLP-1 medication approved for PCOS? Neither semaglutide nor tirzepatide is officially approved for the treatment of PCOS in the EU, UK, or USA. They are approved for type 2 diabetes (Ozempic, Mounjaro) and obesity (Wegovy). Use for PCOS is therefore off-label — outside the approved indications. However, many endocrinologists and gynaecologists have begun offering these medications to women with PCOS and severe insulin resistance or obesity, as the evidence is promising. Traditional PCOS treatment with metformin and the contraceptive pill does not always adequately address the underlying insulin resistance. ## Practical considerations If you are considering GLP-1 medication as part of PCOS treatment, here are the key points to discuss with your doctor: - Blood tests: Have fasting insulin, blood glucose (HbA1c), SHBG, and testosterone measured — this helps determine whether you have insulin-resistant PCOS. - Weight status: The evidence is strongest for women with a BMI above 27–30. It is not impossible at lower BMI, but the evidence is more limited. - Combining with metformin: The combination of semaglutide and metformin showed better outcomes than metformin alone in the above-mentioned trial. - Pregnancy plans: Tell your doctor if you are considering pregnancy within the next 1–2 years. - Side effects: Nausea and gastrointestinal discomfort are the most common side effects, but they typically ease after the first few weeks. Always start low and titrate gradually. ## What to expect Based on the available studies, here is what is realistic to expect from semaglutide treatment for PCOS: - The first signs of improvement (more regular periods, reduced appetite) are typically seen within the first 1–3 months. - Full effect on the menstrual cycle and insulin resistance takes 3–6 months. - Weight loss contributes further to hormonal improvement — the more weight lost, the greater the hormonal benefit. - Effects are maintained as long as the medication is continued. If you stop, PCOS symptoms are likely to return over time. ## Conclusion GLP-1 medications are not a cure for PCOS, but they represent a promising treatment option for women with insulin-resistant PCOS and excess weight. The dual effect — direct improvement of insulin sensitivity and weight loss — precisely targets the central drivers of many PCOS symptoms. Research suggests that up to 8 in 10 women with obesity and PCOS can normalise their menstrual cycle with semaglutide. Always talk to your doctor or gynaecologist before starting GLP-1 treatment for PCOS — and plan carefully if pregnancy is a goal. ## Sources - Forni et al. (2023): Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients — PMC/NIH - Metformin + semaglutide randomised controlled trial in PCOS (2025) — PMC/NIH - GLP-1 Receptor Agonists and PCOS: A Scoping Review — PubMed/NIH - Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS — PMC/NIH - The Potential Utility of Tirzepatide for PCOS — PMC/NIH --- Source: https://clickdose.io/en/articles/glp1-and-pregnancy.html Wegovy, Ozempic, and Mounjaro are now used by millions of people for weight management. But what happens if you are on one of these medications and want to get pregnant — or discover you already are? And can these medications actually affect your fertility? These are questions that many women of childbearing age are asking, and the answers are important to understand. This article summarises what research and regulatory authorities currently recommend. ## GLP-1 medications are not recommended during pregnancy The clear message from the FDA, EMA, and the manufacturers is: stop GLP-1 medication before trying to conceive. These medicines are not approved for use during pregnancy, and animal studies have shown signs of harm to foetuses at high doses. In animal studies with semaglutide (Wegovy/Ozempic) in rats and rabbits, high doses caused foetal death, structural malformations, and growth abnormalities. Similar findings were seen with tirzepatide (Mounjaro) in animal studies. Crucially, these studies used doses far higher than those given to humans — but out of caution, use during pregnancy is not recommended. Human data are more reassuring: a large multicentre observational study published in eClinicalMedicine (2024), covering 168 pregnancies with first-trimester GLP-1 exposure, found no significant increase in congenital anomalies or pregnancy loss compared to controls. A further observational study (2025) involving 1,094 semaglutide-exposed pregnancies reached similar conclusions. Important caveats apply: these are observational studies, not controlled trials, and the data remain limited. The official regulatory recommendation remains: avoid GLP-1 medications during pregnancy and when planning a pregnancy. ## When should you stop the medication? Both semaglutide and tirzepatide remain in the body long after the last injection — a detail many people overlook. - Semaglutide (Wegovy, Ozempic): Has a half-life of approximately 1 week and is essentially cleared from the body within about 5–6 weeks. However, the FDA and manufacturers recommend stopping at least 2 months (8 weeks) before planned conception as an extra safety margin. - Tirzepatide (Mounjaro): Has a slightly shorter half-life (approximately 5 days) and is recommended to be stopped at least 1 month before planned conception — though many clinicians advise 2 months for added caution. These timeframes are designed to ensure the medication has fully cleared the body before conception takes place, particularly during the vulnerable early stages of foetal development. ## What if you became pregnant while on the medication? It happens: a pregnancy is discovered while still on treatment. This is not a crisis, but you should act promptly. - Stop the medication immediately — no gradual taper is needed; discontinue right away. - Contact your doctor within a few days — your doctor can advise on the specific risks based on when during the pregnancy the exposure occurred. - Enrol in a pregnancy registry — Novo Nordisk runs a semaglutide pregnancy exposure registry (PREGNORDISK), and Eli Lilly has a similar one for tirzepatide. Your participation helps researchers better understand any risks. Research suggests that inadvertent first-trimester exposure is likely not associated with a major increase in risk — but this is not a guarantee, and medical follow-up is always important. ## Can GLP-1 medications actually improve fertility? Here is something that surprises many people: for women with obesity and PCOS (polycystic ovary syndrome), GLP-1 medications may actually improve fertility — indirectly, through weight loss. Excess body weight is one of the most common causes of irregular ovulation and reduced fertility in women. Studies show that even a modest 5–10% weight loss can restore regular ovulation and improve pregnancy rates in women with PCOS and obesity. Since GLP-1 medications promote significant weight loss, they can — over time — improve fertility prospects. However, the medication must of course be stopped well before any conception attempt. Researchers are also exploring whether GLP-1 receptors directly influence ovarian function. Early studies (2024–2025) suggest semaglutide may have direct effects on follicle maturation and hormonal balance, but this remains unresolved and requires more research before clinical recommendations can be made. ## Contraception and GLP-1 medications — an important detail Tirzepatide (Mounjaro) may affect the absorption of oral contraceptives. Because the medication slows gastric emptying, oral contraceptive pills may be absorbed more slowly and potentially less completely. The prescribing information recommends using a barrier method (e.g. condoms) or switching to a non-oral contraceptive (e.g. IUD or implant) for 4 weeks after starting and after each dose increase. Semaglutide works by the same mechanism — slowing gastric emptying — so similar precautions apply in practice, even if the product label does not specify this as explicitly. In 2024, the EMA clarified that women of childbearing potential should use effective contraception throughout treatment with semaglutide. ## What about breastfeeding? Neither semaglutide nor tirzepatide is recommended while breastfeeding. It is not known whether either medication is excreted in breast milk, and potential effects on infants have not been studied. Manufacturers recommend choosing either breastfeeding or medication — not both. ## What to do if you are planning a pregnancy A practical checklist for anyone on GLP-1 medication who is considering pregnancy: - Talk to your doctor well in advance — at least 3 months before you want to start trying. - Plan when to stop the medication — 2 months before trying for semaglutide, 1–2 months for tirzepatide. - Discuss alternatives — your doctor can advise on other treatments (e.g. metformin for type 2 diabetes, or lifestyle interventions) during pregnancy. - Keep using effective contraception until you are ready — and remember that tirzepatide may reduce the effectiveness of oral contraceptive pills. - Be realistic about weight — some of the weight lost may return after stopping medication; this is normal and expected. ## Summary GLP-1 medications are powerful tools for weight management, but they require careful planning if you want to have a child. The regulatory message is clear: stop the medication in good time, use contraception during treatment, and speak with your doctor if in doubt. The good news is that inadvertent early-pregnancy exposure is likely not a major risk — but it is not something to rely on. ## Sources - Ceulemans et al. (2024). Use of GLP1 receptor agonists in early pregnancy and reproductive safety. eClinicalMedicine / PMC. - Saraydar et al. (2025). Pregnancy Outcomes After Semaglutide Exposure. PMC/NIH. - Barbour et al. (2025). GLP-1 receptor agonists and preconception planning: a narrative review. PMC. - MotherToBaby. Semaglutide Fact Sheet. NCBI Bookshelf. - MotherToBaby. Tirzepatide (Mounjaro/Zepbound) Fact Sheet. NCBI Bookshelf. - FDA. Wegovy (semaglutide) prescribing information. accessdata.fda.gov. - Mayo Clinic. Semaglutide — Precautions. --- Source: https://clickdose.io/en/articles/glp1-and-skin.html Many people who start Wegovy, Ozempic or Mounjaro are pleased with the weight loss — but gradually notice that their skin doesn't quite keep up. The face can look more hollow, the skin on the arms and belly may sag, and some people find they look older than expected. These changes have been nicknamed "Ozempic face" on social media and are widely discussed by both patients and healthcare professionals. But what is actually happening — and what can you do about it? Here is a thorough overview. ## What is "Ozempic face"? "Ozempic face" is a popular term for the facial changes some people experience during weight loss with GLP-1 medication. It typically refers to: - Sunken cheeks and hollow temples - More pronounced wrinkles and folds - Loss of firmness and volume in the face - A generally more "gaunt" or aged appearance It is important to emphasise that this is not a direct side effect of semaglutide or tirzepatide itself. According to a systematic review in the Aesthetic Surgery Journal (2025), the phenomenon is primarily the result of rapid weight loss — and can occur with any form of rapid weight loss, regardless of method. Because GLP-1 medications can produce relatively fast and significant weight loss, it is seen more frequently here than with slow calorie restriction, for example. ## What happens to the skin during weight loss? Several processes occur in and beneath the skin during weight loss: ### Fat pads disappear Fat is not just something we want to lose — it also acts as "padding" beneath the skin. When this fat disappears rapidly, the skin loses its underlying support and can sag. In the face, patients lost an average of 7% of mid-facial volume per 10 kg of weight loss, according to a radiological study from 2025 (PubMed: 40407186). ### Collagen and elastin are affected Collagen and elastin are the proteins that give skin its firmness and elasticity. Research published in PMC12370548 (NIH, 2025) shows that rapid weight loss can reduce the density of these fibres in the skin. Additionally, GLP-1 receptors on adipose-derived stem cells (ADSC) may be activated, potentially affecting those cells' ability to produce protective cytokines and collagen. In simple terms: the skin can lose some of its "spring". ### Muscle mass can decline Muscles provide volume beneath the skin and contribute to a "full" appearance. Studies show that up to 25–40% of weight lost on GLP-1 medication may come from muscle mass — especially if you are not actively strength training. Declining muscle mass can make loose skin even more visible. ## Is everyone at the same risk? No. Several factors influence how much the skin is affected: - Age: Older skin naturally has fewer collagen fibres and adapts more slowly - Speed of weight loss: The faster the weight loss, the less time the skin has to adapt - Amount of weight lost: A larger total weight loss increases the risk of loose skin - Genetics: Skin type and hereditary factors play a role - Sun damage and smoking: Both break down collagen and worsen outcomes ## What can you do? The good news is that you are far from helpless. Here are the most evidence-based steps: ### 1. Eat enough protein Protein is the building block of both muscle and collagen. When taking GLP-1 medication and eating less, it is easy to under-consume protein. Aim for at least 1.2–1.6 grams of protein per kilogram of body weight per day. Prioritise protein-rich foods such as eggs, chicken, fish, legumes and Greek yogurt. Spread protein intake across meals rather than consuming it all at once. ### 2. Strength train regularly Strength training is probably the single most effective intervention against loose skin. It preserves and builds muscle mass, which fills the skin from within. Even 2–3 sessions per week make a noticeable difference. You don't need to lift heavy — bodyweight exercises like squats, lunges and push-ups are a great starting point. ### 3. Stay hydrated Water is essential for skin cell function and skin barrier integrity. Dehydrated skin looks more slack and wrinkled. Drink adequate water — around 1.5–2 litres per day — and remember that fluid needs increase with physical activity and heat. ### 4. Protect your skin from the sun UV rays are one of the greatest known destroyers of collagen and elastin. Use broad-spectrum sunscreen with SPF 30 or higher every day, even on cloudy days. This simple habit has a large long-term effect on skin quality. ### 5. Avoid smoking Smoking accelerates collagen breakdown and significantly impairs blood supply to the skin. Studies show that smokers have markedly more sagging and wrinkled skin for the same amount of weight loss compared to non-smokers. If you smoke and take GLP-1 medication, quitting is the single action with the greatest positive impact on your skin. ### 6. Skincare products — what works? Certain ingredients have documented effects on collagen production: - Retinoids (vitamin A): Stimulate skin cell turnover and collagen production. Start with a mild strength and use at night. - Vitamin C (ascorbic acid): Antioxidant that supports collagen synthesis. Best used in the morning. - Peptides: Signalling molecules that encourage the skin to produce more collagen and elastin. - Hyaluronic acid: Draws moisture into the skin and creates a more plump appearance. Remember that topical products cannot replace the fundamental lifestyle changes — they are a supplement, not a substitute. ## When should you seek professional help? If you have lost weight rapidly and are unhappy with your skin's condition, it may be worth: - Consulting a dermatologist about your skin type and relevant treatments - Considering non-surgical treatments such as radiofrequency, ultrasound (Ultherapy) or microneedling, which can stimulate collagen production - In severe cases with very loose skin (e.g. after 40+ kg of weight loss), surgical skin tightening can be discussed with a plastic surgeon A 2025 study (PMC12549488) notes that plastic surgeons report up to a 50% increase in facial procedures related to GLP-1-mediated weight loss — a sign that demand for treatments is growing alongside the medication's uptake. ## A word on pace While GLP-1 medication can produce impressive results quickly, it is worth discussing with your doctor whether to titrate slowly and not rush the weight loss more than necessary. A slower, more stable weight loss gives the skin more time to adapt and reduces the risk of pronounced loose skin. ## Conclusion Skin changes are a real and common part of the weight-loss journey with GLP-1 medication — and it can feel frustrating to lose weight and still not look as you expected. But it is important to remember that skin is dynamic tissue that adapts over time. With strength training, adequate protein, good skincare and patience, most people can achieve significant improvements. And for those still unhappy, effective clinical options exist. Always speak to your doctor if you have concerns about skin changes during your treatment. ## Sources - GLP-1RA and the possible skin aging — NIH/PMC (2025) - A Closer Look at the Dermatological Profile of GLP-1 Agonists — PMC (2025) - "Ozempic Face" in Plastic Surgery: A Systematic Review — PMC (2025) - Emergence of "ozempic face" — PMC (2025) - Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists — PubMed (2025) - Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons — PMC (2025) --- Source: https://clickdose.io/en/articles/glp1-and-sleep.html Does Wegovy, Ozempic or Mounjaro affect your night's sleep? The answer is yes — but in two very different ways. Early in treatment, side effects can disrupt sleep. Over the longer term, research shows GLP-1 medications can significantly improve sleep quality — especially for the many patients who suffer from sleep apnea. Here is what you need to know. ## Sleep and weight loss — an overlooked connection Sleep and body weight influence each other in both directions. Poor sleep raises the hunger hormone ghrelin and lowers leptin, the hormone that signals fullness — making you hungrier the next day and increasing the temptation to overeat. On the flip side, excess weight makes it harder to sleep: fat tissue around the neck and abdomen compresses the airway and is the leading cause of obstructive sleep apnea. It is a vicious cycle — and GLP-1 medication can help break it. ## Two phases: short-term disruption, long-term improvement The experience of GLP-1 medication and sleep typically splits into two phases: - Short term (the first weeks): Side effects such as nausea, acid reflux and fatigue can disturb sleep — particularly during dose increases. - Long term (months in): As weight falls and side effects ease, many patients report significantly better sleep quality. ## Fatigue — one of the most common side effects Fatigue is an officially listed side effect of Wegovy and was reported by 11% of participants in clinical trials. The causes are several: - Reduced calorie intake as the body adjusts to a lower energy level - GI side effects such as nausea and vomiting draining energy reserves - Dehydration caused by diarrhoea or vomiting - Blood sugar fluctuations that affect energy levels The good news is that fatigue during dose increases is typically most pronounced in the first one to two weeks on a new dose and gradually subsides. Many patients deliberately schedule their injection for the weekend so they can rest if they feel tired. ## Sleep disturbances and vivid dreams Insomnia is not an officially listed side effect of Wegovy or Ozempic, and clinical trials show its occurrence is roughly the same as in placebo groups. Nevertheless, many users report difficulty falling asleep in the first few weeks — especially around dose escalations — which usually resolves on its own. Another unexpected experience reported by thousands of patients online is unusually vivid dreams. Novo Nordisk states that this is not an officially registered side effect, and the exact mechanism is unknown. One theory is that GLP-1 receptors in the brain influence dopamine and serotonin balance, both of which are involved in sleep cycles. For most people the dreams are simply detailed and immersive rather than distressing, and they tend to fade with time. ## The major breakthrough: GLP-1 and sleep apnea The most dramatic sleep-related finding with GLP-1 medication concerns obstructive sleep apnea (OSA) — a condition in which the airway repeatedly collapses during sleep, causing dozens or even hundreds of breathing interruptions per night. OSA affects an estimated one billion people worldwide and is strongly linked to obesity. ## The SURMOUNT-OSA trial: a landmark study In June 2024, the New England Journal of Medicine published the results of SURMOUNT-OSA — two parallel phase 3 trials of tirzepatide (Mounjaro) in adults with moderate to severe OSA and obesity. The findings were striking: - Tirzepatide reduced the AHI (apnea-hypopnea index — the number of breathing interruptions per hour) by up to 29.3 events per hour, compared with just 5.3 in the placebo group - This represents a reduction of up to 58.7% from baseline - Participants lost an average of 18–20% of their body weight - Systolic blood pressure fell by up to 9.5 mmHg - Patients reported substantially improved quality of life and sleep-related outcomes Based on these results, the US FDA approved tirzepatide in December 2024 as the first medication ever indicated for the treatment of sleep apnea in patients with obesity — a historic milestone. ## What about semaglutide (Wegovy and Ozempic)? Semaglutide is not approved specifically for sleep apnea, but a meta-analysis of GLP-1 receptor agonists as a class found they reduce AHI by approximately 9.5 events per hour on average, alongside an average weight loss of around 11 kg. A large share of this benefit is thought to be mediated through weight loss — and semaglutide produces substantial weight loss that can meaningfully reduce sleep apnea severity on its own. ## Weight loss improves sleep regardless of the mechanism It is important to understand that much of the sleep improvement seen with GLP-1 medication is a downstream consequence of weight loss rather than a direct brain effect of the drug. Research shows that for every 10% reduction in body weight, sleep apnea severity decreases by approximately 26%. As Wegovy, Ozempic or Mounjaro helps you lose weight, pressure on your airway decreases — and sleep improves as a natural result. ## Practical tips for better sleep during treatment - Inject in the morning — nausea and GI discomfort are typically worst in the hours right after the injection; morning dosing reduces the chance of overnight symptoms - Eat lightly in the evening — GLP-1 medication slows gastric emptying; heavy evening meals can cause acid reflux and discomfort when you lie down - Sleep on your side — lying on your back worsens sleep apnea; side-sleeping helps keep the airway open - Stay well hydrated during the day — GI side effects can lead to dehydration, which worsens sleep quality - Be patient with side effects — sleep disturbances during dose increases are usually temporary and settle within one to two weeks - Limit alcohol in the evening — alcohol worsens sleep apnea and disrupts sleep architecture generally ## When should you speak to your doctor? Contact your doctor if you experience: - Loud snoring and waking with a dry mouth or headache - Persistent daytime fatigue despite apparently sufficient sleep hours - A partner who notices you stop breathing during sleep - Sleep problems that persist for more than four to six weeks and are getting worse Untreated sleep apnea raises the risk of cardiovascular disease, type 2 diabetes and depression. Whether or not you are on GLP-1 medication, it is important to have sleep apnea properly diagnosed and treated — possibly with a CPAP device used alongside the medication. ## The bottom line GLP-1 medication and sleep have a nuanced relationship. In the short term, fatigue and GI side effects can disrupt sleep — particularly around dose increases. Over the longer term, research points to meaningful improvements in sleep quality, driven mainly by weight loss and its effect on sleep apnea. For patients living with both obesity and sleep apnea, tirzepatide (Mounjaro) is now the first medication ever approved to treat both conditions simultaneously. ## Sources - Wharton et al. — Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity, NEJM 2024 - FDA — FDA Approves First Medication for Obstructive Sleep Apnea (December 2024) - PMC — GLP-1 receptor agonists for obstructive sleep apnea: systematic review and meta-analysis - PMC — SURMOUNT-OSA full study results --- Source: https://clickdose.io/en/articles/glp1-and-stress.html You are taking your weekly injection reliably, watching your diet, and yet the scale refuses to budge. For many people on Wegovy, Ozempic or Mounjaro, stress — both the mental kind and the physical kind — turns out to be an invisible hand pressing down on the brake. Understanding exactly how stress interferes with weight loss, and what you can do about it, can make a real difference to your results. ## Cortisol: the weight-loss enemy hiding in plain sight When you experience stress — whether that is a looming work deadline, a relationship conflict, or a serious illness — your body releases cortisol, the primary stress hormone. Cortisol is not inherently harmful; it evolved to help you respond to short-term threats. The problem arises when stress is chronic and cortisol levels stay persistently elevated. Chronically high cortisol does several things that directly undermine weight loss: - Promotes abdominal fat storage. Cortisol signals the body to deposit fat preferentially around the abdomen, the most metabolically risky type of fat — and the hardest to shift. - Raises blood glucose. Cortisol causes the liver to release stored glucose into the bloodstream, which in turn triggers insulin secretion. Elevated insulin promotes fat storage and suppresses fat burning. - Slows the metabolism. Prolonged high cortisol can reduce thyroid hormone activity and lower resting metabolic rate, meaning you burn fewer calories at rest. - Increases appetite and cravings. Cortisol directly increases appetite, particularly for calorie-dense, sweet and salty foods — the so-called "comfort foods". The Mayo Clinic notes that stress is one of the most commonly overlooked contributors to weight gain and difficulty losing weight, even in people who are otherwise following a healthy diet and lifestyle. ## Emotional eating and sleep disruption Beyond the direct hormonal effects, stress changes behaviour in ways that compound the problem. ### Emotional eating GLP-1 medication reduces hunger by slowing gastric emptying and signalling satiety to the brain — but it does not fully suppress emotional hunger. Emotional eating is driven not by physical hunger but by the desire to soothe negative emotions. Many people on GLP-1 medication report that while their physical appetite is well controlled, they still find themselves reaching for food when stressed, anxious or bored. If this sounds familiar, you are not failing the treatment — you are experiencing a very human response that requires its own targeted strategies. ### Sleep disruption Stress and poor sleep form a vicious cycle. Stress makes it harder to fall and stay asleep; poor sleep in turn raises cortisol and ghrelin (the hunger hormone), while lowering leptin (the fullness hormone). Even a few nights of disrupted sleep can significantly increase appetite and cravings the following day. Research from the NHS and multiple clinical trials confirms that sleep deprivation is independently associated with weight gain and reduced response to dietary interventions. ## How GLP-1 medication interacts with stress There is encouraging evidence that GLP-1 receptor agonists may do more than simply reduce appetite — they may also directly modulate the stress response. GLP-1 receptors are found not only in the gut and pancreas but throughout the brain, including in the hypothalamus, amygdala and hippocampus — regions that regulate emotional processing, the stress response and anxiety. Animal studies and emerging human data suggest that GLP-1 receptor activation in these areas may: - Reduce anxiety-like behaviour - Dampen the HPA axis (the hormonal stress-response system) - Reduce cortisol release in response to acute stressors A 2024 meta-analysis published in PMC found that GLP-1 receptor agonists were associated with significantly reduced anxiety and depression scores across multiple trials. This is still an active area of research, and not everyone experiences these effects — but it does mean that the medication may offer some degree of psychological benefit beyond weight loss alone. ## Physical stress: illness, injury and surgery Stress is not only psychological. The body treats significant physical illness, surgery or injury as a major stressor, triggering a surge of cortisol and inflammatory markers. This has specific implications when you are on GLP-1 medication: - Nausea and reduced intake. If you are already eating little due to illness, GLP-1 side effects can be amplified, leading to dehydration or nutritional deficiencies. - Delayed gastric emptying and surgery risk. Because GLP-1 medication slows gastric emptying, guidelines from several anaesthesia societies now recommend pausing treatment before elective surgery to reduce the risk of aspiration under anaesthesia. Always inform your surgeon and anaesthetist that you take GLP-1 medication. - Weight regain after illness. A period of significant illness can temporarily stall or reverse weight loss as the body prioritises recovery. This is normal and usually reverses once health is restored. If you are unwell or facing planned surgery, speak to your prescribing doctor about whether to adjust your dose or timing. ## Practical stress management strategies These are not soft suggestions — stress management directly affects the biological environment in which GLP-1 medication operates. Evidence-based strategies include: ### 1. Prioritise sleep Aim for 7–9 hours per night. Establish a consistent bedtime, keep the bedroom cool and dark, and avoid screens for at least 30 minutes before bed. If you have persistent insomnia, speak to your doctor — cognitive behavioural therapy for insomnia (CBT-I) is more effective than medication for long-term sleep quality. ### 2. Move your body regularly Exercise is one of the most powerful stress-reducing interventions available. Even a brisk 20-minute walk lowers cortisol and raises mood-stabilising endorphins. Regular moderate exercise also improves sleep quality, preserves muscle mass during weight loss, and enhances the metabolic benefits of GLP-1 medication. ### 3. Practise mindfulness or breathing exercises Mindfulness-based stress reduction (MBSR) has a robust evidence base for lowering cortisol and reducing emotional eating. You do not need to meditate for an hour a day — even 5–10 minutes of slow, deliberate breathing activates the parasympathetic nervous system and lowers the acute stress response. Apps such as Headspace or Calm can guide you through simple practices. ### 4. Lean on social support Social connection is one of the strongest buffers against chronic stress. Talking to friends, family or a support group about your weight-loss journey can reduce the psychological burden and improve adherence to treatment. Many people find that joining a community of others on GLP-1 medication normalises the experience and provides practical tips. ### 5. Address underlying anxiety or depression If stress is underpinned by anxiety, depression or unresolved trauma, lifestyle strategies alone may not be enough. Cognitive behavioural therapy (CBT) is an effective, evidence-based treatment that addresses the thought patterns driving both emotional distress and emotional eating. Speak to your doctor about a referral if you feel your mental health is significantly affecting your progress. ## When stress might explain a plateau If your weight loss has stalled for four weeks or more despite sticking to your treatment and eating habits, ask yourself: - Have I been under unusually high stress recently — at work, at home or in relationships? - Has my sleep quality worsened? - Am I eating more than usual, particularly in the evenings or when emotionally triggered? - Have I been ill, injured or physically run down? If you can answer yes to any of these, stress is a plausible contributor to the plateau. Addressing it directly — rather than assuming the medication has stopped working — is often the most productive next step. ## When to seek professional help Consider speaking to your doctor or a mental health professional if: - Stress or anxiety is significantly affecting your quality of life - You are experiencing persistent low mood, hopelessness or loss of pleasure in activities - Emotional eating feels out of control - You are relying on alcohol or other substances to cope with stress GLP-1 medication works best as part of a comprehensive approach. Addressing mental health alongside physical health is not a sign of weakness — it is a sign of treating the whole person. ## Sources - Stress and weight gain — Mayo Clinic - Stress — signs, symptoms and management — NHS - GLP-1 receptor agonists and anxiety/depression: a meta-analysis — PMC (2024) - GLP-1 receptors in the brain: distribution and function — PMC (2022) --- Source: https://clickdose.io/en/articles/glp1-and-taste-changes.html You've started Wegovy, Ozempic, or Mounjaro, and suddenly that chicken breast you used to enjoy just doesn't appeal. Or the dessert you loved now tastes oddly sweet — almost sickly. Or you notice that smells seem stronger than before. You are not imagining it. Taste and smell changes are among the lesser-discussed but commonly experienced effects of GLP-1 receptor agonists. Understanding why they happen — and what you can do about them — can make your treatment journey much more comfortable. ## What taste changes do people report on GLP-1 medication? Reports from people taking semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) consistently describe a range of taste-related experiences: - Food aversions: Specific foods — often meat, fried or greasy foods, and very sweet foods — become unappealing or even repulsive - Altered sweetness perception: Previously enjoyable sweet foods taste excessively sweet or artificial - Metallic or altered taste: Some people notice a faint metallic flavour, particularly in the first weeks of treatment - Heightened sense of smell: Odours from cooking, meat in particular, can feel overwhelming - Changed food preferences: Cravings shift — many people find they begin to prefer lighter, less rich foods In a 2023 patient survey published by the Obesity Society, more than 40% of respondents on semaglutide reported notable changes in food preferences or taste perception within the first three months of treatment. ## Why does GLP-1 alter taste perception? The mechanism involves several overlapping pathways: ### GLP-1 receptors in taste cells GLP-1 receptors are not only found in the pancreas and gut — they are also present on taste receptor cells in the tongue and palate. Research published in Chemical Senses (Shin et al., 2008) was among the first to identify GLP-1 receptors in taste buds, suggesting the hormone plays a direct role in modulating taste signalling. When semaglutide or tirzepatide activates these receptors pharmacologically, it can alter how taste signals are processed at the very first stage — the taste bud itself. ### Rewiring the brain's reward response to food GLP-1 receptors are densely expressed in the brain's reward circuits, particularly in the nucleus accumbens and the ventral tegmental area — the same regions involved in pleasure and motivation. When these receptors are activated by GLP-1 medication, the dopamine-driven reward signal from eating rich or calorie-dense foods is significantly dampened. In simple terms: foods that used to trigger a strong pleasure response simply stop doing so. This is closely related to the "food noise" reduction many users report — but it also manifests as a genuine change in perceived pleasantness. ### Slower gastric emptying and smell sensitivity GLP-1 medications slow how quickly the stomach empties. This means food stays in contact with digestive acids longer, and the body may develop a stronger association between certain strong-smelling foods (like meat) and feelings of fullness or mild nausea. Over time, this can translate into a learned aversion where the smell or taste of certain foods is no longer pleasant. ## Why do meat and sweet foods become unappealing? Meat aversion is among the most commonly reported food-specific changes on GLP-1 therapy. There are a few reasons why: - Meat — especially red meat, pork, and chicken — has a strong, complex smell that can become overwhelming when olfactory sensitivity increases - High-protein foods like meat are very satiating. When your appetite and reward response are already blunted by GLP-1, the additional satiety signal from meat may tip the balance into unpleasant fullness before you have eaten much - The texture of meat may also feel different when gastric emptying is slowed Sweet food aversion tends to arise because GLP-1 medication reduces the reward signal from high-sugar foods particularly strongly. Foods that were pleasantly sweet can suddenly register as cloying or artificial-tasting. This is arguably a positive change in terms of dietary habits — but it can feel disorienting at first. ## Does GLP-1 affect your sense of smell too? Yes — heightened smell sensitivity (hyperosmia) is reported by a meaningful minority of GLP-1 users, particularly in the first few weeks. Cooking smells, especially from frying or roasting meat, can feel intrusive or even nauseating. This likely results from the same central nervous system effects that alter taste reward processing, combined with an increased sensitivity to olfactory cues linked to food. Interestingly, some researchers believe this heightened sensitivity may serve as an evolved signal to avoid certain foods when the digestive system is not prepared to process them efficiently — which is broadly what GLP-1 does by slowing gastric emptying. ## How long do taste changes last? For most people, the most pronounced taste changes occur in the first 4 to 12 weeks of treatment, often coinciding with dose escalation. As your body adapts to the medication, many taste alterations settle or become less noticeable. However, some degree of changed food preferences typically persists throughout treatment — which is, in part, why GLP-1 medications are effective at supporting sustained dietary change. If taste changes worsen significantly after initially improving, or are accompanied by other symptoms like severe nausea or vomiting, speak with your doctor — these could indicate that the current dose needs adjustment. ## Does this affect your nutrition? It can, particularly in two areas: - Protein intake: If meat and other protein-rich foods become aversive, it can be easy to under-eat protein. This matters because adequate protein is essential for preserving muscle mass during weight loss — and muscle loss is a real risk on GLP-1 therapy. - Dietary variety: If multiple food groups become unappealing simultaneously, nutritional gaps can develop. This is rare, but worth monitoring. If you notice that your food aversions are limiting your ability to eat a reasonably varied diet, mention this to your doctor or a registered dietitian. ## What can you do? The good news is that most taste changes can be worked around with some practical adjustments: ### 1. Find protein sources that still appeal to you If red meat or chicken is off the table, experiment with other protein-rich options: eggs, fish, dairy products (Greek yogurt, cottage cheese, quark), legumes (lentils, chickpeas, edamame), or tofu. Many people on GLP-1 therapy find that fish and plant-based proteins remain palatable even when meat does not. ### 2. Adjust cooking methods Strong cooking smells are often the trigger rather than the food itself. Try cold preparations (smoked salmon, egg salad, cheese), lighter cooking methods (poaching, steaming), or eating foods at room temperature rather than piping hot. Ventilating your kitchen well while cooking can also reduce the impact of overwhelming smells. ### 3. Manage sweetness sensitivity If sweet foods have become too intense, reduce sugar gradually in recipes and focus on naturally lightly sweet options like berries, apple slices, or plain yogurt with a small amount of honey. Artificially sweetened products can sometimes taste oddly sweet too — reduce these as well if needed. ### 4. Stay well hydrated Dehydration can worsen metallic taste and make food feel less appealing. Aim for 1.5–2 litres of water per day. Herbal teas and sparkling water with a slice of lemon or cucumber can be more appealing alternatives if plain water feels flat. ### 5. Tell your doctor if changes are severe Taste changes are a recognised phenomenon with GLP-1 medication, but they should not prevent you from maintaining adequate nutrition. If you are losing your appetite for nearly all foods or losing weight faster than expected, your doctor may consider adjusting your dose or titration schedule. ## Conclusion Taste changes on GLP-1 medication are real, common, and — for most people — manageable. They reflect the medication's genuine neurological and physiological effects on how your brain and gut process food signals. Rather than fighting these changes, working with them — by adapting your diet to what still appeals — often leads to naturally healthier food choices over time. And for most people, the most intense changes ease significantly after the first couple of months. If you are concerned about how taste changes are affecting your diet or nutrition, your doctor or a registered dietitian can provide personalised guidance. ## Medical disclaimer This article is for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare professional before changing your treatment or diet. ## Sources - Shin YK et al. — GLP-1 Receptors in Taste Cells of the Gut and Tongue, Chemical Senses (2008) - Müller TD et al. — GLP-1 and the gut-brain axis in appetite regulation, Nature Reviews Endocrinology (2022) - Berthoud HR et al. — GLP-1 and reward circuitry: hedonic eating and food aversion, IUBMB Life (2023) - FDA prescribing information — Wegovy (semaglutide) 2023 - NHS — Semaglutide for weight loss: side effects --- Source: https://clickdose.io/en/articles/glp1-and-thyroid.html When you pick up your Wegovy, Ozempic or Mounjaro pen for the first time and read through the information leaflet, you may notice a prominent warning about the thyroid. For many people, this is the most alarming thing in the whole document — and it raises an understandable question: is this medication going to harm my thyroid? The answer requires a bit of context. The warning is real, it is there for a reason, and there are a small number of people who genuinely should not use these medications. But for the vast majority of patients, the thyroid warning does not change the risk-benefit calculation. Here is a clear, honest overview of what we know. ## What does the thyroid warning actually mean? Both semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (Mounjaro) carry what regulators call a black box warning — the most prominent type of safety notice on a prescription drug label. The warning reads that these medications caused thyroid C-cell tumours in rodents during studies conducted at high doses over long periods. C-cells are a small population of cells in the thyroid gland that produce calcitonin, a hormone involved in calcium regulation. In rats and mice exposed to GLP-1 receptor agonists at doses far higher than those used in humans, a dose- and duration-dependent increase in C-cell tumours was observed. Critically, the relevance of these findings to humans is unknown. Human thyroid C-cells have far fewer GLP-1 receptors than rodent C-cells, which may explain why the animal effect has not been replicated in human studies. The warning is a precautionary measure required by regulators whenever this type of signal appears in animal toxicology — it does not mean the drug has been shown to cause thyroid cancer in people. ## Who should not use GLP-1 medications because of thyroid risk? There are two groups for whom these medications are contraindicated due to thyroid concerns: - People with a personal history of Medullary Thyroid Carcinoma (MTC). MTC is a rare cancer that originates in exactly the thyroid C-cells that were affected in the rodent studies. If you have had this type of cancer, GLP-1 receptor agonists are not for you. - People with Multiple Endocrine Neoplasia type 2 (MEN2). MEN2 is a genetic syndrome that strongly predisposes people to MTC. If you or a close family member has been diagnosed with MEN2, these medications are contraindicated. It is important to note that these conditions are rare. The vast majority of people starting GLP-1 therapy are not affected. If you are unsure whether you have a relevant family history, ask your doctor before starting treatment. For people with a history of papillary or follicular thyroid cancer (the most common types), GLP-1 medications are generally not contraindicated — these cancers originate in different thyroid cells (follicular cells, not C-cells). Always discuss your full medical history with your doctor. ## What warning signs should you watch for? Regardless of your history, all patients on GLP-1 medication should be alert to the following symptoms, which could indicate a thyroid problem: - A lump or swelling in the neck that is new or growing - Difficulty swallowing that was not present before - Persistent hoarseness or a noticeable change in your voice - Shortness of breath without an obvious cause If you notice any of these symptoms, contact your doctor promptly. In most cases there will be a completely unrelated explanation, but these symptoms should always be investigated when they arise during treatment. ## Does your thyroid need to be monitored during treatment? For the general population starting GLP-1 medication, routine thyroid cancer screening is not recommended. Medullary thyroid carcinoma is rare, and there is no established benefit to screening people who have no symptoms and no risk factors. However, if you already have a pre-existing thyroid condition — particularly hypothyroidism (an underactive thyroid) — it is worth keeping a closer eye on your thyroid function. As you lose weight on GLP-1 medication, the doses of thyroid hormone replacement you need may change. This is not due to the medication itself affecting your thyroid, but because body weight influences how thyroid medications are distributed and metabolised. Your doctor may recommend periodic TSH (thyroid-stimulating hormone) blood tests to ensure your levels remain optimal. ## What does the research actually show in humans? Since GLP-1 medications were introduced, researchers have actively studied whether a real-world thyroid cancer signal exists in humans. The picture is reassuring for most people, though the research is ongoing. A large observational study published in Diabetes Care (Bezin et al., 2023), which followed over 1.5 million patients, found a statistically significant increase in medullary thyroid cancer risk with long-term use of GLP-1 receptor agonists compared to other diabetes medications. However, the absolute risk remained very small — fewer than 1 additional case per 1,000 patients over a decade — and the study's authors noted limitations including the rarity of MTC and potential confounding factors. Other large studies, including an analysis published in JAMA, have found no overall increase in thyroid cancer risk with semaglutide when compared to other anti-obesity or diabetes medications. Regulators in both the US (FDA) and Europe (EMA) continue to monitor the situation. The current consensus is that the established benefits of GLP-1 therapy — significant weight loss and cardiovascular protection — outweigh the theoretical thyroid risk for the general population, while the contraindications for MTC/MEN2 remain firmly in place. ## Do GLP-1 medications affect thyroid function more broadly? Beyond the cancer question, some patients wonder whether GLP-1 medications affect the day-to-day function of the thyroid — hormone levels, metabolism, energy. The short answer is: not directly in a clinically meaningful way for most people. GLP-1 receptors are present in thyroid tissue, and preclinical research has explored whether GLP-1 signalling plays a role in thyroid hormone regulation. Some small studies have observed minor changes in TSH or calcitonin levels in people taking GLP-1 receptor agonists, but these changes are generally within the normal range and not considered clinically significant. What does change is your body weight — and weight loss can independently affect thyroid function and medication requirements. This is the more practically relevant connection for most patients already being treated for a thyroid condition. ## What if you already have a thyroid condition? Here is a quick summary for people with common thyroid conditions: - Hypothyroidism (underactive thyroid): GLP-1 medications are generally safe. Monitor your thyroid levels as you lose weight, since your levothyroxine dose may need adjusting. - Hyperthyroidism or Graves' disease: Not a contraindication, but discuss with your doctor or endocrinologist, as thyroid hormone levels can interact with metabolic changes from weight loss. - History of papillary or follicular thyroid cancer: Not a contraindication per FDA or EMA labelling. Confirm with your oncologist or endocrinologist. - History of medullary thyroid carcinoma (MTC): Do not use GLP-1 receptor agonists. This is an absolute contraindication. - MEN2 syndrome: Do not use GLP-1 receptor agonists. This is an absolute contraindication. ## The bottom line The thyroid warning on GLP-1 medications is based on animal studies and reflects a genuine regulatory precaution — not a confirmed human risk for most patients. For the overwhelming majority of people who use Wegovy, Ozempic or Mounjaro, the thyroid warning does not change the overall benefit-risk balance, which remains favourable. If you have a personal or family history of medullary thyroid cancer or MEN2, speak to your doctor before starting — these medications may not be right for you. And regardless of your history, be aware of the neck and throat symptoms listed above, and report them promptly if they appear. This article is for informational purposes only and does not constitute medical advice. Always consult your doctor or specialist about your individual treatment and any concerns about side effects. ## Sources - FDA prescribing information — Wegovy (semaglutide): Thyroid C-Cell Tumors warning - FDA prescribing information — Mounjaro (tirzepatide): Thyroid C-Cell Tumors warning - Bezin J et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer — Diabetes Care 2023 - EMA — Ozempic (semaglutide) product information, thyroid section - GLP-1 receptor expression and C-cell tumors — review article, NIH/PMC --- Source: https://clickdose.io/en/articles/glp1-and-type-2-diabetes.html When people hear "Ozempic," they often think of weight loss. And while that reputation is well-earned, it tells only part of the story. These medications were originally developed — and first approved — specifically for type 2 diabetes. For the tens of millions of people living with this condition, GLP-1 drugs offer something that goes well beyond the number on the scale: genuine, meaningful blood sugar control, with a safety profile that older diabetes medications simply cannot match. Here is what GLP-1 medications actually do for type 2 diabetes, how they work in the body, and what you can realistically expect from treatment. ## How GLP-1 drugs work in type 2 diabetes GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after you eat. In people with type 2 diabetes, this system often underperforms. GLP-1 receptor agonists — the class of drugs that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — step in and mimic that hormone, but with a much longer-lasting effect than your body produces on its own. Once the medication activates GLP-1 receptors in the pancreas, three important things happen: - Insulin release is stimulated — but only when blood sugar is actually elevated. The pancreas releases more insulin in response to a meal, bringing glucose back down to normal levels. - Glucagon is suppressed — glucagon is a hormone that tells the liver to release stored sugar into the bloodstream. By dampening this signal, GLP-1 drugs prevent the liver from adding extra glucose when it is not needed. - Gastric emptying slows down — food moves more slowly from the stomach to the small intestine, which flattens the spike in blood sugar that typically follows a meal. Together, these three mechanisms work in concert to keep blood sugar steadier throughout the day — not just after meals, but around the clock. ## Why the low hypoglycemia risk matters One of the most important practical advantages of GLP-1 medications for people with type 2 diabetes is their low risk of hypoglycemia — dangerously low blood sugar. This is a real concern with older diabetes drugs such as sulfonylureas or insulin, which can drive blood sugar too low regardless of what you have eaten. GLP-1 drugs avoid this problem because their mechanism is glucose-dependent. The extra insulin release only kicks in when there is actually glucose present in the bloodstream. When blood sugar is already normal or low, the drugs do not push it any further down. This makes them considerably safer for daily life — driving, exercising, or simply going about your day without the nagging worry of a hypoglycemic episode. ## How much does HbA1c actually fall? HbA1c is the standard measure of long-term blood sugar control — it reflects your average blood glucose over roughly three months. For people with type 2 diabetes, bringing HbA1c down is the central goal of treatment, and GLP-1 medications deliver meaningful reductions. Clinical trials show that semaglutide (Ozempic) reduces HbA1c by approximately 1.5 to 2 percentage points from baseline. To put that in perspective, a drop from 8.5% to 6.5–7% moves many people from poorly controlled diabetes into a well-managed range, significantly reducing the long-term risk of complications such as kidney disease, nerve damage, and vision loss. Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, pushes the numbers even further. In the landmark SURPASS-2 trial, tirzepatide reduced HbA1c by up to 2.4 percentage points at the highest dose — outperforming semaglutide head-to-head in the same study. For people whose diabetes has been hard to control with other medications, that difference can be significant. ## Ozempic vs. Wegovy — same drug, different doses A point of frequent confusion: Ozempic and Wegovy both contain semaglutide, but they are approved for different purposes at different doses. Ozempic (semaglutide 0.5 mg and 1 mg, with a 2 mg option in some markets) is FDA-approved specifically for the treatment of type 2 diabetes in adults. It is designed to lower blood sugar and has also been shown to reduce cardiovascular risk in people with diabetes and existing heart disease. Wegovy (semaglutide 2.4 mg) is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The higher dose produces greater weight loss but is not the standard first choice for blood sugar control alone. If you have type 2 diabetes, your doctor will typically prescribe Ozempic — the diabetes-approved formulation — rather than Wegovy. The distinction matters both clinically and for insurance coverage purposes. ## Mounjaro — the dual agonist advantage Tirzepatide, sold as Mounjaro for type 2 diabetes, works on two hormonal pathways rather than one. In addition to mimicking GLP-1, it also activates receptors for GIP (glucose-dependent insulinotropic polypeptide) — another gut hormone involved in insulin regulation. This dual action appears to deliver additive benefits. In clinical trials, Mounjaro produced the largest HbA1c reductions seen in any approved oral or injectable diabetes medication to date, alongside substantial weight loss. For people with type 2 diabetes who have struggled to hit their blood sugar targets with other treatments, tirzepatide represents a genuinely new level of efficacy. ## Cardiovascular protection — a bonus that matters Type 2 diabetes significantly raises the risk of heart disease. This makes the cardiovascular data on GLP-1 medications particularly important. The SELECT trial, published in 2023, followed over 17,000 adults and found that semaglutide reduced the risk of major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death — by 20% compared to placebo. While SELECT specifically studied people without diabetes, earlier cardiovascular outcome trials in diabetic populations (including SUSTAIN-6) had already shown similar protective effects for people with type 2 diabetes and high cardiovascular risk. This means that choosing a GLP-1 medication for blood sugar control may simultaneously be protecting your heart — a meaningful dual benefit for a population already at elevated cardiac risk. ## What to expect from treatment Understanding the timeline helps set realistic expectations. Here is roughly what happens after starting a GLP-1 medication for type 2 diabetes: - Within the first few weeks — blood sugar levels begin to improve, particularly post-meal spikes. Many people notice they feel less hungry and eat smaller portions. - At the 3-month mark — your doctor will typically measure HbA1c for the first time since starting treatment. This is the first real read on how well the medication is controlling your blood sugar over time. - Over 6–12 months — HbA1c continues to fall as doses are titrated upward according to your doctor's plan. Weight loss, if it occurs, adds additional benefit to blood sugar control. - Ongoing — regular monitoring continues. Most people stay on the medication long-term, as the benefits persist only while the drug is being taken. GLP-1 medications work particularly well alongside metformin, which remains the first-line medication for most people newly diagnosed with type 2 diabetes. They can also be combined with SGLT-2 inhibitors, DPP-4 inhibitors, and other agents as part of a personalised treatment plan. Your doctor will guide what combination makes sense for your situation. ## Using GLP-1 medication safely and correctly Getting the most from GLP-1 treatment means using it correctly. These are injectable medications, typically given once a week via a pre-filled pen. The dose is usually started low and increased gradually — a process called titration — to minimise side effects such as nausea. A few important principles: - Follow your doctor's dosing plan exactly. Do not skip doses or adjust the schedule without medical guidance. Consistency matters for both blood sugar control and tolerability. - Monitor your blood sugar regularly as your doctor recommends, especially when starting treatment or changing doses. Even though hypoglycemia risk is low with GLP-1 drugs alone, it can increase if you are also taking insulin or sulfonylureas. - Count your clicks carefully. Injection pens deliver medication in measured increments — each click corresponds to a specific dose. Miscounting is easy, particularly for people who are new to injectable medications or managing multiple conditions. Tools like ClickDose are designed to make this straightforward and accurate. - Keep up with your HbA1c checks. Blood sugar monitoring at home tells you how you are doing day to day; HbA1c every three months tells you how treatment is working over time. Both matter. GLP-1 medications are a significant advance in the management of type 2 diabetes — but they work best as part of a broader approach that includes a healthy diet, regular physical activity, and close communication with your healthcare team. The medication does a great deal, but it works best when you are working with it. ## Sources - American Diabetes Association — Ozempic (semaglutide) Consumer Guide - Mayo Clinic Press — Health benefits of semaglutide beyond weight loss - FDA Drug Trial Snapshot — Ozempic - Diabetes Care (ADA) — Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes - PubMed — Systematic review of GLP-1 receptor agonists in type 2 diabetes --- Source: https://clickdose.io/en/articles/glp1-and-vitamin-deficiency.html Starting Wegovy, Ozempic or Mounjaro can feel like a real turning point. Appetite drops, food noise fades into the background, and the scale finally starts to move in the right direction. It can feel genuinely liberating. But here is something that does not always come up in those early consultations: eating significantly less also means taking in significantly fewer vitamins and minerals. And over months of treatment, that quiet nutritional gap can start to cause real problems. This is not a reason to stop treatment — it is a reason to be informed. Here is what you need to know about nutrients and GLP-1 therapy. ## Why does GLP-1 medication affect my nutrient intake? GLP-1 medications suppress appetite so effectively that most people end up eating 30–50% less food than they did before starting treatment. And with less food comes less of everything the body needs: vitamins, minerals, fibre, and protein alike. The mechanism is multifaceted. These medications slow gastric emptying and send powerful fullness signals to the brain, which means meals feel satisfying after just a few bites. Many people also experience nausea — particularly in the first few months — which can make it harder to eat nutrient-rich foods like meat, eggs and leafy greens. Add in the disappearance of "food noise" (those persistent background thoughts about eating that used to drive snacking), and it becomes surprisingly easy to simply forget to eat balanced meals. The result is a double nutritional challenge: you eat less food overall, and nausea or food aversions can push you toward blander, less nutritious choices. Over time, this creates the conditions for deficiency — even without any obvious warning signs. ## Which nutrients are most at risk on GLP-1 treatment? Based on clinical research and nutritional guidelines, these are the nutrients that deserve the closest attention during GLP-1 therapy: ### Vitamin B12 B12 is found almost exclusively in animal products — meat, fish, dairy and eggs. It is essential for healthy nerve function and red blood cell production. If reduced appetite leads you to eat less meat or dairy, B12 can quietly drop below optimal levels over several months. Vegans and vegetarians are at particularly high risk, since plant-based sources are almost absent. Symptoms of low B12 include fatigue, tingling or numbness in the hands and feet, and brain fog. ### Vitamin D and Calcium These two nutrients work hand in hand for bone health, muscle function, and immune regulation. Vitamin D is rare in most foods and is mainly synthesised from sunlight — and with fatigue being common early in GLP-1 treatment, many people spend less time outdoors. Calcium is found primarily in dairy and fortified plant milks; if appetite suppression leads to less dairy, calcium intake can fall too. Both deficiencies can increase the risk of bone loss over time, which matters for a treatment often used long-term. ### Iron Iron is needed to transport oxygen in the blood. Eating less red meat — one of the richest dietary sources of well-absorbed (haem) iron — can gradually deplete your stores. Menstruating women are at especially high risk. Low ferritin (iron stores) often shows up as persistent fatigue, difficulty concentrating, and sometimes hair shedding. Importantly, iron deficiency can look almost identical to side effects of GLP-1 therapy itself, so testing is the only way to tell them apart. ### Zinc Zinc supports immune function, wound healing, and — perhaps most relevant here — taste and smell perception. There is a subtle irony: zinc deficiency can itself reduce appetite and alter taste, creating a self-reinforcing cycle. Zinc is found in meat, shellfish, seeds and legumes. Eating less of these foods over a sustained period can lead to gradual depletion. ### Folate (Vitamin B9) Folate is essential for cell division and DNA synthesis, and is particularly critical for anyone who might become pregnant. It is found mainly in leafy green vegetables, legumes, and fortified foods — which tend to be underrepresented in the diet of someone eating 30% less and dealing with nausea. If you are on GLP-1 therapy and thinking about pregnancy, speak to your doctor early — and read more in our article on GLP-1 and fertility. ### Magnesium Magnesium is involved in over 300 enzymatic reactions and supports energy production, muscle function, sleep quality, and mood regulation. It is found in nuts, seeds, whole grains, legumes, and dark chocolate — foods that may be eaten less often when appetite is suppressed. Symptoms of magnesium shortfall are often vague: poor sleep, muscle cramps, fatigue, and irritability. Because these overlap so heavily with the general experience of major dietary change, magnesium deficiency is easy to miss. ## How do I know if I am actually deficient? A blood test is the only reliable way to find out. Symptoms alone are not enough — many deficiencies develop silently, with vague complaints easily attributed to the general process of weight loss and dietary adjustment. Ask your doctor to test: - Vitamin B12 (serum B12) - Folate (serum or red cell folate) - Vitamin D (25-hydroxyvitamin D) - Ferritin (iron stores) - Full blood count (to detect anaemia) - Optionally: zinc, magnesium if symptoms suggest these A baseline panel before or early in treatment is ideal, with a repeat every 6–12 months. This gives you real data to work from, rather than guessing based on how you feel. ## What should I supplement during GLP-1 treatment? Supplementing wisely means not overdoing it — some nutrients are harmful in excess. Here is a sensible starting framework, based on current clinical guidance: - Multivitamin: A broad-spectrum multivitamin is the most practical baseline insurance policy. Most clinical guidelines for long-term GLP-1 users recommend it. Choose one that includes B12, D, iron, zinc, and folate. - Vitamin B12: The recommended daily intake is 2.4 µg. Look for methylcobalamin, which is well absorbed. If your levels are already low, your doctor may recommend sublingual drops or periodic injections for faster correction. - Vitamin D: 10–25 µg (400–1,000 IU) daily is a reasonable maintenance dose for most adults in temperate climates, regardless of diet. Those living in northern latitudes may need more. - Calcium: Prioritise food sources first — fortified plant milks, tinned fish with bones (sardines, salmon), broccoli and kale. Supplement only what food cannot cover. - Iron: Do not supplement iron without a confirmed deficiency from a blood test. Excess iron is harmful and can interfere with the absorption of other minerals. ## How do I stay nourished when I am barely hungry? Eating less does not have to mean eating worse. A few practical habits make a significant difference: - Protein first, always. At every meal, eat your protein source first — eggs, fish, chicken, Greek yogurt, legumes. Protein supports muscle preservation and helps you feel satisfied longer. - Do not skip all meals. Even when appetite is very low, spacing two or three small meals across the day maintains a more consistent nutrient intake than one large meal or erratic eating. - Choose nutrient-dense foods over calorie-dense ones. When you are only eating a small amount, each bite counts more. Salmon, eggs, spinach, and lentils deliver far more nutrition per mouthful than crackers or white bread. - Lean on fortified foods. Fortified cereals, fortified plant milks, and eggs are efficient ways to cover B12, D, and iron when appetite is limited. - Fatty fish twice a week. Salmon, sardines, and mackerel cover B12, vitamin D, and omega-3 in a single serving — three nutritional goals with one choice. ## Should I talk to my doctor about this? Yes — and sooner rather than later. Your prescribing doctor or a registered dietitian can help you understand your individual risk profile, order the appropriate blood tests, and build a supplementation plan that makes sense for your situation. Do not assume that eating less automatically means you are covering your nutritional bases — the evidence suggests the opposite. If you notice symptoms such as persistent fatigue, unusual hair loss, tingling in your hands or feet, frequent illness, or low mood during GLP-1 treatment, mention them at your next appointment. They may point to a correctable nutritional gap. ## Medical disclaimer This article is intended for general informational purposes only and does not constitute medical advice. The information provided here should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Always seek the guidance of your doctor, pharmacist, or other qualified healthcare professional with any questions you may have regarding your medication, diet, or health condition. Never disregard professional medical advice or delay seeking it because of something you have read here. ## Sources - NHS — Vitamins and minerals - Mayo Clinic — Vitamin deficiency - Nutritional Considerations for Patients on GLP-1 Receptor Agonists — PubMed (2024) - EASO — Clinical Practice Guidelines - Micronutrient Deficiency in Obesity — PMC (2024) --- Source: https://clickdose.io/en/articles/injection-technique-for-beginners.html The first time you have to inject yourself with a GLP-1 pen like Wegovy, Ozempic or Mounjaro, it can feel daunting. The good news is that it quickly becomes routine — and it is far easier than most people fear. This guide covers everything you need to know: where to inject, how to do it step by step, and what to avoid. ## What kind of injection is it? Wegovy, Ozempic and Mounjaro are all subcutaneous injections — meaning the medication is delivered into the fatty tissue just beneath the skin, not into a muscle or vein. This layer absorbs the medication slowly and evenly, which is exactly what produces the sustained, week-long effect. The needle on these pens is very short and thin — typically 4–8 mm — and many people describe the injection as almost painless, especially once they have mastered the technique. ## The three recommended injection sites There are three areas of the body approved for subcutaneous injection with GLP-1 pens: ### 1. Abdomen (stomach) The most popular site for most users. Inject into the soft fatty tissue on the side of the abdomen, staying at least two finger-widths (about 5 cm) away from the navel. The abdomen is easy to reach, has a reliably even fat layer, and lets you see exactly what you are doing. Avoid the navel itself and any scar tissue. ### 2. Thigh The front outer area of the thigh — halfway between the knee and the hip — is an excellent alternative. It is practical if you are sitting, and many find it discreet. Avoid injecting here immediately after intense leg exercise, since increased blood flow can alter the rate of absorption. ### 3. Upper arm (back) The back of the upper arm (the triceps area) can be used but is harder to reach on your own. Many people prefer to ask someone for help with this site, or they stick to the abdomen and thigh which they can manage independently. ## Rotation: Why you should never inject the same spot twice in a row It is critically important to rotate your injection site each week. Injecting repeatedly into exactly the same spot can, over time, cause lipohypertrophy — a build-up of fatty tissue that feels like a firm lump under the skin. This can slow the absorption of the medication and make your treatment less effective. A good rule of thumb: move at least 1–2 cm from the previous spot, and wait at least four weeks before returning to the exact same point. Many people rotate between the abdomen one week, the thigh the next, and the upper arm the third. ## Step by step: how to inject - Wash your hands thoroughly with soap and water. Dry them well. - Check the pen. The liquid should be clear and colourless. If it looks cloudy, discoloured, or contains particles, do not use it. If you have taken the pen straight from the fridge, let it warm up at room temperature for 15–20 minutes — cold medication can sting more. - Choose your injection site and clean the skin with an alcohol swab or soap and water. Let the skin dry completely before injecting — otherwise it may sting. - Attach the needle (if your pen requires it) and remove the cap. - Pinch the skin if needed — particularly important if you are lean, to ensure you hit the subcutaneous layer rather than muscle. Hold a firm skin fold between thumb and forefinger. - Insert the needle at a right angle (90 degrees) to the skin surface with a confident, swift motion. - Deliver the dose: Ozempic: Press the dose button all the way down and hold it until the counter shows zero. Then count slowly to six before withdrawing the needle. - Wegovy: Hold the pen against the skin and press. You will see the yellow indicator bar moving. Keep the pen pressed against the skin until the injection is complete (5–10 seconds). - Mounjaro: Follow the instructions in the package leaflet — the lock releases automatically, and you hold the pen against the skin until a click confirms that the injection is finished. - Withdraw the needle at the same angle you inserted it. Do not rub the skin afterwards. - Dispose of the needle safely in a sharps container. Return it to the pharmacy when it is three-quarters full. ## Common mistakes to avoid - Forgetting to rotate. This is the most common mistake and can reduce the effectiveness of your treatment over time. - Injecting with a cold pen. Always allow the pen to reach room temperature when taken from the fridge. - Withdrawing the needle too early. Keep the needle in for the recommended time (typically six seconds for Ozempic) so the full dose is delivered. - Injecting into scars, bruises or hardened skin. Avoid these areas — medication is absorbed poorly there. - Reusing needles. Always use a fresh needle for each injection — used needles are blunt and increase the risk of infection. ## Normal reactions and when to contact your doctor A small red mark or mild itching immediately after the injection is perfectly normal and usually disappears within a day. A small pea-sized bump under the skin is also normal and is simply the medicine depot being gradually absorbed. Contact your doctor if you notice: - Significant redness, swelling or warmth that worsens over the first few days - A hard lump at the injection site that does not go away - Signs of infection: pus, fever or increasing pain - An allergic reaction: hives, difficulty breathing, or swelling of the face and lips ## How ClickDose helps When you use dose-splitting — getting multiple doses from a single pen — precise click counting is essential. ClickDose uses your phone's microphone to automatically detect and count each click as you dial the pen, so you know exactly when to stop, whether your dose is 0.25 mg or 2 mg. It takes the stress out of dosing and lets you focus fully on getting the injection technique right. ## Sources - Wegovy.com — How to Use the Wegovy Pen - Simple Online Pharmacy UK — Wegovy Injection Sites - Fay Nutrition — How to Inject Ozempic: A Step-by-Step Guide - Fella Health — How Deep to Inject Semaglutide --- Source: https://clickdose.io/en/articles/myths-about-weight-loss-medication.html GLP-1 medications like Wegovy, Ozempic and Mounjaro have attracted enormous attention — and with that attention has come a wave of myths. Some people are sceptical, others have unrealistic expectations. In this article we go through seven of the most common misconceptions and set them against what the research actually shows. ## Myth 1: "It's cheating — the easy way out" One of the most common reactions is that weight loss medication is "the lazy solution." This reflects an outdated belief that obesity is purely a matter of willpower. Research shows that obesity is a chronic disease with genetic, hormonal and neurological causes. GLP-1 receptor agonists work biologically: they mimic a natural gut hormone (GLP-1) that regulates hunger signals and blood sugar in the brain. In many people with severe obesity, the body does not produce sufficient satiety signals — the medication helps restore that balance. Treatment still requires lifestyle changes. The major trials — including STEP 1 with semaglutide and SURMOUNT-1 with tirzepatide — combined medication with diet and exercise counselling. The medication is a tool, not a replacement for engagement. ## Myth 2: "You only lose water weight" Not true. Weight loss with GLP-1 medication is primarily fat loss. In the STEP 1 trial, participants taking 2.4 mg semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks — compared with 2.4% in the placebo group. Body composition studies show that most of the loss comes from fat tissue, not water or muscle (provided adequate protein intake and exercise). ## Myth 3: "This medication is only for people with diabetes" Ozempic (semaglutide 1 mg) is approved for type 2 diabetes, but Wegovy (semaglutide 2.4 mg) is specifically approved for the treatment of obesity in adults without diabetes — by the EMA in Europe and the FDA in the USA. Mounjaro/Zepbound (tirzepatide) is approved for both indications. The typical eligibility criteria for Wegovy are a BMI ≥ 30, or ≥ 27 with at least one weight-related condition such as high blood pressure or sleep apnoea. Diabetes is not a requirement. ## Myth 4: "GLP-1 medication is dangerous — it's experimental" Semaglutide has been in clinical use since 2017 (as Ozempic) and is now one of the most extensively studied drugs in recent history. Wegovy has been FDA-approved since 2021 and EMA-approved since 2022. It is not experimental. Like all medications it has side effects — most commonly nausea, vomiting and diarrhoea, especially when starting treatment. These are typically mild to moderate and ease over time. Serious side effects (pancreatitis, gallbladder problems) can occur but are rare. Your doctor assesses the risks and benefits for your individual situation. ## Myth 5: "You become addicted to the medication" GLP-1 medications do not create chemical dependency. There is no euphoric effect, no classical withdrawal. What many people notice when stopping is that hunger and cravings return — that is biology, not addiction. Obesity, like many chronic diseases, often requires ongoing treatment. Just as we would not say that a person with high blood pressure is "addicted" to their blood pressure medication, it is not appropriate to use that word for GLP-1 treatment. ## Myth 6: "The weight always comes back — it's pointless" This is partly true, but context matters. Studies show that many people regain a significant portion of their lost weight within one to two years of stopping the medication. But this happens because the body has a biological "set-point" mechanism that tries to return to baseline — not because the medication failed. For many patients the solution is long-term treatment, just as high blood pressure or high cholesterol is managed continuously. Furthermore, even a temporary weight loss of 10–15% is associated with meaningful health benefits: lower blood pressure, better blood sugar control and reduced risk of cardiovascular disease. ## Myth 7: "You don't need to change your diet while on the medication" The medication significantly reduces hunger, but it does not remove the need for a healthy diet. If you mainly eat ultra-processed foods with low nutritional value, you risk deficiencies in protein, vitamins and minerals — especially because you are eating far less than before. All major clinical trials included dietary counselling as part of the protocol. It is recommended to prioritise protein-rich foods (chicken, eggs, legumes, fish), vegetables and wholegrains, and to limit sugar and processed food. It is not impossible to lose weight without changing habits, but results are far better with a healthy eating plan. ## What does the research say? The most striking results come from: - STEP 1 (semaglutide 2.4 mg): Average weight loss of 14.9% over 68 weeks in adults with obesity (New England Journal of Medicine, 2021). - SURMOUNT-1 (tirzepatide): Up to 22.5% average weight loss at the highest dose over 72 weeks — the largest documented weight loss with any pharmacological agent to date (New England Journal of Medicine, 2022). - SELECT trial (semaglutide 2.4 mg): 20% reduction in risk of heart attack and stroke in overweight people without diabetes (New England Journal of Medicine, 2023). The medication works — but it is not a miracle. It works best as part of a comprehensive approach to weight management. ## When should you talk to your doctor? If you are considering GLP-1 treatment, always consult a doctor first. They can assess whether the medication is right for you, review your risk factors and help set realistic goals. Do not use these medications without a prescription or based solely on online information. ## Sources - Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 2021. nejm.org - Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM, 2022. nejm.org - Lincoff AM et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." NEJM, 2023. nejm.org - FDA. "FDA Approves New Drug Treatment for Chronic Weight Management in Adults." 2021. fda.gov - EMA. "Wegovy — EPAR." ema.europa.eu - NHS. "Semaglutide for weight loss (Wegovy)." nhs.uk --- Source: https://clickdose.io/en/articles/price-and-insurance.html The price of GLP-1 medications like Wegovy, Ozempic and Mounjaro varies dramatically from country to country. In the US, a monthly supply of Wegovy can cost over $1,300, while the same medication in the UK can be obtained for around £92 privately — or just £9.90 on an NHS prescription. This article gives you a clear overview of what these medications cost and who covers the bill across the key markets. ## Quick comparison: monthly cost without subsidy | Country | Wegovy (approx.) | Covered for weight loss? | | Denmark | DKK 2,000–3,000 | No (in general) | | Norway | NOK 1,748 | Under review (blue prescription) | | Sweden | SEK 1,400–1,600 | No | | Germany | €200–300 | No (exception: cardiovascular risk) | | UK | ~£92 private / £9.90 NHS | Yes, via NHS for eligible patients | | USA | ~$1,349 (list price) | Varies widely | ## Denmark In Denmark, Wegovy has no general public subsidy for the treatment of obesity. The Danish Medicines Agency has assessed that the price is not proportionate to the overall clinical value for the broad population. It is possible to apply for an individual subsidy (enkelttilskud) in exceptional cases, but this is rarely granted. Ozempic (semaglutide, the same active ingredient as Wegovy) does have a subsidy for type 2 diabetes, but the rules have tightened progressively. Since November 2024, patients must have tried other diabetes medicines (such as metformin and SGLT-2 inhibitors) without adequate effect before Ozempic qualifies for subsidy. Ozempic cannot be prescribed with a subsidy for weight loss alone. For many Danes using these medications for weight loss, the cost is therefore a purely private expense of approximately DKK 2,000–3,000 per month depending on dose and pen strength. ## Norway In Norway, the situation is evolving rapidly. Ozempic has blå resept (full subsidy) for type 2 diabetes, but since July 2024, it can no longer be prescribed off-label for weight loss with a blue prescription. Wegovy for weight loss was in December 2025 assessed as cost-effective by the Norwegian Medicines Agency (DMP) for patients with BMI ≥ 35 and two comorbidities, or BMI ≥ 40 alone. DMP recommends including Wegovy in the blue prescription scheme for this group. However, the decision remains under political review by the Ministry of Health and Care Services as of April 2026. Without a blue prescription, Wegovy costs approximately NOK 1,748 per month. ## Sweden In Sweden, neither Wegovy nor Mounjaro has received a subsidy from the Dental and Pharmaceutical Benefits Agency (TLV) for the treatment of obesity. TLV has assessed that there is a significant risk that the medications would be used for far more patients than intended — so-called subsidy drift. Without a subsidy, patients typically pay SEK 1,400–1,600 per month for Wegovy and upwards of SEK 2,000 for Mounjaro depending on dose. Ozempic is included in the Swedish högkostnadsskydd (high-cost protection), but only when prescribed for type 2 diabetes. If used for weight loss, the patient pays the full price. ## Germany Under German law (§ 34 SGB V), the public health insurance system (GKV) is generally not permitted to cover medications primarily intended for weight loss. This applies to both Wegovy and Mounjaro. Self-pay costs are approximately €200–300 per month. There is one important exception: in 2024 the EU approved Wegovy for reducing cardiovascular risk in patients with obesity and existing heart disease. In some cases, GKV may cover treatment when it is prescribed for this specific cardiovascular indication. Private health insurance (PKV) may cover Wegovy depending on the terms of the individual policy — contact your insurer for clarification. ## United Kingdom In the UK, it is possible to receive Wegovy through the NHS — but specific criteria under NICE Technology Appraisal 875 (TA875) must be met. You need a BMI of at least 35 kg/m² and at least one weight-related comorbidity (such as type 2 diabetes or high blood pressure), and you must be referred by your GP to a specialist weight management service (Tier 3/4). NHS-funded treatment is capped at a maximum of two years. Waiting times for specialist services are 12–24 months in many areas. If you obtain an NHS prescription, you pay only the standard prescription charge: £9.90 per item in England (free in Scotland, Wales and Northern Ireland). Private treatment typically costs £150–300 per month for the medication alone. A key fact: in the UK, Wegovy retails at around £92 per month privately — a fraction of the US list price. ## United States The US is the most expensive market for GLP-1 medications. Wegovy's official list price is approximately $1,349 per month. Many insurance plans — including a large proportion of private employer-sponsored plans — do not cover weight loss medications. Medicare did not cover Wegovy for weight loss until 2024, when the FDA approved it for reducing cardiovascular risk, opening the door to Medicare Part D coverage for that specific indication. Novo Nordisk offers Wegovy through its NovoCare programme for approximately $349 per month for eligible uninsured patients. Compounded versions of semaglutide (mixed at compounding pharmacies) are available for $200–400, but these are not FDA-approved and carry quality risks. ## Ways to reduce your cost Regardless of which country you live in, there are ways to lower your monthly outlay: - Dose splitting: Because higher-strength pens cost roughly the same as lower-strength ones, you can save significantly by using a stronger pen and only administering the amount you need. Read more in our article on saving money on Wegovy with dose splitting. - Manufacturer programmes: Novo Nordisk and Eli Lilly offer savings card schemes and patient support programmes in certain countries. Ask your pharmacy or contact the manufacturer directly. - Talk to your doctor: In Denmark and Norway your doctor may be able to apply for an individual subsidy if your case is particularly serious. It is not granted automatically, but may be possible. - Compare pharmacies: Prices can vary between pharmacies, especially for private prescriptions. Online pharmacies may offer lower prices in some countries. ## Important note Prices and subsidy rules change regularly. Always check with your doctor or pharmacist for current information about what you can expect to pay and whether you qualify for coverage in your country. ## Sources - Danish Medicines Agency: Wegovy does not receive general conditional subsidy - DMP (Norway): Price offer makes Wegovy cost-effective - Helfo (Norway): Obesity medications on blue prescription - TLV (Sweden): Pharmaceutical benefit decisions - CNBC: Wegovy launches in Germany — but costs weigh heavy - UK Dept. of Health: Accessing Wegovy for weight loss - GoodRx: Tracking insurance coverage for weight loss meds (USA) - KFF Health News: How Denmark got Novo Nordisk to lower Ozempic prices --- Source: https://clickdose.io/en/articles/save-on-wegovy.html Wegovy (semaglutide) is one of the most effective weight-loss medications available today, but the cost can be a serious barrier for many patients. Here is the surprising part: all Wegovy pen strengths cost roughly the same price per pen. Whether you buy a 0.5 mg pen or a 2.4 mg pen, you are paying nearly the same amount. That pricing quirk opens the door to a practical strategy called dose-splitting — and it can save you a significant amount of money. ## Why do all Wegovy pens cost the same? Novo Nordisk prices Wegovy pens per unit rather than per milligram of active ingredient. A 0.5 mg pen and a 2.4 mg pen often have nearly identical list prices. If your prescribed dose is low, you are paying full price for a fraction of the medication inside the pen. But this also creates an opportunity. By purchasing a higher-strength pen and only injecting the amount you need, you can stretch a single pen across multiple doses and cut your costs dramatically. ## What is dose-splitting? Dose-splitting means using a higher-strength pen than your prescribed dose and dialing only the number of clicks that correspond to your actual dose. Wegovy pens are multi-dose injection devices with a precise click-based dosing mechanism — each click delivers an exact amount of medication. For example, if your prescribed dose is 0.5 mg, you can purchase a Wegovy 2.4 mg pen (which contains 3 mL of solution and 300 total clicks) and dial just 16 clicks to get exactly 0.5 mg. A single pen could then last for multiple weekly doses instead of just one. ## Click-count reference table for Wegovy The table below shows how many clicks correspond to common doses for each pen strength. This data is based on the public reference table from bywardfht.ca. ### Wegovy 0.5 mg pen (1.5 mL, 148 clicks total) | Dose | Clicks | | 0.25 mg | 18 clicks | | 0.5 mg | 37 clicks | ### Wegovy 1 mg pen (3 mL, 300 clicks total) | Dose | Clicks | | 0.5 mg | 37 clicks | | 1 mg | 75 clicks | ### Wegovy 1.7 mg pen (3 mL, 300 clicks total) | Dose | Clicks | | 1 mg | 44 clicks | | 1.7 mg | 75 clicks | ### Wegovy 2.4 mg pen (3 mL, 300 clicks total, 0.032 mg/click) | Dose | Clicks | | 0.25 mg | 8 clicks | | 0.5 mg | 16 clicks | | 1 mg | 31 clicks | | 1.7 mg | 53 clicks | | 2 mg | 63 clicks | | 2.4 mg | 75 clicks | ## How much can you actually save? Let's walk through a real example. If your weekly dose is 0.5 mg and you buy a 2.4 mg pen, you use only 16 clicks per dose. With 300 total clicks in the pen, that is enough medication for up to 18 doses. However, since an opened Wegovy pen is stable for up to 6 weeks (42 days) after first use, you can realistically get 6 weekly doses from a single pen. That represents a savings of up to 83% compared to buying a new 0.5 mg pen every week. Even at higher doses the savings are substantial. Using a 2.4 mg pen for a 1 mg dose requires 31 clicks per injection — giving you nearly 10 doses worth of medication per pen, limited to 6 by the shelf-life window. ## Shelf life and storage A key factor in dose-splitting is how long the pen remains stable after first use. Wegovy pens are stable for up to 6 weeks (42 days) after the first injection, when stored properly at room temperature (below 30 °C / 86 °F) or in the refrigerator. This makes it entirely practical to use the same pen over multiple weeks without compromising medication quality. ## Important: talk to your doctor Dose-splitting is an off-label practice. This means it is not the way the manufacturer officially recommends using the pen. You should always discuss dose-splitting with your doctor or pharmacist before starting. They can help ensure your dose is correct and that the approach is safe for your situation. Click counting requires precision. If you miscount, you could receive too much or too little medication — both of which can have consequences. An incorrect dose may lead to side effects or reduced effectiveness of treatment. ## How ClickDose helps This is where ClickDose comes in. Instead of counting clicks manually — which is stressful and error-prone — ClickDose uses your phone's microphone to automatically detect and count each click as you dial the pen. You select your pen strength and desired dose, and the app tells you exactly when to stop. It removes the guesswork and significantly reduces the risk of dosing errors. Whether you are on 0.25 mg or 2 mg, ClickDose keeps track of the clicks for you so you can inject with confidence. --- Source: https://clickdose.io/en/articles/semaglutide-vs-tirzepatide.html If you're exploring weight loss medications like Wegovy, Ozempic, or Mounjaro, you'll quickly come across two names: semaglutide and tirzepatide. These are the active ingredients in these medications — and while both help with weight loss and blood sugar control, they are not the same. This article explains the difference in plain language: how each one works, what the research shows about weight loss, and how to think about which might be right for you. ## What is semaglutide? Semaglutide is the active ingredient in Ozempic and Wegovy. It belongs to a class of drugs called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces after eating. It signals to the brain that you're full, slows the emptying of your stomach, and stimulates insulin production to keep blood sugar stable. Semaglutide mimics this hormone — but stays active far longer than the natural version. It's administered as a weekly injection. - Ozempic (semaglutide): approved for type 2 diabetes, up to 2 mg/week - Wegovy (semaglutide): approved for obesity and overweight treatment, up to 2.4 mg/week ## What is tirzepatide? Tirzepatide is the active ingredient in Mounjaro. It's a dual GLP-1 and GIP receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after meals. It works together with GLP-1: it supports insulin release, reduces appetite, and may improve the body's ability to burn fat. By activating both receptors simultaneously, tirzepatide works through two hormonal pathways rather than one — and research suggests this dual mechanism produces a stronger overall effect on weight loss. - Mounjaro (tirzepatide): in the EU approved for both type 2 diabetes and obesity, up to 15 mg/week ## Weight loss: what does the research say? The most direct head-to-head comparison is the SURMOUNT-5 trial, published in The New England Journal of Medicine in 2025. In this study, 751 adults with obesity (without diabetes) were randomly assigned to either tirzepatide (10 mg or 15 mg) or semaglutide (2.4 mg) for 72 weeks. The results were clear: | Treatment | Average weight loss | | Tirzepatide (Mounjaro) | approx. 20.2% of body weight | | Semaglutide (Wegovy) | approx. 13.7% of body weight | That means a person weighing 220 lbs (100 kg) would lose about 44 lbs (20 kg) with tirzepatide versus about 30 lbs (14 kg) with semaglutide — over the same period. A 2025 meta-analysis that pooled data from multiple clinical trials and real-world studies confirmed this pattern: tirzepatide produced statistically significantly greater weight loss than semaglutide. ## Side effects: are they different? Both medications cause similar side effects, because they both slow gastric emptying and affect appetite. The most common are: - Nausea and vomiting — most common during the early weeks - Diarrhoea or constipation - Stomach cramps and bloating - Fatigue The side effect profiles are broadly comparable. Tirzepatide may cause slightly more frequent gastrointestinal side effects in some patients, likely because of its stronger overall effect. However, this isn't a universal picture — many people tolerate both medications well, and side effects typically ease significantly after the first few weeks as the body adjusts. Slow dose escalation is key. See our article on dose titration for why starting low and going slow matters. ## Dosing and injection pens Both medications are given as weekly subcutaneous injections (under the skin) using an auto-injector pen. The dose is gradually increased over approximately 20 weeks to minimise side effects. | | Semaglutide (Wegovy) | Tirzepatide (Mounjaro) | | Starting dose | 0.25 mg/week | 2.5 mg/week | | Maximum maintenance dose | 2.4 mg/week | 15 mg/week | | Titration period | approx. 20 weeks | approx. 20 weeks | Both pens use a click-based dosing system where each click delivers a precise amount of medication. Counting clicks accurately is important for getting the right dose — and that's exactly what ClickDose helps with. ## Which medication might be right for you? There's no one-size-fits-all answer. The choice depends on your medical history, any other conditions you have, how well you tolerate each medication, cost, and your doctor's assessment. Here are some broad considerations: Semaglutide (Wegovy/Ozempic) may be a good fit if: - You want the most established GLP-1 treatment with years of long-term data - You have cardiovascular disease — semaglutide has approval for reducing cardiovascular risk - You're aiming for 10–15% weight loss and responding well to treatment Tirzepatide (Mounjaro) may be a good fit if: - You have severe obesity and need a more significant degree of weight loss - You've tried semaglutide and haven't had sufficient results - You want the medication with the strongest documented weight loss effect Always talk with your doctor before switching or starting any treatment. They know your full health picture and can give you personalised advice. ## Summary Semaglutide and tirzepatide are both effective medications for weight loss, but they differ in mechanism and strength of effect. Tirzepatide works through two hormonal pathways and typically produces greater weight loss than semaglutide. Semaglutide, in turn, has a long and robust track record and specific approvals — such as cardiovascular protection. The best choice depends on your individual circumstances and should always be made together with your doctor. ## Sources - Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — SURMOUNT-5 (NEJM, 2025) - Comparative Efficacy of Tirzepatide vs. Semaglutide — Meta-analysis (PMC, 2025) - Wegovy — European Medicines Agency (EMA) - Mounjaro — European Medicines Agency (EMA) --- Source: https://clickdose.io/en/articles/side-effects-of-glp1.html Starting a GLP-1 medication like Wegovy (semaglutide), Ozempic (semaglutide) or Mounjaro (tirzepatide) almost always comes with some side effects — especially in the beginning. Knowing what to expect, when symptoms typically peak, and how to ease them can make a big difference in staying on track with your treatment. This article gives you a clear, evidence-based overview. ## The Most Common Side Effects GLP-1 medications work by slowing stomach emptying and signalling fullness to the brain. As a result, the digestive system bears the brunt of most side effects. According to the FDA's official prescribing label for Wegovy, 73% of patients reported gastrointestinal adverse reactions during treatment, compared to 47% on placebo. Most common side effects and their rates in Wegovy trials: | Side Effect | Wegovy | Placebo | | Nausea | 44% | 16% | | Diarrhoea | 30% | 16% | | Vomiting | 25% | 6% | | Constipation | 24% | 11% | For Mounjaro, the rates are somewhat lower but the pattern is the same: nausea and diarrhoea occur in more than 1 in 10 users, with vomiting and constipation affecting up to 1 in 10. Other reactions some people notice: heartburn, bloating, belching, hiccups, fatigue, and changes in taste. ## When Do Side Effects Occur? The good news is that side effects don't have to last the whole treatment. They are typically strongest during dose escalation — the first several months when your dose is gradually increased. Wegovy dose escalation schedule (16 weeks to maintenance): | Week | Dose | | Weeks 1–4 | 0.25 mg | | Weeks 5–8 | 0.5 mg | | Weeks 9–12 | 1.0 mg | | Weeks 13–16 | 1.7 mg | | Week 17 onwards | 2.4 mg (maintenance) | Mounjaro's escalation takes up to 20 weeks, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks up to a maximum of 15 mg. Nausea and other digestive symptoms typically peak in the days after each dose increase, then ease off as the body adjusts. ## Practical Tips to Manage Nausea and Digestive Issues You can significantly reduce discomfort with some simple adjustments. These tips are backed by NHS guidance and Mayo Clinic recommendations: - Eat smaller, more frequent meals. Large meals are much harder to tolerate on GLP-1 medications. - Eat slowly. Put your fork down between bites. Stop when you feel comfortably full — not stuffed. - Avoid fatty and fried foods. High-fat meals are particularly difficult to digest on these medications. Choose baked, steamed or boiled options instead. - Eat bland foods when nauseated. Crackers, toast, plain rice or boiled potatoes are gentle on the stomach. - Stay upright after meals. Avoid lying down for at least 1–2 hours after eating. - Sip water throughout the day — not during meals. Drink between meals rather than with food. Ginger tea can also help with nausea. - Inject before bedtime. Many people find that sleeping through the worst of the nausea makes evenings much more comfortable. - Let the pen warm to room temperature. A cold injection can be more uncomfortable than one taken at room temperature. ## What If Side Effects Feel Unbearable? Talk to your doctor — you don't have to push through at all costs. There are official options for slowing the escalation: - You can delay a dose increase by up to 4 weeks if side effects are too disruptive. - Wegovy: If the 2.4 mg maintenance dose is not tolerated, you can temporarily drop back to 1.7 mg for up to 4 weeks before trying again. - Mounjaro: Your prescriber can pause or reduce the dose during the escalation phase. According to FDA data, 4.3% of Wegovy users stopped treatment due to gastrointestinal side effects. That is not a failure — it is a clinical decision, and dose adjustments often allow treatment to continue successfully. ## Side Effects You Should Never Ignore Most side effects are mild and temporary. However, some symptoms require urgent attention: - Severe abdominal pain that radiates to the back — possible pancreatitis. Seek medical help immediately. - A lump in the neck, difficulty swallowing, or persistent hoarseness — possible thyroid issue. Contact your doctor. - Sudden vision loss or rapidly worsening eyesight — in 2025, the EMA classified a rare eye condition (NAION) as a possible side effect of semaglutide. Seek urgent eye care. - Severe vomiting with signs of dehydration (dark urine, dizziness) — contact your doctor or NHS 111. - Severe upper-right abdominal pain with fever — may indicate gallbladder problems. Always tell your anaesthetist or surgeon that you are on GLP-1 medication before any procedure requiring general anaesthesia or deep sedation. These drugs slow stomach emptying and can increase the risk of aspiration. ## Hair Loss and Fatigue — What Is Causing Them? Some people experience hair thinning in the first months of treatment. This is usually due to rapid weight loss (a condition called telogen effluvium) rather than the medication itself, and it is typically temporary. Fatigue is also reported — making sure you eat enough protein and stay well hydrated can help. ## The Bottom Line Side effects from GLP-1 medications are real and can be frustrating — but for most people they are manageable and improve over time. The key insight is that they peak during dose escalation and typically ease once your body has adjusted to a stable dose. Use the practical tips above, and speak openly with your prescriber if things feel too difficult. ## Sources - FDA — Wegovy (semaglutide) Prescribing Label 2024 - FDA — Mounjaro (tirzepatide) Prescribing Label 2025 - EMA — NAION as very rare side effect of semaglutide (2025) - Mayo Clinic — Semaglutide (subcutaneous route): Side effects & dosage - Mayo Clinic — Tirzepatide (subcutaneous route): Side effects & dosage - NHS Guy's & St Thomas' — GLP-1 agonists: patient information --- Source: https://clickdose.io/en/articles/storing-injection-pens.html Storing your injection pen correctly is essential for the medication to work as intended. GLP-1 medicines such as Wegovy, Ozempic and Mounjaro are biological drugs — they can degrade if exposed to the wrong temperature, direct sunlight or freezing. This guide gives you a clear overview of everything you need to know about storage, whether you are at home or travelling. ## Unopened pens: always in the fridge Pens you have not yet used must be stored in the refrigerator at 2–8 °C. This is a standard fridge temperature. A few important points: - Place the pen in the middle of the fridge — not in the door (too many temperature swings) and not pressed against the back wall (risk of freezing). - Never freeze an unopened pen. A frozen pen is ruined and must not be used — the medication loses its potency, and you may notice the liquid looks different from usual. - Protect from light — keep the pen in its original carton until you are ready to use it. - Always check the expiry date before starting a new pen. ## Opened pens: how long do they last? Once you have taken your first injection, the storage rules change. An opened pen does not necessarily need to be kept in the fridge, but its shelf life is limited. Here are the current guidelines by product: | Product | Shelf life after opening | Max. temperature | | Ozempic (semaglutide) | Up to 6 weeks (42 days) | 30 °C | | Wegovy (semaglutide) | Up to 6 weeks (42 days) | 30 °C | | Mounjaro (tirzepatide) | Up to 30 days | 30 °C | Ozempic and Wegovy can be stored in the fridge (2–8 °C) or at room temperature within the shelf-life period. Mounjaro, however, must be stored unrefrigerated (max. 30 °C) after first use — as stated in the approved SmPC. Always check the current package leaflet, as recommendations may be updated. ## Especially important for dose-splitting If you practise dose-splitting — using one pen for multiple doses over several weeks — the shelf life is particularly critical. Even though a Wegovy 2.4 mg pen theoretically contains many doses, it is only stable for 42 days (6 weeks) after the first injection. You can therefore use it for a maximum of 6 weekly doses, regardless of how many clicks remain. Write the date of first use directly on the pen with a permanent marker so you always know when it expires. ## What you must never do - Freeze a pen — whether unopened or in use. A pen that has been frozen must be discarded. - Re-freeze — a pen that has been at room temperature must not be put back in the freezer. - Expose to direct sun or heat — never leave the pen in a sunny spot, a hot car, or near a radiator. - Shake the pen — GLP-1 solutions are delicate. Do not shake the pen before injecting. ## Check the medication before injecting Before each injection, always inspect the solution in the pen. GLP-1 medication should normally be clear and colourless. Do not use the pen if you notice: - Cloudiness or a hazy appearance - Discolouration (e.g. a yellow or brown tint) - Visible particles or floating matter If in doubt, contact your pharmacist. ## Storage when travelling When travelling with your pen, the room-temperature rules above apply — but there are a few extra precautions: ### Flying - Always carry the pen in your hand luggage — never in checked baggage. The cargo hold can reach temperatures well below freezing, which would ruin your medication. - Airport security generally allows injection pens with a prescription. Carry a copy of your prescription or a letter from your doctor, especially when travelling abroad. - Insulated travel cases such as FRIO pouches keep pens cool without electricity or ice and are ideal for air travel. ### Car and holiday accommodation - A car parked in the sun can reach over 50 °C inside. Never leave the pen in the car. - If you have no access to a fridge, a FRIO cooling pouch or a small cooler with ice packs will work — make sure the temperature does not drop below 2 °C (avoid direct contact with ice). ### Hot climates and summer heat - In a country with high ambient temperatures, prioritise storing the pen in a fridge even if it is already opened — room temperature can quickly exceed 30 °C. - Carry the pen in an inside pocket close to your body rather than in a bag left in direct sunlight. ## What to do if the pen has been stored incorrectly If you are unsure whether the pen has been too warm, too cold or has expired, the golden rule is: do not use it. Contact your doctor or pharmacist. Degraded GLP-1 medication can look normal but may have reduced or no effect — and you risk going a week without correct treatment. ## Disposing of used pens Used pens and needles are clinical waste and must not be placed in household rubbish. Return them to your pharmacy or use an approved sharps container. Most pharmacies accept used sharps free of charge. ## Quick-reference summary | Situation | What to do | | Unopened pen | Fridge 2–8 °C, original carton, never freeze | | Opened pen at home | Fridge or room temperature (max. 30 °C) | | Opened pen while travelling | FRIO pouch or cooler, hand luggage on planes | | Pen has been frozen | Discard it, contact pharmacy | | Pen looks cloudy/discoloured | Do not use, contact pharmacy | ## Sources - NHS — Semaglutide injection: storage information - EMA — Wegovy product information (SmPC) - EMA — Ozempic product information (SmPC) - EMA — Mounjaro product information (SmPC) - FDA — Wegovy and Ozempic prescribing information --- Source: https://clickdose.io/en/articles/wegovy-vs-ozempic-vs-mounjaro.html Wegovy, Ozempic, and Mounjaro are the three most widely used injection pens for treating obesity and type 2 diabetes. All three belong to the class of GLP-1 receptor agonists, but there are significant differences in their active ingredients, pen design, and click mechanics. In this article, we compare them side by side — with a particular focus on what matters if you are counting clicks. ## What are GLP-1 receptor agonists? GLP-1 (glucagon-like peptide-1) is a hormone that your body naturally produces in the gut after a meal. It stimulates insulin production, lowers blood sugar, and reduces appetite. GLP-1 receptor agonists mimic this hormone and amplify its effect. Mounjaro is slightly different: it is a so-called dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This can potentially provide a stronger effect on weight loss and blood sugar control. ## Comparison table | | Wegovy | Ozempic | Mounjaro | | Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly | | Active ingredient | Semaglutide | Semaglutide | Tirzepatide | | Receptor | GLP-1 | GLP-1 | GLP-1 + GIP | | Pen type | FlexTouch | FlexPen | KwikPen | | Click mechanism | Variable mg/click per strength | Fixed 0.01 mg/click | 60 clicks for all strengths | | Approved for | Weight management | Type 2 diabetes | Type 2 diabetes (+ weight loss in some countries) | | Shelf life after opening | 6 weeks | 6 weeks | 30 days | ## Pen mechanics and click counting For those who dose-split, the pen's click mechanism is crucial. Here is where the three pens differ significantly: ### Wegovy (FlexTouch) Wegovy uses Novo Nordisk's FlexTouch pen, designed as a single-dose pen. The click mechanism varies between strengths: a 0.25 mg pen has a different mg-per-click ratio than a 2.4 mg pen. This means you need to know the exact number of clicks for your specific pen strength and desired dose. ClickDose has all this data built in, so you always count the correct number. ### Ozempic (FlexPen) Ozempic uses a FlexPen with a rotatable dose knob. This pen delivers a fixed 0.01 mg per click — regardless of which pen strength you have. This makes click counting more straightforward: for 0.25 mg, you dial 25 clicks. For 0.5 mg, you dial 50 clicks. The consistent mechanism makes Ozempic one of the easier pens to dose-split with. ### Mounjaro (KwikPen) Mounjaro uses Eli Lilly's KwikPen platform. What is unique about Mounjaro is that all strengths contain exactly 60 clicks for a full dose. Whether you have a 2.5 mg or a 15 mg pen, there are always 60 clicks. This makes it simple to calculate fractions: half is 30 clicks, a quarter is 15 clicks, and so on. ## Approved uses It is important to distinguish what the three medications are officially approved for: - Wegovy is specifically approved for weight management in adults with obesity (BMI of 30 or greater) or BMI of 27 or greater with at least one weight-related comorbidity. - Ozempic is approved for the treatment of type 2 diabetes. Although it is widely used off-label for weight loss, that is not its primary approval. - Mounjaro is primarily approved for type 2 diabetes, but in some countries (including the US, under the brand name Zepbound) it has also received approval for weight management. Note that while Wegovy and Ozempic both contain semaglutide, their dosing and intended purpose differ. Your doctor will choose the right medication based on your diagnosis and treatment goals. ## Cost and availability Pricing varies significantly between countries and depends on insurance coverage and subsidy programs. In general, all three medications are expensive without coverage, which is one of the reasons many people consider dose-splitting. It is important to emphasize, however, that savings should never come at the expense of safety. ## ClickDose supports all three No matter which pen you use, ClickDose supports all three medications. Simply select your pen type and strength in the app, and ClickDose automatically calculates the correct number of clicks for your desired dose. The sound sensor counts clicks in real time, so you always know exactly how many clicks you have administered. ClickDose knows all the variations in click mechanics — from Wegovy's variable mg/click to Mounjaro's fixed 60 clicks — and adapts automatically. You do not need to remember the numbers yourself. ## References Content on this page has been reviewed for factual accuracy against the official prescribing information and summary of product characteristics listed below. - Novo Nordisk. Wegovy (semaglutide) Prescribing Information. FDA, revised 2023. accessdata.fda.gov - European Medicines Agency. Wegovy Summary of Product Characteristics. ema.europa.eu - Novo Nordisk. Ozempic (semaglutide) Prescribing Information. FDA. accessdata.fda.gov - European Medicines Agency. Ozempic Summary of Product Characteristics. ema.europa.eu - Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. FDA. pi.lilly.com - European Medicines Agency. Mounjaro Summary of Product Characteristics. ema.europa.eu --- Source: https://clickdose.io/en/articles/weight-loss-with-glp1.html Wegovy, Ozempic and Mounjaro are among the most talked-about weight loss medications available today. But what can you actually expect? How quickly do they work, how much weight will you lose, and what happens when the scale stops moving? This article gives you an honest, plain-language overview based on the best clinical evidence. ## How do GLP-1 medications work? GLP-1 receptor agonists — including semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) — work by mimicking a hormone your body normally releases after eating. They reduce appetite, create a feeling of fullness sooner, and slow down how quickly your stomach empties. The result is that you eat less without necessarily feeling hungry. This isn't just a standard appetite suppressant. These medications actually change the biological signalling that controls hunger and satiety — which is why they work for many people for whom diet alone hasn't been enough. ## What do the clinical trials show? Let's look at the real numbers from the major studies: ### Semaglutide 2.4 mg (Wegovy) — the STEP 1 trial In the large STEP 1 trial (published in the New England Journal of Medicine), participants lost an average of 14.9% of their body weight over 68 weeks (approximately 16 months) with semaglutide 2.4 mg. The placebo group lost only 2.4%. For a person weighing 220 lbs (100 kg), that equals roughly 33 lbs (15 kg) on average. ### Tirzepatide (Mounjaro) — the SURMOUNT-1 trial In the SURMOUNT-1 trial (also in NEJM), participants on the highest dose (15 mg tirzepatide) achieved an average weight loss of 20.9% over 72 weeks. At 10 mg it was 19.5%, and at 5 mg it was 15.0%. The placebo group lost 3.1%. Tirzepatide acts on two hormones (GLP-1 and GIP), which may explain the somewhat greater effect. ## Timeline: when does weight loss happen? Many people ask: "When will I start seeing results?" Here is a realistic timeline: - Weeks 1–4: Most people notice reduced appetite fairly quickly. Some lose a little weight in the first month — typically 2–6 lbs (1–3 kg). - Months 2–6: Weight loss accelerates. This is when most people see the most visible results. You are still titrating up in dose, and the body responds strongly. - Months 6–12: Weight loss continues but the pace slows. You are nearing your maximum effective dose and beginning to reach a new equilibrium. - After 12 months: Most people reach a plateau. Weight loss stalls — but this is not a sign the medication has stopped working; the body has simply adapted. ## What is a weight loss plateau? A plateau occurs when your body has adjusted its metabolism to your lower weight and reduced calorie intake. Your body is not "resisting" the medication — it has simply reached a new balance. Studies show that plateaus typically occur after 9–12 months on a stable dose. It is important to know: even a plateau is a success. Maintaining a lower weight is just as important as losing it in the first place. Research shows that patients who continue treatment maintain their weight loss significantly better than those who stop. ### What can you do about a plateau? - Optimise your diet: Make sure you get enough protein (it protects muscle mass and keeps you fuller for longer). - Move more: Even moderate amounts of exercise can help the body break through a plateau. - Get enough sleep: Poor sleep increases hunger and can counteract the medication's effect. - Talk to your doctor: In some cases, a dose increase or change in treatment may be worth considering. ## Are results the same for everyone? No — and it is important to have realistic expectations. Clinical trials show average figures, but there is significant variation. Some people lose 5%, others 25%. Factors such as starting weight, diet, exercise, sleep, genetics and other health conditions all play a role. If you are not seeing the results you expected after 3–4 months on your target dose, it is a good idea to speak with your doctor. There may be underlying reasons — or a different treatment may suit you better. ## What happens when you stop the medication? It is well documented that many people regain a significant portion of the lost weight when they stop GLP-1 medication. The SURMOUNT-4 trial showed that patients who stopped tirzepatide regained an average of 14% of their body weight over the following 52 weeks — while those who continued lost a further 5.5%. This underlines that GLP-1 medication typically requires long-term treatment to maintain its effect. ## Practical expectations — a quick summary - Expect 10–20% weight loss over 1–1.5 years depending on the medication and dose - Initial results are typically seen within the first couple of months - A plateau after 9–12 months is normal and expected - Weight loss requires long-term treatment to be maintained - Diet, exercise and lifestyle still play an important role ## Sources - Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM (STEP 1). - Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM (SURMOUNT-1). - NHS England. Weight management injections. - Mayo Clinic. Semaglutide (subcutaneous route). - Tremblay & Chaput (2023). Physiology of the Weight Loss Plateau. PMC/NCBI. --- Source: https://clickdose.io/en/articles/what-happens-when-you-stop.html You may have lost significant weight on Wegovy, Ozempic, or Mounjaro — and now you're wondering whether you can stop. Or perhaps you need to stop due to cost, availability, or side effects. It's one of the most common questions among people on GLP-1 treatment: What happens to my weight and health when I stop? Here's what the research actually shows. ## Your body remembers its old weight GLP-1 medications work by suppressing hunger signals and raising the biological threshold for feeling full. As long as you take the medication, your body is in an altered state. When you stop, these signals gradually return to baseline — and for many people, that means hunger comes back and weight goes up again. This is not a sign of weak willpower. It's biology. Obesity is a chronic condition driven by powerful hormonal mechanisms, and GLP-1 medications treat those mechanisms — but don't cure them permanently. Just as blood pressure medication keeps blood pressure down while you take it, GLP-1 medication keeps weight down while you take it. ## What the STEP 1 extension study tells us about semaglutide The most cited study in this area is the extension study to the STEP 1 trial, published in Diabetes, Obesity and Metabolism in 2022. Participants had used semaglutide 2.4 mg (Wegovy) for 68 weeks, losing an average of 17.3% of their body weight. They then stopped the medication and were followed for another 52 weeks. The result was clear: within one year of stopping, participants had regained two-thirds of the weight they had lost. By week 120 (one year after stopping), the average net weight reduction was only 5.6% — compared to the 17.3% achieved during treatment. The weight did not return entirely to baseline — but most of it did. ## What the SURMOUNT-4 trial tells us about tirzepatide For tirzepatide (Mounjaro), the SURMOUNT-4 trial (published in JAMA, 2023) is the most informative study. Participants received tirzepatide for 36 weeks and lost significant weight, after which half continued the medication and half switched to placebo for 52 weeks. Of those who stopped tirzepatide, 82.5% regained at least 25% of their lost weight within one year. By comparison, the group that continued tirzepatide lost a further 5.5% during the same period. The difference was dramatic: continued treatment versus stopping produced very different outcomes. A follow-up analysis also showed that participants who regained the most weight also experienced the greatest reversal of the cardiovascular benefits the medication had provided — including improvements in blood pressure, cholesterol, and blood sugar. ## Does it always go wrong when you stop? Not necessarily. A large real-world study from EPIC Research (2024) followed thousands of patients who stopped semaglutide or liraglutide and found that: - 55.7% of patients maintained their weight or continued to lose weight one year after stopping - 17.7% regained all the weight they had lost or more - The rest fell somewhere in between This shows that outcomes are highly individual. Factors like dietary changes, exercise habits, sleep quality, and stress levels all play a role in whether weight stays off after stopping. ## What happens to your health beyond weight? GLP-1 medications don't only cause weight loss — they also improve blood pressure, blood sugar, cholesterol, and other markers of cardiovascular health. These improvements are not permanent. Research shows that most of these health markers gradually return toward baseline as weight is regained. For patients with prediabetes, this is particularly important: studies show that many who stopped semaglutide had reverted to prediabetic status one year after stopping — even though their blood sugar had normalised during treatment. ## Weight regain is faster than after a diet A new study from the University of Oxford (January 2026) compared weight regain after stopping medication versus stopping a diet programme. The conclusion was that weight returned faster after stopping medication — approximately 0.3 kg per month faster than stopping a dietary programme. This underscores that the medication actively suppresses the biological mechanisms driving weight gain, and these mechanisms are ready to reassert themselves as soon as the medication is gone. ## When does it make sense to stop? There can be good reasons to stop GLP-1 medication: - Cost or access: The medication is expensive and not always covered by insurance or public health systems. - Side effects: Nausea, vomiting, or other persistent side effects can make treatment intolerable. - Pregnancy or planned pregnancy: GLP-1 medications are not recommended during pregnancy. - Goal reached: Some patients and doctors choose to try maintaining weight through lifestyle changes alone after a period on medication. Always talk to your doctor before stopping treatment. A gradual taper may in some cases allow for a smoother transition than an abrupt stop — though research in this area is still limited. ## What can you do to preserve your weight loss? If you stop or plan to stop, there are things that can help you maintain some of your weight loss: - Protein at every meal: Protein increases satiety and helps preserve muscle mass, which is important for metabolism. - Regular exercise: Strength training in particular helps keep metabolism up and prevents muscle loss instead of fat loss. - Sleep and stress management: Poor sleep and chronic stress significantly increase the hunger hormone ghrelin — and can accelerate weight regain. - Long-term eating habits: The dietary changes you made during treatment — fewer sugary drinks, less processed food, greater attention to portion sizes — are worth holding on to. - Follow-up with your doctor: Regular check-ins can help catch weight regain early and plan the next steps. ## Is GLP-1 medication a lifelong treatment? For many patients, the answer appears to be yes — just as is the case with medication for high blood pressure or high cholesterol. Obesity is a chronic disease, and for many people it requires chronic treatment. That doesn't mean everyone needs to take the medication forever, but it does mean that continuing long-term treatment is a realistic and legitimate option if it is possible and appropriate. This is an important conversation to have with your doctor — not a decision that should be made alone. ## Summary - Most people regain a significant portion of lost weight when they stop GLP-1 medication - The STEP 1 extension study shows that two-thirds of weight loss returns within one year of stopping semaglutide - 82.5% of those who stopped tirzepatide in SURMOUNT-4 regained at least 25% of lost weight - Health benefits such as improved blood pressure and blood sugar gradually reverse - Around 55% do relatively well after stopping in real-world studies - Lifestyle changes — diet, exercise, sleep — play a crucial role in whether weight stays off ## Sources - Wilding et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. PMC/NCBI. - Aronne et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: SURMOUNT-4. JAMA. - EPIC Research (2024). Many Patients Maintain Weight Loss a Year After Stopping Semaglutide and Liraglutide. - University of Oxford (2026). Stopping weight-loss drugs linked to faster regain than ending diet programmes. - Scientific American. Does Stopping Ozempic Cause Rebound Weight Gain and Health Problems? --- Source: https://clickdose.io/en/articles/what-is-click-counting.html If you use an injection pen like Wegovy, Ozempic, or Mounjaro, you have probably noticed the small clicks when you turn the dose dial. Each click corresponds to a precise amount of medication. Click counting is simply the practice of counting these clicks to measure a specific dose — typically a dose that differs from the pen's preset doses. ## How does an injection pen work mechanically? Modern injection pens such as Novo Nordisk's Wegovy and Ozempic or Eli Lilly's Mounjaro are precision instruments. Inside the pen sits a cartridge of medication and a screw mechanism that pushes a plunger forward. When you turn the dose knob, the plunger advances in small, controlled increments — and each increment produces an audible click. For Wegovy and Ozempic pens, each click corresponds to 0.01 mg of semaglutide (for the 1 mg pen). This means a full dose of 0.25 mg requires 25 clicks, while 0.50 mg requires 50 clicks. Mounjaro pens work on the same principle but deliver tirzepatide instead of semaglutide. The pens are designed as single-use, fixed-dose devices. However, mechanically there is nothing preventing you from dialing any number of clicks and thus selecting a custom dose. ## Why do people count clicks? There are several reasons patients choose to count clicks rather than use the pen's standard doses: ### Dose splitting to save money GLP-1 medications like Wegovy and Ozempic are expensive. In many countries, a single pen costs hundreds or even thousands of dollars. The pricing structure is often such that a higher-dose pen does not cost proportionally more than a lower-dose pen. By purchasing a higher-concentration pen and splitting it into multiple smaller doses, patients can save significantly. For example, an Ozempic 1 mg pen contains enough medication for four 0.25 mg doses. If the price of a 1 mg pen is nearly the same as a 0.25 mg pen, the savings can be as much as 75%. ### Flexible dose titration Many patients experience side effects such as nausea when starting GLP-1 medications or increasing their dose. By counting clicks, you can titrate upward in smaller steps than the standard doses the pen is designed for. Instead of jumping from 0.25 mg straight to 0.50 mg, you could go to 0.30 mg, then 0.35 mg, and so on. ### Using remaining medication when switching pens When a pen is running low, click counting helps you use the remaining medication rather than discarding it. Instead of throwing away a pen with a small amount left, you can count clicks to use the rest and supplement with a new pen. ## The challenge of manual click counting Counting clicks manually sounds simple, but in practice it is surprisingly difficult. The clicks are short and uniform, and it is easy to lose count — especially when you need to count 50, 75, or even more clicks. A miscount of just a few clicks can mean a dose that deviates from what you intended. Additionally, it requires concentration and a quiet environment, and many patients feel uncertain about whether they counted correctly. That uncertainty can lead to either overdosing or underdosing. ## How ClickDose helps ClickDose is a browser-based tool that solves this problem. It uses the microphone on your phone or computer to listen for the pen's clicks and counts them automatically in real time. You simply turn the dose knob while ClickDose listens, and you can read the exact click count on your screen. Benefits of ClickDose: - Automatic counting — no risk of losing count - Real-time display — see the count as you dial - No installation required — runs directly in your browser - Free to use — no subscription or payment - Private — audio is processed locally and never sent to any server Simply set your desired dose in number of clicks, start the recording, and slowly turn the pen's dose knob. ClickDose detects each click and notifies you when you have reached the target number. ### Important note on off-label use Dose splitting and custom dosing are off-label uses of injection pens. This means it is not the way the pen has been approved for use by regulatory authorities. You should always discuss your dosing with your doctor before changing your prescribed dose. ClickDose is not a medical device and does not provide medical advice. ## Who uses click counting? Click counting is widespread in online communities for GLP-1 medication users, particularly on Reddit, Facebook groups, and various health forums. It is especially popular in countries where GLP-1 medications are not covered by insurance, or where there are supply shortages and patients are trying to stretch their supply. It is also used by patients who want a slower titration to minimize side effects, and by patients who are tapering off the medication. ## Summary Click counting is a practical technique that gives injection pen users the ability to select precise, custom doses. While it requires care and should ideally be done in consultation with a doctor, it can help save money and tailor dosing to individual needs. With a tool like ClickDose, the process becomes easier and more reliable. --- Source: https://clickdose.io/en/articles/when-medication-stops-working.html You started treatment with Wegovy, Ozempic or Mounjaro, and for the first few months the weight came off steadily. Then — it stopped. The scale isn't moving. What's going on? Has the medication stopped working? The answer is more nuanced than a simple yes or no, and it has far more to do with biology than willpower. ## What is a weight loss plateau? A weight loss plateau is a period where your weight remains stable despite continuing your treatment. It is not a sign that the medication has been "used up" or that your body has become immune to it. It's a normal biological response that happens to almost everyone who loses weight — regardless of the method. Plateaus occur because your body is remarkably good at adapting. When you lose weight, your body burns fewer calories — simply because there's less of you to maintain. On top of that, your metabolism slows in a process called adaptive thermogenesis: the body starts conserving energy because it perceives weight loss as a survival threat. ## When does a plateau typically occur? In the large clinical trials with semaglutide (Wegovy) and tirzepatide (Mounjaro), most participants reached their maximum weight loss between 20 and 60 weeks (roughly 5 to 14 months). For most people, weight loss begins to visibly slow after 6–9 months on a stable dose, and a true plateau is very common after 9–12 months. It's important to understand: even a plateau is a success. Maintaining a 10–20% weight loss is enormously beneficial for health — it significantly reduces the risk of type 2 diabetes, cardiovascular disease, and joint problems. ## What happens in your body? When the body loses weight, it activates several counter-regulatory mechanisms. Research shows these responses are strong and persistent: - Metabolic rate falls: For every 10% of body weight lost, resting metabolic rate drops significantly. Your body simply burns fewer calories than expected. - Ghrelin (the hunger hormone) rises: Your body produces more ghrelin, which sends signals to the brain that you are hungry — even when you've eaten enough. - Leptin (the satiety hormone) falls: You produce less leptin, which normally signals fullness to the brain. The result is you don't feel as satisfied after meals as you used to. - Muscle mass decreases: Weight loss involves not just fat but also some muscle tissue — and muscle burns more energy than fat, even at rest. GLP-1 medications are highly effective at suppressing appetite, but they cannot fully override these deeply ingrained biological adaptations. This is not a lack of willpower — it is nature's resistance to weight loss. ## Who doesn't respond to the medication? The vast majority of users experience meaningful weight loss, but clinical studies show that 10–17% of semaglutide users are "non-responders" — losing less than 5% of their starting weight despite correct use and correct dosing. These individuals are not non-compliant; there are typically biological reasons: - Type 2 diabetes: People with diabetes lose an average of 9–10% with semaglutide, versus 14–15% for those without. Insulin resistance and diabetes medications play a role. - Biological sex: Men lose an average of 8–9%, women 14–16%. Hormonal and physiological differences are the likely cause. - Genetics: Individual variations in GLP-1 receptor sensitivity can mean the medication doesn't signal as strongly in everyone. ## Lifestyle and medical factors that can reduce effectiveness Beyond biological factors, there are circumstances you can influence — and medical conditions your doctor should assess: - Insufficient sleep: Sleep deprivation raises ghrelin and lowers leptin — exactly the hormones the medication is trying to regulate. Fewer than 7 hours per night can directly undermine your treatment. - Chronic stress: Elevated cortisol promotes fat storage (particularly around the abdomen) and increases cravings for calorie-dense foods. - Certain medications: Corticosteroids (e.g. prednisolone), antipsychotics and some antidepressants can cause significant weight gain and work against GLP-1 treatment. Discuss this with your doctor. - Thyroid function: Hypothyroidism (underactive thyroid) slows metabolism and can significantly stall weight loss. Ask your doctor to check your thyroid levels if progress is very poor. - PCOS: Polycystic ovary syndrome makes weight loss harder for many women, even on GLP-1 medication, due to insulin resistance and hormonal disruption. - Dose still too low: If you are still on a low starter dose and have had no side effects, you may not have reached your maintenance dose yet. The titration process can take 4–5 months. ## What can you do about a plateau? A plateau does not mean treatment has failed. Here are evidence-based steps that can help: - Increase protein intake: Protein boosts satiety, protects muscle mass during weight loss and requires more calories to digest than carbohydrates or fat. Aim for 1.2–1.6 g of protein per kg of body weight per day. - Strength training 2–3 times a week: Muscle burns more energy than fat, even at rest. Resistance training helps preserve muscle mass and can restart your metabolism. - Prioritise sleep: 7–9 hours of sleep per night is documented to support weight loss treatment. Good sleep hygiene is an underrated part of the therapy. - Manage stress: Mindfulness, regular exercise and social connection can lower cortisol and support weight loss. - Review your titration: Talk to your doctor about whether you have reached the right maintenance dose and whether any adjustment is needed. ## When should you contact your doctor? Reach out to your doctor if: - You have been on your target dose for 3–4 months without achieving at least 5% weight loss - You suspect an underlying condition (e.g. underactive thyroid, PCOS, depression) - You are considering switching from semaglutide to tirzepatide — in the head-to-head SURMOUNT-5 trial, tirzepatide achieved average weight loss of 20.2% versus 13.7% for semaglutide - You are taking other medications that may be working against your weight loss Any change in treatment or dosing should always be made in consultation with your doctor. ## Key takeaways - A plateau after 6–12 months is normal and biologically expected - Biological adaptations — not lack of willpower — are the primary cause of plateaus - 10–17% of users are non-responders, often for biological reasons - Sleep, stress, diet and exercise have a major influence on treatment effectiveness - Talk to your doctor if you see no effect at all after 3–4 months on your target dose ## Sources - Ghusn et al. (2024). Semaglutide for weight loss: unanswered questions. Frontiers in Endocrinology. - Ghusn et al. (2024). Semaglutide for weight loss: unanswered questions. PMC/NCBI. - Wilding et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide. PubMed/NEJM. - Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM (STEP 1). - Mayo Clinic. Semaglutide (subcutaneous route). - NHS England. Weight management injections.